The Translational Machinery as a Target for Radiosensitization by Hayman, Thomas John
University of South Florida
Scholar Commons
Graduate Theses and Dissertations Graduate School
January 2013
The Translational Machinery as a Target for
Radiosensitization
Thomas John Hayman
University of South Florida, thayman@health.usf.edu
Follow this and additional works at: http://scholarcommons.usf.edu/etd
Part of the Oncology Commons
This Dissertation is brought to you for free and open access by the Graduate School at Scholar Commons. It has been accepted for inclusion in
Graduate Theses and Dissertations by an authorized administrator of Scholar Commons. For more information, please contact
scholarcommons@usf.edu.
Scholar Commons Citation
Hayman, Thomas John, "The Translational Machinery as a Target for Radiosensitization" (2013). Graduate Theses and Dissertations.
http://scholarcommons.usf.edu/etd/4690
 
 
 
The Translational Machinery as a Target for Radiosensitization 
 
 
 
by 
 
 
 
Thomas J. Hayman 
 
 
 
 
 
A dissertation submitted in partial fulfillment 
of the requirements for the degree of 
Doctor of Philosophy 
Department of Molecular Medicine 
College of Medicine 
University of South Florida 
 
 
 
Co-Major Professor: Philip J. Tofilon, Ph.D. 
Co-Major Professor: Robert J. Deschenes, Ph.D. 
Michael J. Barber, D.Phil. 
Srikumar P. Chellappan, Ph.D. 
Peter G. Medveczky, M.D. 
 
 
Date of Approval: 
May 15, 2013 
 
 
 
Keywords: eIF4E, S6K, mTOR, mRNA Translation, Radiosensitization 
 
Copyright © 2013, Thomas J. Hayman 
 
 
 
  
ACKNOWLEDGMENTS 
 
 I would like to thank my advisor Dr. Phil Tofilon for the scientifically rigorous 
training that he has provided me over the past several years.  This training will provide an 
excellent foundation for my continuing scientific career.  Secondly, I would like to thank 
the other members of my lab, as their discussions and guidance have been extremely 
valuable to me.  Furthermore, I would like to thank the Radiation Oncology Branch at the 
National Cancer Institute for providing me with a great environment to learn and grow as 
a scientist.  The University of South Florida Morsani College of Medicine has been vital 
in helping me to achieve the goal of obtaining a Ph.D.   My family’s support has truly 
been a blessing and has allowed me to persevere.  Lastly, I would like to thank Ashley 
Loveless, who has been my foundation throughout this journey. 
i	  	  
 
 
 
 
 
TABLE OF CONTENTS 
 
List of Tables ..................................................................................................................... iii 
 
List of Figures .................................................................................................................... iv 
 
Abstract .............................................................................................................................. vi 
 
Chapter 1: Introduction ...............................................................................................1 
 
Chapter 2: Methods.....................................................................................................7 
 
Chapter 3: Translation Initiation Factor eIF4E is a Target for Tumor Cell 
Radiosensitization ...................................................................................13 
 Note to Reader .......................................................................................................13 
 Abstract ..................................................................................................................13 
 Introduction ............................................................................................................14 
 Results ....................................................................................................................15 
 Discussion ..............................................................................................................28 
 
Chapter 4: Ribosomal Protein S6 Kinase 1 as a Determinant of Cellular 
Radiosensitivity.......................................................................................31 
 Abstract ..................................................................................................................31 
 Introduction ............................................................................................................31 
 Results ....................................................................................................................34 
 Discussion ..............................................................................................................37 
 
Chapter 5: Allosteric versus ATP-Competitive mTOR Inhibition and 
Radiosensitivity.......................................................................................40 
 Note to Reader .......................................................................................................40 
 Abstract ..................................................................................................................40 
 Introduction ............................................................................................................41 
 Results ....................................................................................................................42 
 Discussion ..............................................................................................................54 
 
Chapter 6: ATP-Competitive mTOR Inhibition by the Clinically Available 
mTOR Inhibitor INK128 Enhances In Vitro and In Vivo 
Radiosensitivity of Pancreatic Adenocarcinoma ....................................58 
 Abstract ..................................................................................................................58 
 Introduction ............................................................................................................59 
 Results ....................................................................................................................60 
ii	  	  
 Discussion ..............................................................................................................73 
 
Chapter 7: Overall Conclusions ................................................................................77 
 
References ..........................................................................................................................81 
 
Appendices .........................................................................................................................91 
 
 
iii	  	  
 
 
 
 
 
LIST OF TABLES 
 
Table 1: Functions of mRNAS increasingly bound to eIF4E after irradiation ................25 
 
Table A1: List of 1124 genes increasingly bound to eIF4E after irradiation .....................92 
  
iv	  	  
 
 
 
 
 
LIST OF FIGURES 
 
Figure 1: Post-transcriptional regulation and radiation .....................................................4 
 
Figure 2: Effect of eIF4E knockdown on clonogenic cell survival .................................17 
 
Figure 3: The effects of eIF4E knockdown on cellular radiosensitivity .........................18 
 
Figure 4: Mechanism of radiosensitization by eIF4E knockdown ..................................20 
 
Figure 5: The effect of radiation on eIF4E activation .....................................................22 
 
Figure 6: Rip Chip analysis of the effects of radiation on eIF4E mRNA clients ............24 
 
Figure 7: Effects of ribavirin on radiosensitivity ............................................................27 
 
Figure 8: The effects of S6K1 knockdown on cellular radiosensitivity ..........................35 
 
Figure 9: The effects of S6K1 knockdown on PDCD4 expression .................................36 
 
Figure 10: Effects of rapamycin and PP242 on mTORC1/2 activity ................................44 
 
Figure 11: The effect of radiation on mTOR activity ........................................................45 
 
Figure 12: Effects of mTOR inhibitors on cellular radiosensitivity ..................................47 
 
Figure 13: Influence of PP242 on radiation-induced γH2AX foci ....................................48 
 
Figure 14: The effects of the timing of PP242 treatment on cellular 
radiosensitivity .................................................................................................50 
 
Figure 15: The effects of PP242 on radiation-induced tumor growth delay .....................53 
 
Figure 16: Effects of INK128 on mTORC1/2 activity ......................................................61 
 
Figure 17: Effects of INK128 on cellular radiosensitivity ................................................62 
 
Figure 18: Influence of INK128 on radiation-induced γH2AX foci .................................63 
 
v	  	  
Figure 19: The effects of INK128 treatment on mTOR activity in pancreatic 
tumor xenografts ..............................................................................................66 
 
Figure 20: The effects of INK128 on PSN1 tumor xenograft eIF4F complex 
formation ..........................................................................................................68 
 
Figure 21: The effects of duration of mTOR inhibition on in vitro and in vivo 
radiosensitivity .................................................................................................70 
 
vi	  	  
 
 
ABSTRACT 
 
 Current approaches aimed at improving the efficacy of radiation as a cancer 
treatment modality involve the development and application of molecularly targeted 
radiosensitizers, a strategy that requires a thorough understanding of the fundamental 
processes comprising the cellular radioresponse.  Recent data indicating that radiation 
modifies gene expression primarily through translational control rather than 
transcriptional events suggests that mRNA translation contributes to cell survival after 
irradiation.  The overall goal of this project is to determine whether the regulatory/rate-
limiting components of the translational machinery provide targets for tumor cell 
radiosensitization.  The majority of translation in mammalian cells occurs in a cap-
dependent manner and is highly dependent on eIF4E.  As such, we investigated a 
regulatory role for eIF4E in cellular radiosensitivity.  eIF4E knockdown enhanced the 
radiosensitivity of tumor but not normal cells.  eIF4E knockdown inhibited the dispersal 
of radiation-induced γH2AX foci.  Furthermore, radiation was found to increase the 
binding of >1000 unique mRNAs to eIF4E, many involved in DNA replication, 
recombination, and repair.  S6 kinase 1 (S6K1), also an important regulatory component 
of the translational machinery, enhances the translation of specific mRNA 
subpopulations, independent from eIF4E, and mediates ribosome biogenesis.  The role of 
S6K1 in determing cell survival after radiation was determined in several tumor cell lines 
vii	  	  
and one normal cell line.  S6K1 knockdown enhanced the radiosensitivity of all 3 tumor 
lines.  In contrast S6K1 knockdown had no effect on the cellular radiosensitivity of the 
one normal line tested.  The mechanistic target of rapamycin (mTOR) is a critical kinase 
in the regulation of gene translation and has been suggested as a potential target for 
radiosensitization.  Importantly, it plays a major role in regulating eIF4E availability as 
well as S6K1 activity.  The radiosensitizing activities of the allosteric mTOR inhibitor 
rapamycin with that of the ATP competitive mTOR inhibitor PP242 were compared.  
Based on immunoblot analyses, whereas rapamycin only partially inhibited mTORC1 
activity and had no effect on mTORC2, PP242 inhibited the activity of both mTOR 
containing complexes.  In the two tumor cell lines evaluated, PP242 treatment 1h before 
irradiation increased radiosensitivity, whereas rapamycin had no effect.  PP242 had no 
effect on the cellular radiosensitivity of a normal lung fibroblast line.  PP242 exposure 
did not influence the initial level of γH2AX foci after irradiation, but did significantly 
delay the dispersal of radiation-induced γH2AX foci.  Finally, PP242 administration to 
mice bearing U251 xenografts enhanced radiation-induced tumor growth delay.  A next 
generation analog of PP242, INK128, is currently undergoing analysis in clinical trials.  
Given our data showing ATP-competitive mTOR inhibition is a strategy for tumor 
radiosensitization as  well as the fact that radiotherapy is a primary treatment modality for 
locally advanced pancreatic ductal adenocarcinoma, the effects of INK128 on pancreatic 
cancer radiosensitivity were determined.  In three pancreatic cancer cell lines addition of 
INK128 immediately after radiation resulted in radiosensitization.  Consistent with the 
effects of PP242 on other cell lines, INK128 exposure did not influence the initial level of 
γH2AX foci after irradiation, but did significantly delay the dispersal of radiation-
viii	  	  
induced γH2AX foci.  Furthermore, in pancreatic tumor xenografts INK128 inhibits 
mTOR activity as well as cap-complex formation in a time-dependent manner.  Lastly, 
INK128 treatment significantly prolonged the radiation-induced tumor growth delay of 
pancreatic tumor xenografts.  In summary, the data provided in this thesis have begun to 
characterize the role of the translational machinery in determining the cellular response to 
radiation. 
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CHAPTER 1: 
Introduction 
 It is estimated in 2013 that there will be approximately 1.6 million non-skin 
cancers diagnosed in North America (cancer.org), of which approximately 75% of these 
patients will receive radiotherapy at sometime during their treatment course.  As 
radiotherapy continues to be a primary treatment modality for the majority of patients 
undergoing cancer therapy, the development of strategies to improve its efficacy could 
benefit a large number of patients.  This has led to an emphasis upon the development of 
molecularly targeted radiosensitizers, a strategy that requires a thorough understanding of 
the mechanisms mediating cellular radioresponse.  Along these lines, radiation-induced 
post-translational modifications of existing proteins (e.g. phosphorylation and 
ubiquitination) have been the subject of extensive investigation.  These modifications 
have been linked causally to cellular radiosensitivity and play important roles in the DNA 
damage response (DDR) and signal transduction pathways.  As such, these modifications 
have provided a rich source of potential targets for radiosensitization.  Additionally, as 
radiation has previously been shown to induce changes in the transcription of numerous 
genes, the modulation of gene expression has also been thought to play a role in the 
cellular radioresponse.  That is, similar to prokaryotes radiation-induced changes in gene 
expression in mammalian cells may constitute a protective or adaptive response against 
radiation-induced cell death.  As such, it has been generally thought that defining the 
inducible genes as well as the mechanisms governing their expression may provide not 
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only novel insight into the fundamental radioresponse, but may also lead to the 
identification of targets for radiation sensitizers.   
 To examine the radiation-induced control of gene expression numerous studies 
have published results of various analyses of total cellular mRNA (e.g. northern, RT-PCR 
and microarray) in a number of normal cells and tissue as well as for tumor cell lines 
grown both in vitro and in vivo (1-6).  However, comparison of these changes in the 
transcriptome reveals few commonly affected genes among the cell types evaluated or 
even among tumor cell lines originating from tumors of identical histologic origin.  In 
addition, whereas these analyses accurately reflect changes in mRNA abundance, the 
radiation-induced changes in mRNA levels do not correlate with changes in the 
corresponding protein product.  While there are exceptions involving individual genes 
(2), the majority of radiation-induced changes in mRNA abundance have not been 
extended to the protein level.  Along these lines, Skanderová et al. directly compared 
radiation-induced proteins with their corresponding mRNAs and reported no correlation 
for the 10 proteins evaluated (7).  As protein expression is the functional and operational 
end product of gene expression, the lack of correlation between radiation-induced 
changes in mRNA abundance and protein expression, as well as the established 
heterogeneity among the cell lines, it is difficult to assign a functional consequence to 
radiation-induced gene expression.  Consistent with the aforementioned findings Birell et 
al. showed that after irradiation of yeast, there was little to no relationship between 
radiation radiation-induced transcriptional changes and survival after irradiation (8). 
 A fundamental assumption of these analyses is that radiation-induced changes in 
gene expression are primarily the result of modifications in transcription.  However, in 
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addition to transcription, numerous post-transcriptional processes contribute to the 
control of gene expression.  In contrast to prokaryotic cells, mammalian transcription and 
translation are not directly coupled, with each event confined to separate cellular 
compartments (nucleus versus cytoplasm; Figure 1).  Consistent with this uncoupling,  
there is a poor correlation between changes in mRNA abundance and protein expression 
in eukaryotic cells exposed to a number of types of stress (9-12).  Furthermore even 
under basal growth conditions the agreement between mRNA and protein expression 
profiles was shown to be at best 65% in a study paneling the NCI-60 cell lines (13).  
Accounting for the discrepancy between the transcriptome and the proteome is 
translational control (14-16), which has been shown to play an important role in 
regulating gene expression during such fundamental processes as embryogenesis (17), T-
cell activation (18), growth factor signaling (19), and tumorigenesis (20). 
 More recent studies have begun to define the effects of radiation on translational 
control (21-22).  The initiation of translation involves the recruitment of mRNAs to 
polyribosomes (polysomes), and as such the association of a given mRNA with 
polysomes can then be used as an indicator of translational activity (15).  To perform 
global profiling of mRNAs undergoing translation (the translatome) these studies 
employed microarray analysis of polysome-bound mRNA after radiation in a several cell 
lines and these results were compared to radiation-induced changes in the transcriptome.  
A study from our laboratory initially focused on the U87 glioma cell line and showed that 
radiation affects ~10 fold more genes at the translational level than on the transcriptional 
level (22).  Furthermore, there was no overlap between genes affected translationally and 
transcriptionally in U87 cells (22).  Important with regards to functional consequence, a 
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Figure 1:  Post-transcriptional regulation and radiation. 
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correlation between radiation-induced changes in polysome-bound mRNAs and changes 
in the corresponding protein product was established, with 14/16 proteins evaluated 
showing consistent changes in translational activity and protein expression (22).  It was 
then further shown that radiation-induced changes in translation were similar among 3 
glioma cell lines, in contrast to radiation-induced changes in the transcriptome (22).   
A second study published by our laboratory extended the results of the previously 
mentioned study by profiling radiation-induced translational changes in a panel of 18 cell 
lines, comprised of both tumor and normal cell lines (21).  In contrast to changes in the 
transcriptome, radiation-induced translational changes clustered according to the tissue of 
origin (e.g. pancreatic carcinoma cell lines versus glioma cell lines).  Network analyses 
showed that the mRNAs affected at the translational level belonged to distinct functional 
categories and were not a random collection of genes (21).  Furthermore, many of these 
functional categories appeared to histology-specific.  Importantly, as the potential to 
exploit differences in tumor and normal cells is of critical importance for therapeutic 
application, many of the changes were exclusive to tumor or normal cells (21).  
Consistent with our results another laboratory has recently published analysis of 
polysome-bound mRNA and has shown radiation to affect the translation of numerous 
mRNAs that are functionally related (23).  Although translational control of gene 
expression appears to be a component of the cellular radioresponse, whether specific 
molecules of the translational machinery are determinants of the cellular radiosensitivity 
has yet to be determined, and is the subject of this thesis. 
There are numerous processes involved in the post-transcriptional control of gene 
expression (e.g. mRNA splicing, export, stability, and translation initiation) (24).  Each of 
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these processes can operate independently to regulate gene expression at the post-
transcriptional level.  RNA-binding proteins (RBPs), of which there are > 700 in humans, 
play important roles in the regulation of each of the post-transcriptional processes (24). 
Clearly, the mechanisms mediating the translational control of gene expression are 
extremely complex with each step/event subject to regulation by environmental signals 
including potentially radiation.  In fact, radiation has been shown to influence the 
components of the post-transcriptional gene expression infrastructure as well as the 
signaling pathways involved in their regulation (25-27).  These processes, for the most 
part, culminate in translation initiation and ribosome binding, the final and rate limiting 
steps in mRNA translation (Figure 1) (28).  Among the proteins regulating translation 
initiation are eIF4E and S6K (29).  Furthermore, the mechanistic target of rapamycin 
(mTOR), which plays a major role in determining gene translation in response to 
environmental and oncogenic stress, regulates the availability of eIF4E and activity of 
S6K (29).  Thus, to determine whether radiation-induced translation control of gene 
expression influences radiosensitivity, these specific components of the translational 
machinery were the focus of this thesis. 
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CHAPTER 2: 
Methods 
 
Cell lines and treatments:  MDA-MB-231 (breast adenocarcinoma), A549 (lung 
adenocarcinoma) DU145 (prostate adenocarcinoma), and MRC9 (normal lung 
fibroblasts) were obtained from American Type Culture Collection (ATCC).  U251 
(glioma) cells were obtained from the Division of Cancer Treatment and Diagnosis 
Tumor Repository (DCTD), National Cancer Institute (NCI).  Miapaca-2, Panc1, and 
PSN1 (all pancreatic cancer cell lines) were kind gifts from Dr. Deborah Citrin’s 
laboratory.  The cell lines were maintained in DMEM (MDA-MB-231 and U251), RPMI 
(A549, Miapaca-2, Panc1, and PSN1), or MEM (DU145 and MRC9) media 
supplemented with 10% FBS (Invitrogen, Carlsbad CA).  ATCC employs short tandem 
repeat DNA fingerprinting, karyotyping, and cytochrome C oxidase to authenticate cell 
lines.  Primary human mammary epithelial cells (HMEC) were obtained from GIBCO in 
2010 and maintained in complete Mammary Epithelial Growth Medium (Lonza).  All 
cells were cultured less than 6 months after resuscitation.  Cell cultures were maintained 
in an atmosphere of 5% CO2/95% air at 37°C.  Ribavirin (Sigma-Aldrich), PP242 
(Sigma-Aldrich or Chemdea) and rapamycin (EMD-Biochemicals) were dissolved in 
dimethyl sulfoxide.  Cell cultures were irradiated using a 320 X-ray source (Precision 
XRay Inc.) at a dose rate of 2.3 Gy/min. 
siRNA Transfection:  A pool of four siRNA duplexes (SMARTpool) targeted to 
eIF4E or S6K1 and a non-targeted siRNA pool (scramble) were purchased from 
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Dharmacon Inc (Lafayette, CO).  Transfection with the respective siRNA pool was 
carried out with cell cultures at 60-70% confluency using Dharmafect 1 transfection 
reagent (Dharmacon) per manufacturer’s protocol.  All experiments were carried out 72 h 
post transfection. 
Clonogenic Survival Assay: To evaluate radiosensitivity, cells were plated at 
clonal density in 6-well plates, allowed to attach, followed by the specified drug and/or 
radiation treatment protocol. 10 to 14 days after seeding, plates were stained with 0.5% 
crystal violet, the number of colonies determined, and the surviving fractions were 
calculated.  Radiation survival curves were generated after normalizing for the 
cytotoxicity induced by eIF4E knockdown, S6K1 knockdown, rapamycin, PP242, or 
INK128 treatment alone.  Dose enhancement factor defined as the ratio of the dose of 
radiation required to reduce surviving fraction to 0.1 in untreated cells to the dose of 
radiation required to reduce surviving fraction to 0.1 in treated cells.  Data presented are 
the mean ± SEM from at least 3 independent experiments. 
Immunoblotting and antibodies:  Cells were lysed in 50mM Tris-HCl (pH 7.5), 
150mM NaCl, 2mM EDTA, 2mM EGTA, 25mM NaF, 25mM β-glycerophosphate, 0.2% 
Triton X-100, 0.3% NP-40, and 0.1mM sodium orthovanadate (for cytoplasmic proteins), 
or 50mM Tris-HCL (ph 8.0), 1% SDS, and 10mM EDTA (for nuclear proteins); 
supplemented with 1x phosphatase inhibitor cocktails II and III (Sigma-Aldrich), and 1x 
HALT protease inhibitor cocktail (Thermo Scientific) for 15 minutes on ice.  Total 
protein was quantified using BCA protein assay (Thermo Scientific); separated by SDS-
PAGE; transferred to PVDF (Millipore) and probed with the indicated antibodies.  Bands 
were visualized using Pierce ECL Western Blotting Substrate (Thermo Scientific).  Anti-
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eIF4E, anti-CHK1, anti-4E-BP-1, anti-phospho-eIF4E S209, anti-phospho-4E-BP-1 
T37/46, anti-phospho-4E-BP-1 S65, anti-AKT, and anti-phospho-AKT s473 antibodies 
were purchased from Cell Signaling Technology.  Anti-β-actin and anti-eIF4G antibodies 
were obtained from Sigma-Aldrich and BD Biosciences, respectively.  Anti-Rad51 and 
anti-Rad17 antibodies were purchased from Santa Cruz Biotechnologies.  Donkey-anti-
rabbit and sheep-anti-mouse Horseradish Peroxidase conjugated secondary antibodies 
were purchased from GE Healthcare. 
Cell Cycle Analysis: Cell cycle phase distribution was determined by flow 
cytometric analysis.  Cells were trypsinized, fixed with 70% ethanol, stained with Guava 
Cell Cycle Reagent (Millipore), and analyzed with the Guava EasyCyte flow cytometer 
(Millipore). 
Apoptotic Cell Death:  Cells undergoing apoptosis were quantified according to 
annexin V staining (Annexin V Apoptosis Detection Kit, BD Biosciences).  Briefly, for 
each treatment condition cells were resuspended in 1x Annexin V Binding Buffer and 
incubated with Annexin V-Cy5 antibody in the dark at room temperature.  Hoechst 33258 
was added for live/dead discrimination and samples analyzed by flow cytometry (BD 
Biosciences LSRII flow cytometer). 
Immunofluorescent analysis of γH2AX foci:  To visualize foci, cells, grown in 
chamber slides, were fixed with 4% paraformaldehyde, permeabilized with 0.1% Triton 
X-100, and blocked with 1% bovine serum albumin (BSA) in PBS containing 5% goat 
serum.  The slides were incubated with antibody to phospho-H2AX (Millipore) followed 
by incubation with goat-anti-mouse-Alexa488 (Invitrogen) and mounted with Prolong 
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gold anti-fade reagent containing 4', 6-diamidino-2-phenylindole (Invitrogen) to visualize 
nuclei.  Cells were analyzed on a Zeiss upright fluorescent microscope. 
Mitotic Catastrophe:  Cells, grown in chamber slides, were fixed with a 10% 
neutral buffered formalin solution and incubated with  antibody to α-tubulin (Sigma-
Aldrich) followed by incubation with goat anti-mouse with Alexa-488 antibody and 
mounted with Prolong gold anti-fade reagent containing 4', 6-diamidino-2-phenylindole.  
Cells with nuclear fragmentation, defined as the presence of two or more distinct nuclear 
lobes within a single cell were classified as being in mitotic catastrophe. 
Cap-Binding Assay:  eIF4F cap complex formation was measured using m7-GTP 
batch chromatography (30).  Briefly, cells were lysed in 20mM Tris-HCl (pH 7.4), 
150mM NaCl, 1mM EDTA, 1mM EGTA, 1mM β-glycerophosphate, 1mM sodium 
orthovanadate, 1% Triton X-100, 0.2mM PMSF, 1x phosphatase inhibitor cocktails II 
and III (Sigma-Aldrich), and 1x HALT protease inhibitor cocktail (Thermo Scientific) for 
15m on ice.  400µg of lysate were pre-cleared for 1h at 4°C then incubated with m7-GTP 
Sepharose 4B beads (GE Healthcare) overnight at 4°C.  Beads were washed three times 
with lysis buffer; bound protein was eluted, denatured, and then separated using SDS-
PAGE followed by immunoblotting for eIF4G and eIF4E. 
RIP-Chip and Microarray Analysis:  The RIP-Chip kit and anti-eIF4E antibody 
were obtained from MBL International (Woburn, Ma); the procedure was performed in 
biological triplicate according to manufacturer’s protocol.  Briefly, 107 cells were washed 
followed by lysis and isolation of the cytoplasmic fraction, which was then pre-cleared 
with Protein-A sepharose beads at 4°C for 1h.  The lysates were then split into equal 
parts; half was incubated with eIF4E conjugated Protein-A sepharose beads and half was 
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incubated with IgG conjugated Protein-A sepharose beads (negative control).  The RNA 
associated with each type of bead was then eluted and isolated.  
The isolated RNA was amplified using GeneChip 3’ IVT Express Kit 
(Affymetrix) and hybridized to GeneChip Human genome U133A 2.0 array chips 
(Affymetrix) per manufacturer’s protocol.  Using Affymetrix Expression Console, Mas5 
normalization was performed on all data sets.  An expression cutoff of p < 0.05 was 
implemented to filter all data.  The negative control expression values (IgG) were 
subtracted from their respective sample counterparts on a probeset basis; the three 
replicates were then averaged.  Probesets that had fold increase > 1.5 (radiation to 
control) or went from an expression value less than or equal to 0 before radiation to 
positive expression value after radiation (not bound to bound) were then further analyzed 
by Ingenuity Pathway Analysis (IPA).  IPA curates a database that is defined by 
interactions reported in the literature.  Gene lists are uploaded to IPA and network 
analysis was performed.  The IPA analysis was performed using the IPA database 
available in October-December 2011.  The data have been deposited in NCBI’s Gene 
Expression Omnibus (31) and are accessible through GEO Series accession number GSE36179. 
In vivo Tumor Growth Delay:  Eight to ten-week-old female athymic nude mice 
(NCr nu/nu; NCI Animal Production Program, Frederick, MD) were used in these 
studies.  Animals are caged in groups of 5 or less and fed animal chow and water ad 
libitum.  A single cell suspension of U251 (107 cells), Miapaca-2 (5 x 106 cells), or PSN1 
(5 x 106 cells) was injected subcutaneously into the right hind leg.  When tumors grew to 
a mean volume of approximately 210 mm3 (U251) or 180 mm3 (PSN1) mice were 
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randomized into four groups: vehicle treated controls (5% N-Methylpyrrolidone, 15% 
Polyvinylpyrrolidone, and 80% water), drug treated (PP242 or INK128), radiation (at 
dose specified for specific experiment), or drug/radiation combination.  The treatment 
protocols are described in detail in the results sections of their respective chapters.  
Radiation was delivered locally using a Pantak X Ray source with animals restrained in a 
custom designed lead jig.  To obtain tumor growth curves, perpendicular diameter 
measurements of each tumor were measured 2 to 3 times per week with a digital caliper 
and volumes were calculated using a formula (L x W2) / 2.  Data are expressed as mean ± 
SEM tumor volume.  Each experimental group contained between 5-7 mice.  All animal 
studies were conducted in accordance with the principles and procedures outlined in the 
NIH Guide for Care and Use of Animals.  
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CHAPTER 3: 
Translation Initiation Factor eIF4E is a Target for Tumor Cell Radiosensitization 
 
Note to Reader 
 Portions of the results have been previously published (Hayman TJ, Williams ES, 
Jamal M, Shankavaram UT, Camphausen K, and Tofilon PJ (2012). Translation initiation 
factor eIF4E is a target for tumor cell radiosensitization. Cancer Res  72, 2362-2372.) and 
are utilized with permission of the publisher.  Eli Williams helped design and complete 
experiments; Muhammad Jamal helped with data acquisition; Uma Shankavaram assisted 
with bioinformatics analysis; Kevin Camphausen and Philip Tofilon helped to design and 
oversee project. 
Abstract 
A core component in the cellular response to radiation occurs at the level of 
translational control of gene expression.  Because a critical element in translation control 
is the availability of the initiation factor eIF4E, which selectively enhances the cap-
dependent translation of mRNAs, we investigated a regulatory role for eIF4E in cellular 
radiosensitivity.  eIF4E knockdown enhanced the radiosensitivity of tumor cell lines but 
not normal cells.  Similarly, pharmacological inhibition of eIF4E with ribavirin also 
enhanced tumor cell radiosensitivity.  In tumor cells eIF4E attenuation did not affect cell 
cycle phase distribution or radiation-induced apoptosis, but it delayed the dispersion of 
radiation-induced γH2AX foci and increased the frequency of radiation-induced mitotic 
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catastrophe.  Radiation did not affect 4E-BP1 phosphorylation or cap-complex formation 
but it increased eIF4E binding to >1000 unique transcripts including many implicated in 
DNA replication, recombination and repair.  Taken together, our findings suggest that 
eIF4E represents a logical therapeutic target to increase tumor cell radiosensitivity. 
Introduction 
In eukaryotic cells the majority of translation occurs in a cap-dependent manner, 
which involves eIF4E binding to the 7-methyl guanosine (m7G) cap on the 5’ end of an 
mRNA resulting in the recruitment of eIF4G and eIF4A to form the eIF4F initiation 
complex and subsequently ribosome binding (32).  This process is a final and rate-
limiting step in translation initiation and is highly dependent on the availability of eIF4E.  
Elevated levels of eIF4E preferentially enhance the translation of mRNAs with long, 
highly structured 5’ untranslated regions (UTRs), which tend to encode proteins related 
to cell proliferation and survival such as c-myc, Bcl2, FGF-2, and survivin (33-34).  
Moreover, eIF4E also promotes the nucelocytoplasmic shuttling of select mRNAs such as 
cyclin D and ornithine decarboxylase (ODC) with their increased cytoplasmic levels 
leading to increased translation (33-34).  Thus, via at least 2 mechanisms eIF4E plays a 
critical role in the regulating gene translation. 
At the cellular level elevated eIF4E has been implicated in oncogenesis (35).  
Overexpression of eIF4E has been shown to drive the malignant transformation of 
primary human mammary epithelial cells (36) and immortalized rodent cells (37) with 
ectopic expression of eIF4E in animal models increasing the incidence of a variety of 
tumor types (38).  Evaluation of biopsy and surgical specimens indicates that eIF4E 
expression is frequently elevated in a number of human cancers including breast, 
15 
 
prostate, head and neck, and lung (33, 39).  Increased eIF4E levels have also been 
associated with malignant progression (40) as well as poor therapeutic outcome (41-42).  
Finally, in preclinical models inhibition of eIF4E activity results in cytotoxicity for tumor 
but not normal cells (42-43).  Given eIF4E’s function in the translational control of gene 
expression and data suggesting that it contributes to the neoplastic phenotype, we have 
defined the consequences of eIF4E knockdown on the radiosensitivity of tumor and 
normal cell lines.  The data presented here indicate loss of eIF4E activity selectively 
enhances tumor cell radiosensitivity through an inhibition of DNA double strand break 
repair.  In addition, radiation is shown to significantly increase the number of mRNAs  
Results 
 To determine whether eIF4E plays a role in determining radiosensitivity 3 tumor 
lines (MDA-MB-231, breast carcinoma; DU145, prostate carcinoma; A549, lung 
carcinoma) and 2 normal cell lines (HMEC mammary epithelial and MRC9 lung 
fibroblasts) were evaluated using the clonogenic survival assay.  Each cell line was 
treated with siRNA specific to eIF4E or non-targeted siRNA; 72h after transfection 
cultures seeded at clonal density for survival analysis.  As shown in Figure 2A, siRNA to 
eIF4E reduced eIF4E protein levels significantly when compared to non-targeted siRNA.  
The effects of eIF4E knockdown alone on the survival of each cell line are shown in 
Figure 2B.  eIF4E knockdown significantly reduced clonogenic survival of all three 
tumor lines.  As compared to the tumor cells, eIF4E knockdown induced significantly 
less cytotoxicity in the normal cell lines.  These results are consistent with previous 
reports showing that tumor cells are more dependent on eIF4E for survival than normal 
cells (43-44). 
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 The effects of eIF4E knockdown on cellular radiosensitivity are shown in Figure 
3.  For this study cells were treated as described above, trypsinized and irradiated 6h after 
seeding.  Treatment with siRNA to eIF4E resulted in an increase in the radiosensitivity of 
each of the 3 tumor cell lines as compared to non-targeted siRNA (Figure 3A-C).  The 
dose enhancement factors at a surviving fraction of 0.1 (DEFs) for MDA-MB-231, 
DU145, and A549 were 1.34, 1.24, and 1.44, respectively.  The same experiment was 
performed on the two normal cell lines (Figure 3D-E).  In contrast to the tumor cell lines, 
eIF4E knockdown had no effect on the radiosensitivity of the two normal cell lines.  
These results suggest that eIF4E contributes to survival after irradiation of tumor but not 
normal cells. 
 To investigate the mechanism responsible for the tumor cell radiosensitization 
induced by eIF4E knockdown we focused on MDA-MB-231 cells.  Given that eIF4E has 
been reported to influence translation of a number of proteins involved in cell cycle 
regulation (45), a reduction in eIF4E levels could result in cell cycle phase redistribution.  
Because such an effect can be a critical factor in determining radiosensitivity, flow 
cytometry was used to determine the cell cycle distribution in MDA-MB-231 cells after 
eIF4E knockdown.  As shown in Figure 4A the cell cycle phase distribution pattern was 
not significantly altered at 72h after exposure to eIF4E siRNA as compared to non-
targeted siRNA.  These results indicated that redistribution of cells into a radiosensitive 
phase of the cell cycle does not account for eIF4E knockdown-mediated enhancement in 
radiation-induced cell killing. eIF4E knockdown has been shown to induce apoptosis in 
breast cancer cell lines (46).  To determine whether the increase in radiosensitivity 
resulting from eIF4E knockdown was due to an enhancement of radiation-induced 
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Figure 2:  Effect of eIF4E knockdown on clonogenic cell survival.  Cultures were 
transfected with siRNA specific to eIF4E (eIF4E KD) or non-targeted siRNA (Scramble).  
A) Representative immunoblots from each cell line showing extent of eIF4E protein 
reduction 72h after transfection.  B) 72h post-transfection cells were plated at specified 
densities and colony-forming efficiency was determined 10-14 days later.  Surviving 
fractions for eIF4E KD cells were calculated after normalizing to the surviving fraction 
obtained for cells receiving the scrambled siRNA.  Values shown represent the means + 
SE for 3-4 independent experiments.  *p < 0.04 according to Student’s t test (all tumor 
cell lines compared to HMEC). 
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Figure 3:  The effects of eIF4E knockdown on cellular radiosensitivity.  A) MDA-MB-
231, B) A549, C) DU145, D) MRC9, and E) HMEC cells were transfected with non-
targeted siRNA (Scramble) or siRNA specific for eIF4E (eIF4E KD).  72h post-
transfection cells were plated, allowed to attach for 6h, and irradiated.  Colony-forming 
efficiency was determined 10-14 days later and survival curves were generated after 
normalizing for cell killing from siRNA alone.  DEFs were calculated at a surviving 
fraction of 0.1.  Values shown represent the mean + SE for 3-4 independent experiments.  
* p < 0.05; ** p < 0.1 according to Student’s t test. 
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apoptosis, we determined Annexin V staining at 24 and 48h after exposure to 6 Gy for 
cells exposed to siRNA to eIF4E and non-target siRNA.  As expected for a solid tumor 
cell line, radiation alone did not induce a significant apoptotic response, and this response 
was not significantly enhanced with eIF4E knockdown (data not shown).  These results 
indicate that apoptosis is not the mechanism of cell death following radiation in eIF4E 
deficient cells. 
 The critical lesion responsible for radiation-induced cell death is the DNA double 
strand break (DSB).  Because γH2AX foci correspond to radiation-induced DSBs and 
their dispersal correlates with DSB repair (47-48), the effects of eIF4E knockdown on 
radiation-induced γH2AX were evaluated in MDA-MB-231 cells (Figure 4B).  At 1h 
after exposure to 2 Gy no difference in foci levels was detected between control cells 
(non-targeted siRNA) and cells in which eIF4E was knocked down, suggesting that 
eIF4E levels have no effect on the initial level of radiation-induced DSBs.  However, at 6 
and 24h after irradiation (2 Gy) the number of γH2AX foci remaining in the eIF4E 
knockdown cells was significantly greater than in control cells.  Additionally, a 
significant level of γH2AX foci retention was observed in eIF4E deficient cells 24 h after 
4 Gy when compared to non-targeted siRNA treated cells.  These data suggest that eIF4E 
knockdown results in an inhibition of radiation-induced DNA DSB repair. 
 Given the apparent inhibition of DSB repair and no increase in radiation-induced 
apoptosis after eIF4E knockdown, we hypothesized that the mechanism of cell death 
involved an increase in radiation-induced mitotic catastrophe.  Cells with nuclear 
fragmentation, defined as the presence of two or more distinct nuclear lobes within a 
single cell, were classified as being in mitotic catastrophe.  As shown in Figure 4C, eIF4E 
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Figure 4:  Mechanism of radiosensitization by eIF4E knockdown.  In the following 
experiments MDA-MB-231 cells were transfected with siRNA specific to eIF4E (eIF4E 
KD) or non-targeted siRNA (Scramble).  All experiments were carried out 72 hours post-
transfection.  A) Cell cycle phase distribution was determined. Values represent the mean 
of three independent experiments.  B) Cells were irradiated with 2 or 4Gy and collected 
at the specified time; γH2AX foci were counted in at least 50 cells per condition.  Values 
shown represent the means + SE for 3 independent experiments, *p < 0.04 according to 
Student’s t test (eIF4E KD compared to scramble).  C) Cells were irradiated (2 Gy) and 
collected at the specified time points.  Cells were classified as being in mitotic 
catastrophe by the presence of nuclear fragmentation, which was defined as a single cell 
containing two or more distinct nuclear lobes.  At least 50 cells per condition were 
scored.  Values represent the mean + SE for 3 independent experiments.  *p< 0.04
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knockdown resulted in a significant increase in the percentage of cells undergoing mitotic 
catastrophe at 48 and 72h after exposure to 2 Gy.  These results suggest the increase in 
radiosensitivity following eIF4E knockdown involves the inhibition of DSB repair after 
radiation, which then contributes to an increase in the number of cells undergoing mitotic 
catastrophe. 
 A critical regulator of eIF4E is 4E-BP1, which binds to eIF4E preventing its 
interaction with eIF4G and subsequently eIF4F complex formation (49).  
Phosphorylation of 4E-BP1 releases eIF4E resulting in eIF4F formation and cap-
dependent translation (28); it has been reported that exposure of normal human cell lines 
to 8 Gy induces 4E-BP1 phosphorylation (25).  However, exposure of MDA-MB-231 
cells to 2 Gy under conditions used for clonogenic survival analysis (Figures 1-2) did not 
increase 4E-BP phosphorylation (Figure 5A), with densitometry shown in Figure 5B.  
Post-translational activation of eIF4E via phosphorylation at S209 has also been shown to 
influence eIF4E activity (50); radiation had no effect on eIF4E phosphorylation (Figure 
5A).  m7-GTP batch chromatography is a standard approach for assessing eIF4F cap-
complex formation (25, 30).  Consistent with the lack of effect on 4E-BP1 and eIF4E 
phosphorylation, radiation had no effect on cap-complex formation, as evidenced by the 
lack of a change in bound eIF4G levels (Figure 5B).  These results suggest that radiation 
does not increase the overall activity of eIF4E or cap-dependent translation initiation in 
general. 
 It is important to emphasize that eIF4E binding to a mRNA exists downstream of 
a multitude of complex post-transcriptional changes of which many are subject to 
regulation by radiation (as noted in Introduction).  To further investigate the role of 
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Figure 5:  The effect of radiation on eIF4E activation.  A) MDA-MB-231 cells were 
irradiated (2 Gy) and collected at the specified times and subjected to immunoblot 
analysis.  Actin was used as a loading control.  B) Densitometric quantitation of 
phosphor:total 4E-BP1 levels from immunoblot in Panel A.  C) m7-GTP affinity 
chromatography was performed on MDA-MB-231 cells that were irradiated and collected 
1h after 2 Gy, and compared to unirradiated counterparts.  m7-GTP bound and unbound 
proteins (flow through) were resolved via SDS-PAGE followed by immunoblot analysis.  
eIF4E was used as a loading control.  Blots are representative of two independent 
experiments. 
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eIF4E in mediating these post-transcriptional changes induced by radiation, we 
determined whether radiation influences the mRNAs bound to eIF4E using RIP-Chip 
analysis (RNA-Binding protein immunoprecipitation followed by microarray analysis of 
the bound mRNAs).  In this experiment, MDA-MB-231 cells were irradiated (2 Gy), 6h 
later cytoplasmic lysates were collected and eIF4E was immunoprecipitated.  RNA was 
then eluted from the immunoprecipitated eIF4E and subjected to microarray analysis, 
which was compared to the same process performed on unirradiated cells.  In this 
analysis irradiation was found to increase the eIF4E binding of 1124 unique transcripts 
(either fold increase > 1.5 or not bound to bound as described in Materials in Methods).  
The full list of genes is shown in Table A1 (Appendices). These transcripts were then 
subjected to Ingenuity Pathway Analysis (IPA), which distributes genes into networks 
defined by known interactions and then matches these networks with specific biologically 
significant pathways.  The top ten biological functions associated with the eIF4E bound 
mRNAs are shown in Figure 6A.  The specific functions of the genes contained within 
the DNA Replication, Recombination, and Repair category are further delineated (Figure 
6B) and shown to encompass many aspects of the DNA damage response, including DSB 
repair and checkpoint control.  To illustrate the interactions between the mRNA whose 
binding to eIF4E was affected by radiation, the top ten networks and their associated 
functions are shown in Table 1.  Whereas there are numerous functions associated with 
these networks, of particular interest with respect to radiosensitivity is Network 4 (Figure 
6C), which includes genes associated with DNA Replication, Recombination and Repair.  
Notably, this network contains several hub proteins: Rad17, Rad51, and CHEK1 each of 
which influences several other proteins.  Network 6, which involves genes participating 
24 
 
 
 
Figure 6:  Rip Chip analysis of the effects of radiation on eIF4E mRNA clients.  MDA-MB-231 cells were irradiated 
(2 Gy) and collected 6 hours later.  eIF4E was immunoprecipitated, RNA bound to eIF4E was isolated and subjected to 
microarray analysis and mRNAs whose binding to eIF4E after irradiation were classified using IPA.  A) Left panel: top 
ten biological functions (containing 100 or more genes) of the mRNAs whose binding to eIF4E was increased by 
radiation; right panel: the biological functions of the mRNAs (with greater than 10 genes) within the DNA Replication, 
Recombination, and Repair category are further delineated. B) Network 4 is shown with dark red indicating not bound 
to bound and lighter red indicating fold increase > 1.5.  C) Network 6 is shown with dark red indicating not bound to 
bound and lighter red indicating fold increase > 1.5.  D) Immunoblot analysis of DNA Damage Response related 
proteins predicted by RIP-Chip analysis to be induced by radiation.  MDA-MB-231 cells were irradiated (6 Gy) and 
collected at the specified times.  Actin was used as a loading control.  Blots are representative of two independent 
experiments. 
A. B. 
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Table 1:  Functions of mRNAs increasingly bound to eIF4E after irradiation	  
Functions associated with the top ten networks for genes that were increasingly bound to eIF4E after radiation 
(2Gy 6h) in MDA-MB-231 cells. 
 ID   Score Focus  Molecules Top Functions 
1   46 33 Genetic Disorder, Skeletal and Muscular Disorders, Neurological Disease 
2  44 33 Cancer, Cellular Movement, Connective Tissue Development and Function 
3  44 32 Cancer, Infectious Disease, Respiratory Disease 
4  42 31 DNA Replication, Recombination, and Repair, Cell Cycle, Gene Expression 
5  39 30 Cellular Function and Maintenance, Cellular Compromise, Tissue 
Development 
6  39 30 RNA Post-Transcriptional Modification, Dermatological Diseases and 
Conditions, Genetic Disorder 
7  37 29 Post-Translational Modification, Cellular Movement, Cell Cycle 
8  35 28 Amino Acid Metabolism, Small Molecule Biochemistry, Cellular Assembly 
and Organization 
9  33 27 Post-Translational Modification, Protein Degradation, Protein Synthesis 
10   32 27 Endocrine System Development and Function, Lipid Metabolism, Molecular 
Transport 
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in RNA post-transcriptional processing is shown in Figure 6D; it also includes several 
hub proteins (e.g., ELAVL1, snRNP, and PRPF4).  This network illustrates eIF4E’s 
capacity to modulate the post-transcriptional regulation of gene expression both 
directly,as an RNA Binding Protein (RBP), and indirectly through its influence on other 
proteins involved in post-transcriptional mRNA processing.  The data presented in Figure 
6 indicate that genes targeted by eIF4E after irradiation are not a random collection, but 
instead are functionally related mRNA subsets. 
 Given eIF4E’s role in cap-dependent translation, an increase in the binding of a 
given mRNA to eIF4E would be expected to result in an increase in its corresponding 
protein product.  Thus, to investigate the functional significance of the RIP-Chip analysis, 
we determined the effects of radiation on the levels of three of the hub proteins from 
Network 4 (CHK1, Rad17, and Rad51), proteins with established roles in the DNA 
damage response (51-53).  MDA-MB-231 cells were irradiated (6 Gy) and collected for 
protein analysis at times out to 24h.  As shown in Figure 6E, the levels of CHK1, Rad17, 
and Rad51 were increased after irradiation, consistent with a correlation between the 
mRNAs whose binding to eIF4E was increased after irradiation and the increase in their 
corresponding protein. 
 Because the data presented above suggest that eIF4E may serve as a target for 
radiosensitization, we determined the effects of ribavirin on the radiosensitivity of MDA-
MD-231 cells.  Whereas initially described as an anti-viral therapy, recent laboratory 
studies have shown that ribavirin inhibits eIF4E activity (44, 54) providing a basis for 
clinical trials as an anti-neoplastic treatment.  To test whether pharmacological inhibition 
of eIF4E results in similar radiosensitization to eIF4E knockdown, MDA-MB-231 cells 
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Figure 7:  Effects of ribavirin on radiosensitivity.  MDA-MB-231 cells were plated for 
clonogenic survival analysis and treated with 50 µM ribavirin for 1h, followed by 
radiation. Ribavirin was left on for the duration of the clonogenic assay.  Values represent 
the mean + SE for 3 independent experiments.
28 
 
were plated for clonogenic survival analysis, treated with 50 µM ribavirin, a 
concentration that inhibits eIF4E activity in breast cancer cells (42), for 1h and irradiated.  
Ribavirin treatment alone reduced the surviving fraction to 0.30 + 0.07, similar to that 
induced by eIF4E knockdown.  As shown in Figure 7 this ribavirin treatment protocol 
enhanced the radiosensitivity of MDA-MB-231 cells with a DEF of 1.35.  These results 
suggest that targeting eIF4E may be a valid strategy for radiosensitization. 
Discussion 
Based on γH2AX data, the mechanism through which eIF4E influences tumor cell 
radiosensitivity appears to involve DNA DSB repair.  It is unlikely that this translation 
initiation factor directly participates in the DSB repair process suggesting that the 
mechanism involves an aspect of the post-transcriptional regulation of gene expression.  
We have previously shown that radiation affects the translation of certain subsets of 
mRNAs through recruitment of existing mRNAs to and away from polysomes (21-22).  
The RIP-Chip results presented here showing that radiation enhances the binding of 
eIF4E to specific mRNA subpopulations is consistent with the radiation-induced 
translational control of gene expression.  Moreover, a major subset of the mRNAs whose 
eIF4E binding was increased by radiation corresponded to those coding for proteins 
involved in DNA Replication, Recombination and Repair and Cell Cycle, which could 
then play a role in determining radiosensitivity.  A role for radiation-induced gene 
translation in the cell survival response is suggested by the recent work by Singh et.al. 
showing that DNA DSBs are generated not only from the initial radiation deposition, but 
also from chemical processing occurring for hours after exposure to radiation (55).  In 
this situation a requirement for the rapid increase in DNA repair proteins may contribute 
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to the recovery process.  However, based on the experiments using siRNA to knockdown 
eIF4E (Figure 3), it is not possible to determine whether the tumor cell radiosensitization 
was the result of eliminating the radiation-induced enhancement in gene translation 
and/or changes in mRNA translation that are induced before irradiation.  Along these 
lines, the eIF4E inhibitor ribavirin enhanced MDA-MD-231 cells radiosensitivity when 
given 1h before irradiation (Figure 7).  Clearly, the mechanisms through which the 
reduction of eIF4E levels affect radiation-induced tumor cell killing require additional 
investigation. 
Whereas knockdown of eIF4E levels induced radiosensitization of tumor cells, 
the same procedure had no effect on the radiosensitivity of normal cell lines.  This tumor 
selectivity may involve the increased dependence of tumor cells on eIF4E activity.  For 
both ribavirin and an antisense oligonucleotide (ASO) to eIF4E, tumor cells are more 
sensitive in terms of cytoxicity than normal cells. (42-43)  Consistent with these previous 
findings knockdown of eIF4E in the current study reduced survival of the tumor cell lines 
to a greater degree than on the normal cells.  eIF4E serves as a funnel point (56) for a 
number of oncogenic pathways reflecting the consequences of activation of RTKs along 
with Ras and PI3K pathways (34, 57-58).  The elevated eIF4E availability under these 
circumstances then putatively enhances the translation selectively and disproportionally 
of genes mediating cell proliferation and survival and other processes contributing to the 
neoplastic phenotype (59).  It would seem that many of the eIF4E dependent genes whose 
translation is increased in tumor cells may also contribute to the ability of the cell to 
survive after a variety of insults including radiation. 
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Whereas the mechanisms remain to be completely defined, in the study described 
here knockdown of eIF4E was shown to enhance the radiosensitivty of 3 human tumor 
lines while having no effect on the radiosensitivity of 2 normal cell lines.  These data 
suggest that eIF4E provides a tumor selective target for radiosensitization.  Because 
laboratory data has already indicated that eIF4E contributes to the neoplastic phenotype, 
strategies for targeting eIF4E are being investigated at the preclinical and clinical setting.  
One approach is the use of an ATP-active site inhibitor of mTOR.  In contrast to 
allosteric mTOR inhibitors, i.e. rapalogs, the active site inhibitors completely inhibit 
mTORC1 function, preventing the phosphorylation of the mTOR substrate 4E-BP1, 
which prevents release of eIF4E and limits its availability for eIF4F formation (60).  An 
additional approach has been the development of small molecule inhibitors of the eIF4E-
eIF4G interaction, which prevent complete formation of the eIF4F cap-complex (61).  
Inhibiting eIF4E expression with an eIF4E ASO has been shown to reduce eIF4E levels 
and to inhibit tumor cell growth in preclinical models (43).  Finally, there has been 
considerable pre-clinical data evaluating ribavirin as an eIF4E activity inhibitor (44, 54).  
The mTOR active site inhibitors, ribavirin, and the eIF4E ASO are currently in clinical 
trials both as single agents (59, 62-63), as well as in combination with chemotherapy 
(64).  The data presented in the current study showing that reduced eIF4E expression 
selectively enhances tumor radiosensitivity supports the clinical evaluation of these 
eIF4E-targeting strategies in combination with radiotherapy. 
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CHAPTER 4: 
Ribosomal Protein S6 Kinase 1 as a Determinant of Cellular Radiosensitivity 
Abstract 
The ribosomal protein S6 kinases (S6Ks) are downstream effectors of the mTOR 
kinase and regulate a wide variety of cellular processes including translation initiation, 
ribosome biogenesis, and cell growth.  Furthermore, the S6Ks are activated in a variety of 
malignancies and are associated with an enhancement of the malignant phenotype.  To 
determine the role of S6K1 in regulating intrinsic cellular radiosensitivity, a panel of 3 
tumor cell lines initiated tumors of different histologic origin and one normal cell line 
were treated with siRNA to S6K1.  S6K1 knockdown enhanced the radiosensitivity of all 
3 tumor lines as determined by clonogenic survival analysis.  In contrast, S6K1 
knockdown had no effect on the cellular radiosensitivity of the normal lung fibroblast 
line, MRC9.  S6K1 knockdown increased expression of PDCD4, a tumor suppressor 
implicated in the cellular DNA damage response.  Taken together these results suggest 
S6K1 is a potential tumor specific target for the enhancement of cellular radiosensitivity, 
and that its effects may be in part mediated by increased expression of PDCD4. 
Introduction 
  As described in Chapter 2 we have shown that eIF4E, a critical and rate-limiting 
component of the translational machinery determines tumor cell radiosensitivity, and 
plays an integral role in the translational response to radiation.  In addition to eIF4E, the 
p70 ribosomal protein S6 kinases (S6Ks) have a critical role in the regulation of mRNA 
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translation (65).  There are two distinct genes encoding the p70 S6Ks (S6K1 and S6K2) 
(49).  Most work characterizing these proteins has been done with S6K1, whereas there is 
less known about the function of S6K2 (49).  S6K1 is a downstream effector of mTORC1 
and regulate a wide variety of cellular processes including translation initiation, ribosome 
biogenesis, lipid synthesis, de novo pyrimidine synthesis, and cell growth (66).  It exerts 
control over the translational machinery at multiple levels.  The first identified substrate 
of S6K1 was ribosomal protein S6 (rpS6) a component of the 40S ribosome subunit that 
positively regulates translation and protein synthesis (66).  There is conflicting evidence 
that S6K1 selectively regulates the translation of mRNAs containing 5’ TOP (terminal 
oligopyrimidine) tracts (67-68).  These mRNAs typically encode ribosomal proteins and 
translation factors (69).  S6K1 also controls levels of the tumor suppressor, PDCD4 
(programmed cell death 4) (70), a negative regulator of translation that inhibits the 
translation initiation factor eIF4A (71), a RNA helicase that is a component of the eIF4F 
cap-complex.  eIF4A helicase activity is important for the unwinding of 5’ UTRs that are 
highly structured (65).  PDCD4 phosphorylation by S6K is followed by ubiquitylation via 
the ubiquitin	   ligase	   SCF-­‐β-­‐TRCP, and proteosomal degradation (70).  Degradation of 
PDCD4 causes the release of eIF4A from PDCD4 and allows eIF4A to associate with the 
eIF4F cap-complex (70).   Importantly, in the context of our study, PDCD4 has been 
linked to the cellular DNA damage response (72-73).  In particular, PDCD4 knockdown 
of the human tumor cell line, HeLA, has been shown to decrease sensitivity to UV 
irradiation (74).  Additionally, S6K enhances translation via phosphorylation of the 
initiation factor eIF4B.  eIF4B phosphorylation by S6K1 enhances the helicase activity of 
eIF4A (65).  This activation of eIF4B has been shown to correlate with its ability to 
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promote the translation of mRNAs with long and structured 5’ UTRs (29).  Lastly, S6K1 
phosphorylates and inactivates the repressor of translation elongation eEF2K (eukaryotic 
elongation factor 2 kinase).  eEF2K functions to phosphorylate and inhibit eEF2, a 
protein that mediates the translocation step of translation elongation (75).   
 S6K is activated, either through phosphorylation, or overexpression in a wide 
variety of malignancies and has been associated with poor prognosis in breast cancer (66) 
and gliomas (76).  Activation in breast (77), colon (78), and liver tumors (79) was 
associated with a more malignant phenotype.  S6K has been associated with glial 
transformation (80).  Additionally, in several breast cancer cell lines, S6K has been 
associated with regulating cell survival (81).  Activation of the mTOR/S6K pathway has 
also been associated with resistance to traditional chemotherapies (e.g. cisplatin) (66).  
Several factors (EGF, HGF, and SCF) and cytokines signal through S6K to partially exert 
their oncogenic activity (66).  As such there has been considerable interest in the 
development of agents targeting S6K, with several in clinical trials: LY2584702 and 
XL418 (66).  As radiation influences the translation of specific subsets of mRNAs, and 
S6K1 regulates translation, we addressed on the role of S6K1 in the cellular 
radioresponse in both tumor and normal cells.   Reduction of S6K1 levels via siRNA 
knockdown enhanced the radiosensitivity of 3 tumor lines but not of normal lung 
fibroblasts.  Furthermore, consistent with previous literature, S6K1 knockdown induced 
the expression of PDCD4 in A549 cells.   These data provide initial insight into the role 
of S6K1 in regulating the cellular radioresponse as well as provide the basis for further 
studies investigating the application of S6K inhibitors with radiotherapy. 
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Results 
 To test the hypothesis that S6 kinase plays a role in determining cellular 
radiosensitivity we employed a siRNA mediated approach to reduce S6K1 levels.  Using 
3 tumor lines originated from tumors of distinct histologies (A549 lung adenocarcinoma, 
MDA-MB-231 breast carcinoma, and Panc1 pancreatic adenocarcinoma) and 1 normal 
cell line (MRC9 lung fibroblasts) the effects of S6K1 knockdown on cellular 
radiosensitivity were evaluated with the clonogenic survival assay.  Each cell line was 
treated with siRNA specific to S6K1 (S6K KD) or non-targeted siRNA (scramble); 72h 
after transfection cultures were trypsinized to generated a single cell suspension and 
seeded at clonal density for survival analysis.  The effects of S6K1 knockdown on cell 
survival were determined.  As shown in Figure 8A, siRNA to S6K1 reduced S6K1 
protein levels significantly when compared to non-targeted siRNA.  Treatment with 
S6K1 siRNA reduced the surviving fraction to 0.77 ± 0.03, 0.68 ± .10, 0.30 ± .01, and 
0.11 ± 0.05 in A549, MDA-MB-231, Panc1, and MRC9 cells respectively.  These data 
indicate that in vitro S6K knockdown does not have a consistent cytotoxic effect with 
respect to tumor versus normal cells. 
The effects of S6K1 knockdown on cellular radiosensitivity are shown in Figure 
8.  For this study cells were treated as described above, and irradiated 6h after seeding.  
Treatment with siRNA to S6K1 resulted in an increase in the radiosensitivity of each of 
the 3 tumor cell lines as compared to non-targeted siRNA (Figure 8B-D).  The dose 
enhancement factors at a surviving fraction of 0.1 (DEFs) for A549, MDA-MB-231, and 
Panc1 were 1.35, 1.42, and 1.44, respectively.  The same experiment was performed on 
the normal lung fibroblast cell line (Figure 8E).  In contrast to the tumor cell lines, S6K1 
knockdown had no effect on the radiosensitivity of the normal cell line, MRC9.  These 
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Figure 8:  The effects of S6K1 knockdown on cellular radiosensitivity.  Cells were 
transfected with siRNA to S6K1 (S6K KD) or non-targeted siRNA (Scramble). A, 
immunoblots from each cell line showing extent of S6K protein reduction 72 hours after 
transfection.  A549 (B), MDA-MB-231 (C), Panc1 (D), and MRC9 (E), cells were plated 
seventy-two hours posttransfection, allowed to attach for 6 hours, and irradiated.  
Colony-forming efficiency was determined 10 to 14 days later, and survival curves were 
generated after normalizing for cell killing from siRNA alone.  DEFS were calculated at 
a surviving fraction of 0.1. 
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Figure 9:  The effects of S6K1 knockdown on PDCD4 expression.  A) Immunoblot 
analysis 6K1 and PDCD4 expression in untreated cells (control) or cells transfected with 
siRNA to S6K1 (S6K KD) or  non-targeted siRNA (Scramble).  Actin was used as a 
loading control. 
37 
 
results suggest that S6K1 contributes to survival after irradiation of tumor but not normal 
cells. 
As described in the Introduction the expression of the tumor suppressor PDCD4 
has been shown to be controlled by S6K (70).  To determine whether S6K knockdown 
results in increased expression of PDCD4 in the cell lines studied immunoblot analysis of 
A549 and Panc1 cells treated with siRNA to S6K or non-targeted siRNA was performed.  
The results of this analysis are shown in Figure 9.  In both cell lines PDCD4 expression 
was increased upon treatment with siRNA specific to S6K relative to the non-targeted 
siRNA control, consistent with previous reports. 
Discussion 
 Whereas the mechanism of radiosensitization remains to be defined, in the study 
presented here knockdown of S6K1 was shown to increase the radiosensitivity of 3 tumor 
lines initiated from tumors of different histologies.  In contrast to the 3 tumor cell lines 
tested, S6K knockdown had no effect on the cellular radiosensitivity of the normal lung 
fibroblast line MRC9.  In order to make a definitive conclusion about the possible tumor 
specificity of S6K1 as a target for enhancing radiosensitivity, these results should be 
extended to other normal cell lines.  However, our initial investigations suggest that 
S6K1 appears to be a potential tumor selective target.  Whereas we have not defined the 
exact mechanisms regarding this potential tumor selectivity, there are numerous studies,  
both pre-clinically and clinically, showing over-expression and hyperactivation of S6K in 
tumor versus normal tissue (66, 76-79).  Furthermore, as described in the Introduction, 
S6K is controlled primarily by mTORC1.  Numerous genetic alterations and upstream 
signaling events (e.g. Ras mutations and PI3K/AKT activation) that affect mTORC1 
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signaling have been reported in the context of oncogenesis and tumor progression (82).  
Additionally, S6K plays an important regulatory role in the control of mRNA translation 
(49).  Data from our laboratory have shown radiation to control gene expression primarily 
through regulation of gene translation (21-22).  These experiments also examined the 
translational response to radiation in tumor versus normal cells (21).  Importantly tumor 
cells and normal cells had strikingly different translational responses to ionizing radiation 
exposure (21).  It is possible to speculate that this potential tumor selective enhancement 
in radiosensitization seen with S6K1 knockdown is due to the aforementioned differences 
in S6K regulation and activity.  Determining the differences responsible for this potential 
tumor selectivity in the context of S6K1 as a target for radiosensitization will be the 
subject for future investigation. 
 In the context of DNA damage, PDCD4 has been shown to play a role in 
determining cell survival after exposure to DNA damage.  Specifically, PDCD4 
knockdown of HeLa cells has been shown to increase survival to ultraviolet radiation 
(74).  This affect was attributed to PDCD4’s ability to suppress the translation of p53 
responsive genes, such as p21 and GADD45a (74).  While work remains to be done in 
establishing a causal role of PDCD4 in mediating S6K1 knockdown-induced 
radiosensitization, our results are in general agreement with this study as we show that 
S6K knockdown increases PDCD4 expression and decreases cell survival after exposure 
to ionizing radiation. 
In addition, as described in the introduction, S6K1 plays an important role in the 
regulation of cap-dependent translation through its control of eIF4A.  eIF4A has been 
shown to selectively control the translation of oncogenic transcripts (83).  Silvestrol, a 
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naturally occurring compound, has been reported to inhibit the activity of eIF4A and 
suppress translation of specific subsets of oncogenic mRNAs (84).  Furthermore, 
combination of silvestrol with the DNA damaging agent doxorubicin showed a 
synergistic effect in extending survival (85).  This combination therapy with silvestrol 
and doxorubicin was only synergistic in mice that harbored activation of the mTOR 
pathway.  Additionally, there is data in inflammatory breast cancer cells showing that 
eIF4A knockdown or pharmacologic inhibition results in radiosensitization (86).  Given 
these reports as well as our data showing an increase in PDCD4, a repressor of eIF4A 
activity, it is possible to conclude that S6K1 knockdown’s influence on radiosensitivity 
may be in part due to effects of increased PDCD4 expression on eIF4A activity.  
Additionally, given the data showing eIF4A inhibition synergizes with DNA damage 
only in the context of hyperactive PI3K/mTOR signaling (85) and the established 
activation of PI3K/mTOR signaling observed in tumor cells, it is possible that this is the 
mechanism for the potential tumor specific radiosensitization observed.  In conclusion, 
these data suggest that targeting S6K is a potential target for tumor selective 
radiosensitization; however, the mechanisms underlying this effect largely remain 
undetermined and will be the subject of future investigation. 
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CHAPTER 5: 
Allosteric versus ATP-Competitive mTOR Inhibition and Radiosensitivity 
 
Note to Reader 
 Portions of the results have been previously published (Hayman	   TJ	   Kramp	   T,	  Kahn	   J,	   Jamal	  M,	   Camphausen	   K,	   Tofilon	   PJ.	   Competitive	   but	   not	   allosteric	  mTOR	  kinase	   inhibition	   enhances	   tumor	   cell	   radiosensitivity.	   Translational	   Oncology.	  2013;	  in	  press.) and are utilized with permission of the publisher.  Tamalee Kramp and 
Muhammad Jamal assisted with animal experiments; Jenna Kahn assisted with in vitro 
data acquisition; Kevin Camphausen and Philip Tofilon helped to design and oversee 
project. 
Abstract 
The mechanistic target of rapamycin (mTOR) is a critical kinase in the regulation 
of gene translation and has been suggested as a potential target for radiosensitization.  
The goal of this study was to compare the radiosensitizing activities of the allosteric 
mTOR inhibitor rapamycin with that of the ATP competitive mTOR inhibitor PP242.  
Based on immunoblot analyses, whereas rapamycin only partially inhibited mTORC1 
activity and had no effect on mTORC2, PP242 inhibited the activity of both mTOR 
containing complexes.  Irradiation alone had no effect on mTORC1 or mTORC2 activity.  
Clonogenic survival was used to define the effects of the mTOR inhibitors on in vitro 
radiosensitivity.  In the two tumor cell lines evaluated, PP242 treatment 1h before 
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irradiation increased radiosensitivity, whereas rapamycin had no effect.  Addition of 
PP242 to culture media immediately, 1, or 6h after irradiation also enhanced the 
radiosensitivity of both tumor lines.  To investigate the mechanism of radiosensitization, 
the induction and repair of DNA double strand breaks were evaluated according to 
γH2AX foci.  PP242 exposure did not influence the initial level of γH2AX foci after 
irradiation, but did significantly delay the dispersal of radiation-induced γH2AX foci.  In 
contrast to the tumor cell lines, the radiosensitivity of a normal human fibroblast cell line 
was not influenced by PP242.  Finally, PP242 administration to mice bearing U251 
xenografts enhanced radiation-induced tumor growth delay.  These results indicate that in 
a preclinical tumor model PP242 enhances tumor cell radiosensitivity both in vitro and in 
vivo and suggest this effect involves an inhibition of DNA repair. 
Introduction 
A primary determinant of eIF4E activity is the mechanistic target of rapamycin 
(mTOR), which plays a critical role in regulating mRNA translation and protein synthesis 
in response to a variety of environmental signals (82).  mTOR exists in two distinct 
complexes:  mTOR complex 1 (mTORC1), which includes Raptor, Pras40, Deptor, and 
Mlst8, and mTOR complex 2 (mTORC2), which includes Rictor, mSin1, Protor1/2 and 
Mlst8 (82).  The major substrates for mTORC1 kinase activity are eIF4E-binding protein 
1 (4E-BP1), and the ribosomal protein s6 kinase 1 (S6K1).  In the hypophosphorylated 
state, 4E-BP binds to eIF4E preventing its association with eIF4G, the formation of the 
eIF4F complex, and cap-dependent translation (28).  However, when 4E-BP1 is 
phosphorylated by mTORC1 it is released from eIF4E and the eIF4F cap-complex is 
assembled.  The substrates of mTORC2 are less well defined, but include  AGC kinases 
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such as AKT, SGK, and PKC (65).  Of note, mTORC2 phosphorylation of AKT at s473 
can indirectly lead to enhancement mTORC1 activation (87-88). 
mTOR is a major downstream effector of a number of signaling pathways (e.g. 
PI3K/AKT, RAS/MAPK, and RTKs) (56, 82).  Because these pathways are frequently 
activated or dysregulated in tumors, mTOR has been considered a target for cancer 
therapy (89).  Most studies of mTOR have focused on the use of the allosteric inhibitor 
rapamycin and its analogs (rapalogs), which incompletely inhibit mTORC1 output and do 
not inhibit mTORC2 (90).  In the context of cancer treatment, these drugs have shown 
modest activity with respect to patient outcomes (59).  The resistance of some tumors to 
rapalogs as single agents has been attributed to their incomplete inhibition of 4E-BP1 
phosphorylation, feedback activation of AKT, and/or the lack of mTORC2 inhibition (90-
91).  In contrast to the allosteric inhibitors, more recently developed ATP-competitive 
inhibitors of mTOR inhibit mTORC1 output more completely and inhibit mTORC2, 
which prevents the feedback activation of AKT following S6K inhibition (87, 92-95).  
Given mTOR’s role in regulating eIF4E activity, we have defined the consequences of an 
allosteric (rapamycin) and ATP-competitive (PP242) mTOR inhibitor on the 
radiosensitivity of tumor and normal cells.  The data presented here indicate that the 
mTORC1/2 inhibition achieved using the ATP-competitive inhibitor PP242 enhances 
tumor cell radiosensitivity in vitro and in vivo and suggest that this effect involves an 
inhibition of DNA double-strand break (DSB) repair. 
Results 
To investigate the effects of rapamycin and PP242 on tumor cell radiosensitivity, 
two human cell lines initiated from solid tumors were used: MDA-MB-231 (breast 
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carcinoma) and U251 (glioma).  Initially, mTORC1 and mTORC2 activity was 
determined in each cell line after a 1h exposure to PP242 or rapamycin (Figures 10A and 
B).  The goal of this analysis was not only to compare drugs with respect to inhibitory 
activity but to also define the minimal concentration of each drug necessary to elicit the 
maximally achievable mTOR kinase inhibition.  Towards this end, the levels of p-S6K 
(t389) and p-4E-BP1 (t37/46 and s65) were used as readouts for mTORC1 activity; p-
AKT (s473) was used as a marker for mTORC2 activity.  Rapamycin exposure reduced 
p-S6K and marginally reduced p-4E-BP1 levels in both cell lines with essentially the 
same reductions induced by 5 and 10nM.  No further reductions in these indicators of 
mTORC1 activity were achieved by increasing rapamycin concentrations out to 500 nM 
(data not shown), consistent with previous reports (59, 96).  PP242 exposure (1 and 2 
µmol/L) reduced p-S6k levels to a similar degree as rapamycin.  However, PP242 was 
considerably more effective at reducing the levels of p-4E-BP1 than rapamycin, as 
previously shown (92-93).  In contrast to rapamycin, PP242 inhibited the phosphorylation 
of AKT at s473 in both tumor cell lines, indicative of an inhibition of mTORC2 activity.  
Thus, as reported for other cell lines (92-93), in U251 and MDA-MB-231 cells PP242 
inhibits the rapamycin resistant functions of mTOR. 
 To determine whether irradiation influences mTOR activity, U251 and MDA-
MB-231 cells were exposed to 2 Gy and collected for immunoblot analysis at times out to 
6h (Figures 11A and B).  Based on levels of p-AKT, p-S6K, and p-4E-BP1, radiation did 
not increase mTORC1 or mTORC2 activity in either of these tumor cell lines.  These 
measures were conducted using cells grown under optimal in vitro conditions (i.e. 10% 
FBS) applicable to clonogenic survival analysis.  Whereas previous reports showed that 
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Figure 10:  Effects of rapamycin and PP242 on mTORC1/2 activity.  A) U251 and B) 
MDA-MB-231 cells were treated for 1h with the specified dose of inhibitor.  Cells were 
collected and subjected to immunoblot analysis.  Actin was used as a loading control. 
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Figure 11:  The effect of radiation on mTOR activity.  A) U251 and B) MDA-MB-231 
cells were irradiated (2 Gy) and collected at the specified times and subjected to 
immunoblot analysis.  Actin was used as a loading control.  Immunoblots are 
representative of two independent experiments. 
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radiation increased mTORC1 and mTORC2 activity in tumor cells, those studies were 
performed using serum starved cells (97-98). 
 The effects of the mTOR inhibitors on tumor cell radiosensitivity as measured by 
clonogenic survival analysis are shown in Figure 12A and B.  For this study, cells were 
plated at clonogenic density, allowed to attach (5-6 h); the indicated concentration of 
inhibitor was added 1h before irradiation.  Twenty-four hours after irradiation media was 
removed, fresh drug-free media was added and colonies determined 10-14 days later.  
Based on the data shown in Figure 10, a concentration of 10 nmol/L rapamycin was used, 
which induces the maximum achievable level of mTORC1 inhibition.  Rapamycin (10 
nmol/L, 25h) alone did not reduce the surviving fraction of U251 cells.  Moreover, 
addition of rapamycin 1h before irradiation had no effect on the radiosensitivity of U251 
cells (Figure 12A).  In U251 cells 1 and 2 µmol/L of PP242 added 1h prior to irradiation 
increased radiosensitivity in a dose-dependent manner (Figure 12A), consistent with its 
dose-dependent mTOR inhibition (Figure 10A), resulting in dose enhancement factors at 
a surviving fraction of 0.1 (DEFs) of 1.27 and 1.52, respectively.  PP242 alone at 2 
µmol/L slightly reduced the U251 surviving fraction to 0.91 ± 0.04 and had no effect on 
survival at 1 µmol/L.  To determine whether these effects were unique to U251 cells, a 
similar analysis was used for MDA-MB-231cells (Figure 12B).  Rapamycin (10 nmol/L, 
25h) alone had no effect on the surviving fraction of MDA-MB-231 cells and had no 
effect on the radiosensitivity of MDA-MB-231 cells.  PP242 (2 µmol/L, 25h) alone 
reduced surviving fraction of MDA-MB-231 cells to 0.83 ± 0.06; when PP242 was added 
1h prior to irradiation enhanced their radiosensitivity with a DEF of 1.34.  These data 
suggest that in contrast to the allosteric mTOR inhibitor rapamycin, the ATP-competitive 
47 
 
 
 
 
Figure 12:  Effects of mTOR inhibitors on cellular radiosensitivity.  A) U251, B) MDA-
MB-231, and C) MRC9 cells were plated, allowed to attach for 5-6h, and the indicated 
concentration of inhibitor was added 1h before irradiation.  Twenty-four hours after 
irradiation media was removed and fresh drug-free media was added.  Colony-forming 
efficiency was determined 10-14 days later and survival curves were generated after 
normalizing for cell killing from drug alone.  Values shown represent the mean + SEM 
for 3 independent experiments. 
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Figure 13:  Influence of PP242 on radiation-induced γH2AX foci.  A) U251 and B) 
MDA-MB-231 cells were exposed to the indicated dose of PP242 1h prior to irradiation 
(2 Gy).  Cells were collected at the specified time; γH2AX foci were counted in at least 
50 nuclei per condition.  Values shown represent the means + SEM for 3 independent 
experiments, *p < 0.05 according to Student’s t test (PP242 compared to control).
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inhibitor PP242, which more completely inhibits mTORC1 and inhibits mTORC2, 
enhances radiation-induced cell killing.  The same experiment using PP242 was 
performed using the normal lung fibroblast line, MRC9 (Figure 12C).  PP242 alone had 
no effect on MRC9 survival and, in contrast to the tumor cell lines, had no effect on the 
radiosensitivity of MRC9 cells.  These results suggest that PP242 induces a tumor 
selective increase in radiosensitivity. 
 The critical lesion responsible for radiation-induced cell death is the DNA double 
strand break (DSB).  Because γH2AX foci correspond to radiation-induced DSBs and 
their dispersal correlates with DSB repair (47-48), the effects of PP242 on radiation-
induced γH2AX were evaluated in U251 and MDA-MB-231 cells (Figure 13 A and B).  
In this study PP242 was added 1h before irradiation (2 Gy) with γH2AX nuclear foci 
determined at times out to 24h.  In U251 cells 1 hour after irradiation, no difference in 
foci levels was detected between control (vehicle) and PP242 treated cells, suggesting 
that mTOR inhibition had no effect on the initial levels of radiation-induced DSBs.  
However, at 6 and 24 h after irradiation (2 Gy), the number of γH2AX foci remaining in 
the PP242 (1 and 2 µmol/L) treated cells was significantly greater than in control cells.  
This effect was PP242 dose-dependent, consistent with the dose-dependent effect on 
radiosensitivity in U251 cells.  In MDA-MB-231 cells 1 hour after irradiation, no 
difference in foci levels was detected between vehicle treated and PP242 treated cells. 
However, at 24h after irradiation, the number of γH2AX foci remaining in the PP242 (2 
µmol/L) treated cells was significantly greater than in vehicle treated cells.  These data 
suggest that PP242 induces radiosensitization via an inhibition of the repair of radiation-
induced DNA DSBs. 
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Figure 14:  The effects of the timing of PP242 treatment on cellular radiosensitivity. A-
B) U251 and C) MDA-MB-231 cells were plated and allowed to attach.  Cells were then 
exposed to PP242 (2 µmol/L) either 24h before irradiation (24h Pre-IR), immediately 
after (Immediately Post-IR), 1h after (1h Post-IR), or 6h after (6h Post-IR) irradiation.  
Media was removed and fresh drug-free media was added 24h after irradiation.  Colony-
forming efficiency was determined 10-14 days later and survival curves were generated 
after normalizing for cell killing from drug alone.  Values shown represent the mean + 
SEM for 3 independent experiments. 
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In the initial treatment protocol evaluating the effects of PP242 on radiosensitivity 
(Figure 12) the mTOR inhibitor was added to the culture media 1h before irradiation.  To 
determine whether this was the optimal exposure protocol for radiosensitization as well 
as to generate insight into the mechanisms involved, PP242 (2 µmol/L) was added to 
culture media at various times before or after irradiation followed by clonogenic survival 
analysis.  In each experiment PP242 was removed 24h after exposure to radiation and all 
survival curves were generated after normalizing for cell killing caused by PP242 
treatment alone.  Addition of PP242 immediately after irradiation enhanced the 
radiosensitivity of U251 cells (Figure 14A) with a DEF of 1.60.  Addition of PP242 at 1 
and 6h after irradiation also resulted in radiosensitization (DEFs of 1.50 and 1.26, 
respectively), although the enhancement was substantially less for the 6h time point 
(Figure 14B).  Treatment of U251 cells with PP242 24h prior to irradiation did not 
enhance their radiosensitivity (Figure 14B).  These treatment protocols were also 
evaluated using MDA-MB-231 cells (Figure 14C).  PP242 exposure for 24h before 
irradiation had no effect on the radiosensitivity of MDA-MB-231 cells, whereas drug 
addition immediately or 1h after irradiation enhanced radiosensitivity (DEFs of 1.88 and 
1.71, respectively) with the sensitization also present, albeit diminished, at the 6h time 
point (DEF of 1.31).  The data presented in Figures 14 indicate that the PP242-induced 
radiosensitization also occurs when the drug was added to culture media after irradiation. 
To determine whether the enhancement of tumor cell radiosensitivity measured in 
vitro extends to an in vivo tumor model, U251 cells were grown as xenografts in nude 
mice.  Initially, the ability of PP242 to inhibit mTOR activity in U251 xenografts was 
defined.  PP242 (100 or 200 mg/kg) was delivered by oral gavage to mice bearing U251 
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leg tumors; 6h later tumors were collected and subjected to immunoblot analysis.  As 
shown in Figure 15A, a consistent reduction of p-AKT and p-4EBP1 levels, indicative of 
mTORC2 and mTORC1 inhibition, respectively, was detected in tumors isolated from 
mice that received the PP242 at 200 mg/kg.  Based on these results, a combination 
protocol was designed using 200 mg/kg PP242 and 2 Gy and the consequences on U251 
tumor growth rate determined.  Specifically, mice bearing U251 leg tumors (~210 mm3) 
were randomized into four groups: vehicle, PP242, radiation, and PP242 plus radiation.  
PP242 was delivered once a day (200 mg/kg, oral gavage) for four days with the tumor 
locally irradiated (2 Gy) 2h after each of the four drug treatments.  The growth rates of 
U251 tumors exposed to each treatment are shown in Figure 15B.  For each group, the 
time to grow from 210 mm3 (volume at time of treatment initiation) to 1,000 mm3 was 
calculated using the tumor volumes from the individual mice in each group (mean ± 
SEM).  These data were then used to determine the absolute growth delays (the time in 
days for tumors in treated mice to grow from 210 to 1000 mm3 minus the time in days for 
tumors to reach the same size in vehicle treated mice). 
For U251 tumors (Figure 15B) the absolute growth delays for the PP242 alone 
and radiation alone groups were 1.0 ± 0.4 and 12.9 ± 2.1 days, respectively.  The growth 
delay in mice treated with the combination of PP242 and radiation was 20.0 ± 1.3 days, 
which is greater than the sum of the growth delays caused by PP242 alone and radiation 
alone.  To obtain a dose enhancement factor (DEF) comparing the tumor radioresponse in 
mice with and without PP242 treatment, the normalized tumor growth delays were 
determined, which accounts for the contribution of PP242 to tumor growth delay induced 
by the combination treatment.  Normalized tumor growth delay was defined as the time 
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Figure 15:  The effects of PP242 on radiation-induced tumor growth delay.  A) Mice 
bearing U251 glioma xenografts were exposed to vehicle or PP242 (oral gavage) at the 
indicated dose.  Six hours later tumors were collected and subjected to immunoblot 
analysis using actin as a loading control.  Each lane represents the tumor from an 
individual mouse.  B) When U251 tumors reached approximately 210 mm3 in size, mice 
were randomized into four groups: vehicle, PP242 (200 mg/kg administered once daily 
by oral gavage), radiation (2 Gy once daily), and PP242 plus radiation.  PP242 was 
delivered once a day (200 mg/kg by oral gavage) for four days with the tumor locally 
irradiated (2 Gy) 2h after each of the four drug treatments.  Each group contained five 
mice.  Values represent the mean tumor volumes + SEM. 
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in days for tumors to grow from 210 to 1000 mm3 in mice exposed to the 
combined modality minus the time in days for tumors to grow from 210 to 1000 mm3 in 
mice treated with PP242 only.  The DEF, obtained by dividing the normalized tumor 
growth delay in mice treated with the radiation/PP242 combination (19.0) by the absolute 
growth delay in mice treated with radiation only (12.9), was 1.5.  Thus, whereas PP242 
delivered alone had no significant effect U251 tumor growth, the ATP-competitive 
mTOR inhibitor enhanced the radiation-induced tumor growth delay.  
Discussion 
 
 Previous investigations into mTOR as a potential target for tumor cell 
radiosensitization have focused on rapamycin and various rapalogs.  The conclusions of 
such studies have been somewhat inconsistent with radiosensitization detected for some 
tumor cell lines (97-99) but not others (100-102).  Clearly, such inconsistencies may be 
attributed to cell type specificity and/or differences in treatment protocols.  However, an 
additional complicating factor is that rapamycin is an incomplete inhibitor of mTOR 
kinase.  That is, although rapamycin inhibits the S6 kinase phosphorylation mediated by 
mTORC1, it only partially inhibits mTORC1 dependent 4E-BP1 phosphorylation and 
does not inhibit mTORC2 activity (90).  Consequently, attempts to correlate 
radiosensitization with targeting of mTOR have been limited to the evaluation of S6K 
phosphorylation (97-101).  Along these lines, in a study that evaluated multiple 
rapamycin concentrations, Murphy et al. showed that exposure of sarcoma cell lines to 
300 nmol/L rapamycin resulted in radiosensitization, yet 3 nmol/L was sufficient to 
eliminate detectable levels of p-S6K, a concentration that had no effect on 
radiosensitivity (98).  Thus, as illustrated by this study, the relationship between 
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rapamycin, mTOR activity and radiosensitization is unclear.  To better understand the 
potential for mTOR to serve as a target for radiosensitization, we defined the 
radiosensitivity of tumor cells treated with the ATP-competitive mTOR inhibitor PP242, 
which in addition to inhibiting S6 kinase activation, inhibits 4E-BP phosphorylation as 
well as the mTORC2 activity (92-93).  The data presented here show that for the two 
human tumor cell lines evaluated PP242 exposure, in contrast to rapamycin, enhanced 
radiation-induced cell killing. 
Given the number of mTORC1 and mTORC2 substrates, whether PP242-induced 
radiosensitization is initiated via a single downstream event or whether multiple mTOR 
substrates are involved remains to be determined.  However, as previously reported (32, 
92, 103) and shown here, although rapamycin and PP242 inhibit S6 kinase 
phosphorylation to approximately the same degree, PP242 exposure results in a 
considerably more effective inhibition of 4E-BP1 phosphorylation.  Feldman et al (92) 
reported that the PP242-mediated inhibition of 4E-BP1 phosphorylation prevents its 
release of eIF4E, thus reducing the level of eIF4E available for cap-dependent translation.  
Such a scenario would be consistent with our recent data showing that reduced eIF4E 
levels increase tumor cell radiosensitivity (104) and suggests that inhibiting the mTOR 
mediated phosphorylation of 4E-BP1 at least plays a role in PP242-induced 
radiosensitization. 
Based on analysis of γH2AX foci induction and dispersion, it appears that PP242-
mediated radiosensitization is the result of an inhibition of DNA double strand break 
repair.  Furthermore, the radiosensitization obtained when PP242 was added at times out 
to 6h after irradiation suggests that mTOR inhibition affects a later stage in the DNA 
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repair process.  Although the direct interaction of mTOR or one of its substrates with a 
component of the DNA repair machinery cannot be eliminated, the role of mTOR as a 
critical regulator of gene translation in response to a variety of stress and environmental 
signals may also provide a mechanistic basis for the inhibition of DSB repair in PP242 
treated cells.  A recent study using microarray analysis of polysome-bound RNA showed 
that after PP242 exposure, among the genes whose translation was significantly 
suppressed included a number corresponding to DNA repair proteins (103).  Ribosome 
profiling also indicated that among the genes whose translation was reduced after PP242 
exposure were a number involved in DNA repair (105).  With respect to the effects 
PP242 on radiosensitivity, microarray analysis of polysome-bound RNA has shown that 
radiation-induced changes in gene expression can be primarily attributed to translational 
control processes (21-22).  Moreover, in our recent study using RIP-Chip analysis (104), 
irradiation of MDA-MB-231 cells was found to increase eIF4E binding to over 1000 
unique transcripts, a significant number of which were associated with the functional 
category of DNA Replication, Recombination and Repair.  Thus, the PP242-mediated 
inhibition of gene translation may also play a role in its radiosensitizing actions, which 
will be the subject of future studies. 
It has previously been reported that mTOR activity is increased at 15 minutes 
after irradiation with a return to control levels by 1h (106).  Whereas we did not evaluate 
mTOR activity at times less than 1h after irradiation, addition of PP242 at times up to 6h 
after irradiation was shown to result in radiosensitization.  This would suggest that if 
there was a transient increase in mTOR activity after irradiation returning to control 
levels by 1h, it was not critical to the mechanism of PP242-induced radiosensitization.  
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Furthermore, the study by Contessa et al. used serum-starved cells, which results in a 
reduction in basal mTOR activity as compared to standard growth conditions (106).  In 
contrast, we determined the effects of radiation on mTOR activity using the same 
conditions of clonogenic survival analysis (media supplemented with 10% serum). 
Whereas PP242 exposure enhanced the radiosensitivity of human tumor cell lines, 
the same procedure had no effect on the radiosensitivity of the normal fibroblast line 
MRC9.  Because mTOR activity in MRC9 cells was reduced by PP242 treatment to the 
same extent as in the tumor cells (data not shown), the lack of radiosensitization may 
reflect the previously established fundamental differences in mTOR activity and/or 
function in tumor versus normal cells (88).  To further evaluate the clinical potential of 
PP242 delivered in combination with radiotherapy, its effects on mTOR activity and 
radiation-induced tumor growth delay were defined in a preclinical model system.  
Although PP242 inhibited mTOR activity in U251 xenografts, drug delivery for 4 days 
had no significant effect on tumor growth rate, which is in contrast to previous studies 
showing substantial tumor growth inhibition with prolonged daily PP242 treatment (93, 
107).  However, this drug treatment protocol did result in a significant increase in 
radiation-induced tumor growth delay.  A number of ATP-competitive mTOR inhibitors 
are being evaluated in clinical trials (64).  The data presented here showing that PP242 
enhances tumor cell radiosensitivity both in vitro and in vivo suggests that these 
inhibitors delivered in combination with radiotherapy may be of value as a cancer 
treatment strategy. 
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CHAPTER 6: 
ATP-Competitive mTOR Inhibition by the Clinically Available mTOR Inhibitor 
INK128 Enhances In Vitro and In Vivo Radiosensitivity of Pancreatic 
Adenocarcinoma 
Abstract 
 As shown in Chapter 5, ATP-competitive inhibition of mTOR is required for 
tumor radiosensitization.  Radiotherapy is a primary treatment modality for the treatment 
of locally advanced pancreatic ductal adenocarcinoma, where its use improves local 
control and survival.  Additionally, constitutive mTOR activation has been shown in 
pancreatic adenocarcinoma.  The purpose of this study was to define the effects of the 
clinically available ATP-competitive mTOR inhibitor, INK128, on pancreatic cancer 
radiosensitivity.  Clonogenic survival was used to define the effects of INK128 on 
cellular radiosensitivity. In 3 pancreatic cancer cell lines addition of INK128 immediately 
after radiation resulted in radiosensitization.  Removal of drug from culture media either 
12 or 24 but not 6h resulted in radiosensitization.  To investigate the mechanism of 
radiosensitization, the induction and repair of DNA double strand breaks were evaluated 
according to γH2AX foci.  INK128 exposure did not influence the initial level of γH2AX 
foci after irradiation, but did significantly delay the dispersal of radiation-induced 
γH2AX foci.  INK128 inhibits mTOR activity in vivo in a time and dose-dependent 
manner.  Inhibition of mTOR by INK128 inhibits cap-complex formation in PSN1 tumor 
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xenografts.  Finally, the effects of INK128 on in vivo tumor radiosensitivity were defined 
and optimized using both in vitro and in vivo pharmacodynamic data. 
Introduction 
As described in Chapter 5 our laboratory recently compared the effects of the two 
classes of mTOR inhibitors on tumor cell radiosensitivity.  ATP-competitive mTOR 
inhibition by PP242 enhanced tumor cell radiosensitivity both in vitro and in vivo (108).  
However, PP242 has been shown to have poor pharmacokinetic and pharmacodynamics 
properties in vivo (105).  This led to the development of an analogue of PP242, INK128 
(105), which possesses much-improved in vivo pharmacodynamics and pharmacokinetic 
properties.  INK128 is currently undergoing analysis in the clinical trial setting now (64).   
The overall survival rate for patients with pancreatic ductal adenocarcinoma 
(PDAC) remains dismal with an overall survival rate of approximately 5% despite 
advances in systemic therapy (109-110).  Gemcitabine is the standard systemic therapy 
(111), however local control is an important component of therapy as it has been reported 
that approximately one-third of pancreatic cancer mortality is due to local disease (112).  
The importance of local control is highlighted by clinical data showing the combination 
of radiation with gemcitabine significantly prolongs survival when compared to 
gemcitabine alone (113).  However, whereas there have been improvements in therapy, 
the prognosis for patients with pancreatic adenocarcinoma still remains poor.  This 
emphasizes the need for the development of agents aimed at improving the efficacy of 
radiotherapy.  High incidences of activating mutations in K-RAS have been reported in 
PDAC (114).  These activating mutations in K-RAS increase MAPK as well as 
PI3K/AKT/mTOR signaling (114).  Consistent with the role of activating mutations in K-
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RAS it has been reported that approximately 70% of PDAC have constitutive mTOR 
activation (115).  Given the proposed role of eIF4E and mTOR as determinants of tumor 
radiosensitivity, as well as the reported activation of mTOR in PDAC, the effects of the 
clinically available mTOR ATP-competitive inhibitor INK128 on pancreatic cancer cell 
radiosensitivity were defined.  The data presented here indicate that mTORC1/2 
inhibition by INK128 enhances PDAC radiosensitivity in vitro and in vivo and that this 
effect involves inhibition of DNA double strand break repair.  Furthermore, these data 
provide preclinical insight into the design of protocols combining radiation and mTOR 
ATP-competitive inhibitors. 
Results 
 To investigate the effects of mTOR inhibition by the mTOR ATP-competitive 
inhibitor INK128 on pancreatic cancer cell radiosensitivity, 3 human pancreatic cancer 
cell lines were used: Miapaca-2, Panc1, and PSN1.  Initially mTORC1 and mTORC2 
activity was determined in each cell line after various length of exposure to INK128 
(Figure 16).  Towards this end, the levels p-4E-BP1 (t37/46) were used as readouts for 
mTORC1 activity; p-AKT (s473) was used as a marker for mTORC2 activity.  INK128 
exposure in all three cell lines reduced activity of mTORC1 and mTORC2 in a time-
dependent manner, consistent with reports in the literature (105). 
 The effects of INK128 on pancreatic cancer cell radiosensitivity as measured by 
clonogenic survival analysis are shown in Figure 17A-C.  For this study cells were plated 
at clonogenic density, allowed to attach overnight, irradiated, followed immediately by 
adding the specified concentration of INK128.  This protocol was chosen based upon our 
recently published work showing maximal radiosensitization by the ATP-competitive 
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Figure 16:  Effects of INK128 on mTORC1/2 activity.  A) The indicated cells were 
treated with the specified dose of inhibitor.  Cells were collected at the specified time 
points and subjected to immunoblot analysis.  Actin was used as a loading control. 
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Figure 17:  Effects of INK128 on cellular radiosensitivity.  A) Miapaca-2, B) Panc1, C) 
PSN1, and D) MRC9 cells were plated, allowed to attach overnight, irradiated and the 
indicated concentration of inhibitor was added immediately after radiation.  Twenty-four 
hours after irradiation media was removed and fresh drug-free media was added.  
Colony-forming efficiency was determined 10-14 days later and survival curves were 
generated after normalizing for cell killing from drug alone.  Values shown represent the 
mean + SEM for 3 independent experiments. 
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mTOR inhibitor PP242 when added immediately after radiation (108).  Twenty-four 
hours after irradiation media was removed, fresh drug-free media was added and colonies 
determined 10-14 days later.  INK128 treatment alone reduced the surviving fraction to 
0.85 ± 0.02 in Miapaca-2 cells.  In contrast, INK128 treatment had no effect on the 
surviving fraction of Panc1 or PSN1 cells.  In all 3 pancreatic cancer cell lines treatment 
with INK128 immediately after irradiation resulted in an increase in cellular 
radiosensitivity.  The dose-enhancement factors at a surviving fraction of 0.1 (DEF) were 
1.33, 1.45, and 1.37 for Miapaca-2, Panc1, and PSN1 cells respectively.  The same 
experiment using INK128 was performed using the normal lung fibroblast line, MRC9 
(Figure 17D).  INK128 treatment alone reduced the MRC9 surviving fraction to 0.73 ± 
0.05, and in contrast to the 3 pancreatic cancer cell lines had no significant effect on the 
radiosensitivity of MRC9 cells.  These results are consistent with our previous results 
where PP242 enhanced tumor but not normal cell radiosensitivity (108).  These results 
suggest that INK128 treatment causes an increase in the radiosensitivity of pancreatic 
cancer cells. 
 The critical lesion responsible for radiation-induced cell death is the DNA double 
strand break (DSB).  Because γH2AX foci correspond to radiation-induced DSBs and 
their dispersal correlates with DSB repair (47-48), the effects of INK128 on radiation-
induced γH2AX were evaluated in PSN1 cells (Figure 18).  In this study the same 
treatment protocol used for the clonogenic survival assays above was used, which 
consisted of adding INK128 immediately after irradiation (2 Gy) with γH2AX nuclear 
foci determined at times out to 24h.  No difference in foci levels was detected between 
control (vehicle) and INK128 treated cells 1 hour after irradiation, suggesting that mTOR 
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Figure 18:  Influence of INK128 on radiation-induced γH2AX foci.  A) PSN1 cells were 
exposed to the indicated dose of INK128 immediately after irradiation (2 Gy).  Cells 
were collected at the specified time; γH2AX foci were counted in at least 50 nuclei per 
condition.  Values shown represent the means + SEM for 3 independent experiments, *p 
< 0.05 according to Student’s t test (INK128 compared to control). 
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inhibition has no effect on the initial levels of radiation-induced DSBs.  However at 6 and 
24h after irradiation, the number of γH2AX foci reaming was significantly greater in the 
inhibition has no effect on the initial levels of radiation-induced DSBs.  However at 6 and 
24h after irradiation, the number of γH2AX foci reaming was significantly greater in the 
INK128 treated cells relative to control cells.  These data are consistent with our recently 
published data showing eIF4E knockdown and pharmacologic inhibition of eIF4E by the 
mTOR ATP-competitive inhibitor PP242 delay the dispersal of radiation-induced γH2AX 
foci.  These results suggest that INK128-mediated radiosensitization is caused by an 
inhibition of radiation-induced DNA DSB repair. 
 Understanding the pharmacodynamic and pharmacokinetic properties of a drug is 
critical for the rational design of protocols combining radiation and chemotherapies.  To 
begin to evaluate these effects in a preclinical setting Miapaca-2 and PSN1 cells were 
grown as xenografts in nude mice.  The ability of INK128 to inhibit mTOR activity in 
both Miapaca-2 and PSN1 xenografts (Figure 19 A and B respectively) was determined 
via immunohistochemical analysis of p-4E-BP1 (t37/46) an established marker for 
mTOR activity.  INK128 (1 or 3 mg/kg) was delivered by oral gavage to mice bearing 
Miapaca-2 or PSN1 tumor xenografts; tumors were collected either 2 or 6h after 
drugging, and processed for immunohistochemical analysis.  In Miapaca-2 tumor 
xenografts treatment with INK128 (both 1 and 3 mg/kg) inhibited mTOR activity 2 hours 
after the initial dose as judged by a decrease in p-4E-BP1 staining, with a more 
pronounced inhibition with the 3 mg/kg dose.  6 hours after INK128 treatment mTOR 
activity is beginning to increase, albeit not to control levels, with a greater return to 
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Figure 19:  The effects of INK128 treatment on mTOR activity in pancreatic tumor 
xenografts.  Mice bearing Miapaca-2 (A) or PSN1 (B)  xenografts were exposed to 
vehicle or the indicated dose of INK128 (oral gavage).  Tumors were collected 2 or 6 
hours later and prepared for immunohistochemical staining. Sections were probed with an 
antibody specific to p-4E-BP1 T37/46 followed by staining with a FITC coupled 
secondary antibody (green).  Nuceli were visualized with DAPI (blue).   Each image is of 
representative of at least two mice per treatment group. 
A. Miapaca-2 
B. PSN1 
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baseline in the 1 mg/kg treated tumors.  In PSN1 tumor xenografts treatment with both 1 
and 3 mg/kg inhibited mTOR activity to a similar degree 2 hours after the initial drug 
dose.  Consistent with the results obtained for Miapaca-2 tumor xenografts, 6 hours after 
drug dosing mTOR activity is beginning to return.  These results suggest that INK128 
inhibits mTOR activity in a dose and time-dependent manner in pancreatic tumor 
xenografts. 
 As described in the Introduction, mTOR controls eIF4F cap-complex formation 
primarily by phosphorylation of the translation inhibitor 4E-BP1.  Upon phosphorylation, 
4E-BP1 is released from the 5’ mRNA cap followed by binding of eIF4G and 
subsequently the initiation of translation (32).  To extend the immunohistochemical 
analysis of INK128-mediated mTOR inhibition to its effects on in vivo cap-complex 
formation, m7-GTP batch chromatography was employed on tumor PSN1 tumor 
xenografts treated with INK128 (3 mg/kg) and collected 2 or 6 hours later (Figure 20).  
m7-GTP batch chromatography is a standard approach for assessing eIF4F cap-complex 
formation (25, 30).  Consistent with the constitutive phosphorylation of 4E-BP1 seen by 
immunohistochemical staining (Figure 19) vehicle treated mice have substantial eIF4F 
cap-complex formation as judged by bound eIF4G.  Treatment with INK128 decreased 
eIF4F cap-complex as evidenced by an increase in bound 4E-BP1 and decrease in bound 
eIF4G.  Furthermore, consistent with the time-dependent effect on mTOR activity seen 
by immunohistochemical staining, the effects of INK128 treatment on eIF4F cap-
complex formation were time dependent with bound eIF4G beginning to increase 6 hours 
after drugging.  These results suggest that in vivo mTOR inhibition by the mTOR ATP-
competitive inhibitor, INK128, results in a decrease in eIF4F cap-complex formation. 
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Figure 20:  The effects of INK128 on PSN1 tumor xenograft eIF4F complex formation.  
A) m7-GTP affinity chromatography was performed on PSN1 tumor xenografts that were 
exposed to 3 mg/kg INK128 (oral gavge) or vehicle and collected at the specified 
timepoints.  m7-GTP bound proteins were resolved via SDS-PAGE followed by 
immunoblot analysis.  eIF4E was used as a loading control.  Each lane represents the 
tumor from an individual mouse. 
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To determine whether the observed radiosensitization in vitro could be translated to an in 
vivo setting a tumor regrowth delay experiment was performed using PSN1 tumor 
xenografts in nude mice.  Based upon the immunohistochemical analysis of INK128 
treatment in PSN1 xenografts, a combination protocol was designed using INK128 and a 
single fraction of 6 Gy.  Specifically, mice bearing PSN1 leg tumors (~180mm3) were 
randomized into four groups: vehicle, INK128 (3 mg/kg, delivered by oral gavage), 
radiation (6 Gy), and the combination of INK128 and radiation.  INK128 was delivered 
once immediately after the locally delivered radiation dose.  The growth rates of PSN1 
tumors exposed to each treatment are shown in Figure 21A. As shown there was no 
difference in the growth rates of mice receiving radiation or mice that received the 
combination of radiation and a single dose of INK128.  As such, this treatment protocol 
did not result in an enhancement of in vivo tumor radiosensitivity.  The initial treatment 
protocol evaluating the effects of INK128 on pancreatic cancer cell radiosensitivity in 
vitro consisted of adding INK128 to culture media and removing drug 24h after radiation.  
In light of the lack of sensitization seen in the single dose in vivo tumor growth delay 
experiments as well as the immunohistochemical analysis showing mTOR activity 
beginning to return as early as 6h post a single drug dose we postulated that duration of 
mTOR inhibition post-radiation could be an important factor in the determining the 
radiosensitization seen with INK128 treatment.  To begin to address this question in vitro 
we performed clonogenic survival analysis with PSN1 cells using a modified treatment 
protocol.  This protocol consisted of addition of INK128 to culture media immediately 
after radiation and removing the drug 6, 12, or 24h post-radiation.  The results of this 
analysis are shown in Figure 21B.  In all 3 treatment protocols INK128 alone had no 
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Figure 21:  The effects of duration of mTOR inhibition on in vitro and in vivo radiosensitivity.  .  When 
PSN1 tumor xenografts reached approximately 180 mm3 in size, mice were randomized into four groups: 
vehicle, INK128 (oral gavage), radiation, and INK128 plus radiation.  A) The tumors were locally 
irradiated (6 Gy) followed by a single dose of INK128 (3 mg/kg.)  Each group contained six mice.  Values 
represent the mean tumor volumes + SEM.  B.) PSN1 cells were plated at clonal density and allowed to 
attach overnight irradiated and INK128 (4µM) was added immediately after irradiation.  At the specified 
times after irradiation media was removed and fresh drug-free media was added.  Colony-forming 
efficiency was determined 10-14 days later and survival curves were generated after normalizing for cell 
killing from drug alone.  DEFs were calculated at a surviving fraction of 0.1.  Values shown represent the 
mean + SEM for 3 independent experiments.  C) INK128 was delivered twice daily (1.5 mg/kg) for two 
days with the tumor locally irradiated (6Gy) 1h after the first drugging followed by a second drug dose 
delivered 6h later.  INK128 alone contained 5 mice and all other group contained 6 mice.  Values represent 
the mean tumor volumes + SEM.  D) INK128 was delivered twice daily (1.5 mg/kg) for 4 days with the 
tumor locally irradiated (2 Gy) 1h after the first drugging followed by a second drug dose delivered 6h 
later.  On the fifth day INK128 was delivered twice with each dose separated by 7h.  The INK128/radiation 
combination group contained 6 mice and all other group contained 7 mice.  Values represent the mean 
tumor volumes + SEM. 
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effect on the surviving fraction.  The treatment protocol where INK128 was removed 6h 
post-irradiation had no significant effect on the radiosensitivty of PSN1 cells, whereas 
removing INK128 12 or 24h after irradiation enhanced PSN1 tumor cell radiosensitivity 
with DEFs of 1.23 and 1.33 respectively.  These data suggest that duration of mTOR 
inhibition after radiation is an important determinant of the radiosensitizing effects seen 
with INK128 treatment. 
In light of the in vitro data suggesting that sustained mTOR inhibition beyond 6h 
is critical for radiosensitization with INK128 as well as immunohistochemical analysis 
and eIF4F cap-complex formation data in PSN1 tumors suggesting mTOR activity begins 
to return as early as 6h after a single drug exposure, a modified tumor growth delay 
experiment combining radiation and INK128 was designed.  Specifically, mice bearing 
PSN1 tumor xenografts were randomized into four treatment groups: vehicle, INK128 
(1.5 mg/kg), radiation, or combination treatment.  This experiment was performed with a 
single dose of locally delivered radiation (6 Gy) given 1h after INK128 treatment.  
INK128 was given again 6h after irradiation, followed the next day by two additional 
INK128 doses separated by 7h.  The effects of the different treatment protocols on tumor 
growth are shown in Figure 21C.  For each group the time to grow from 180mm3 
(volume of tumors at initiation of treatment) to 1000mm3 was calculated using the tumor 
volumes from the individual mice in each group (mean ± SEM).  These data were then 
used to determine the absolute growth delays.  For PSN1 tumors the absolute growth 
delay for radiation alone was 6.3± 0.7 days.  INK128 treatment alone had no significant 
effect on tumor growth delay.  For tumors treated with the combination of INK128 and 
radiation the absolute growth delay was 12.3 ± 0.4 days.  Importantly, this growth delay 
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is greater than the sum of the growth delays from the individual treatments indicative of 
an enhancement of tumor radiosensitivity.  To obtain a dose enhancement factor (DEF) 
comparing the tumor radioresponse in mice with and without INK128 treatment, the 
normalized tumor growth delays were determined, which accounts for the contribution of 
INK128 to tumor growth delay induced by the combination treatment.  Normalized tumor 
growth delay was defined as the time in days for tumors to grow from 180 to 1000 mm3 
in mice exposed to the combined modality minus the time in days for tumors to grow 
from 180 to 1000 mm3 in mice treated with INK128 only.  The DEF, obtained by 
dividing the normalized tumor growth delay in mice treated with the radiation/INK128 
combination (12.3) by the absolute growth delay in mice treated with radiation only (6.3), 
was 2.0.  Consistent with in vitro data, these in vivo data suggest extended mTOR 
inhibition for periods longer than 6h are required for INK128-induced radiosensitization. 
To extend the single dose in vivo tumor growth delay study to a clinically relevant 
radiation protocol, a tumor growth delay experiment was performed with fractionated 
radiation.  Specifically, mice bearing PSN1 tumor xenografts were randomized into four 
treatment groups: vehicle, INK128 (1.5 mg/kg), radiation (2Gy x 4), or combination 
treatment.  This experiment was performed with locally delivered radiation (2 Gy) given 
1h after INK128 treatment.  INK128 was given again 6h after irradiation.  This was 
performed for four consecutive days.  On the fifth day two additional INK128 doses 
separated by 7h were given.  The effects of the different treatment protocols on tumor 
growth are shown in Figure 21D.  For each group the time to grow from 180mm3 
(volume of tumors at initiation of treatment) to 1000mm3 was calculated using the tumor 
volumes from the individual mice in each group (mean ± SEM).  These data were then 
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used to determine the absolute growth delays (the time in days for tumors in treated mice 
to grow from 180mm3 to 1000 mm3 minus the time in days for tumors to reach the same 
size in vehicle treated mice).  For PSN1 tumors the absolute growth delays for INK128 
alone and radiation alone were 1.0 ± 0.6 and 3.7 ± 0.6 days respectively.  For tumors 
treated with the combination of INK128 and radiation the absolute growth delay was 10.1 
± 1.8 days.  Importantly, this growth delay is greater than the sum of the growth delays 
from the individual treatments, indicative of an enhancement of tumor radiosensitivity.  
Normalized tumor growth delay was defined as the time in days for tumors to grow from 
180 to 1000 mm3 in mice exposed to the combined modality minus the time in days for 
tumors to grow from 180 to 1000 mm3 in mice treated with INK128 only.  The DEF, 
obtained by dividing the normalized tumor growth delay in mice treated with the 
radiation/INK128 combination (9.1) by the absolute growth delay in mice treated with 
radiation only (3.7), was 2.5.  Consistent with the single radiation dose experiment the 
combination of INK128 with a clinically relevant fractionated radiation protocol 
enhanced in vivo tumor radiosensitivity. 
Discussion 
 Based upon the analysis of radiation-induced γH2AX foci after radiation in PSN1 
cells treated with INK128 it appears that the mechanism of radiosensitization involves an 
inhibition of DNA DSB repair.  These results are consistent with our recently published 
results showing mTOR ATP-competitive inhibition of tumor cell lines resulted in an 
inhibition of DNA DSB repair.  Furthermore in vitro clonogenic survival analysis 
showing maintenance of mTOR inhibition for greater than 6h was required for effective 
radiosensitization, suggests that INK128 inhibits a later stage of DNA DSB repair.  
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Although the direct interaction of mTOR or one of its substrates with a component of the 
DNA repair machinery cannot be eliminated, the role of mTOR as a critical regulator of 
gene translation in response to a variety of environmental and stress signals may provide 
a mechanistic basis for the inhibition of DSB repair in INK128 treated cells.  A recent 
study using microarray analysis of polysome-bound RNA showed that after PP242 
exposure, the translation of genes suppressed included many corresponding to DNA 
repair proteins (103).  Furthermore, another recent report using ribosome profiling to 
identify actively translated mRNAs showed INK128 treatment inhibited the translation of 
many mRNAs encoding proteins related to DNA DSB repair (105).  As microarray 
analysis of polysome-bound RNA has shown that radiation-induced changes in gene 
expression can be primarily attributed to translational control processes (21-22) it is 
possible to conclude that INK128’s effects on radiosensitivity are due in part to inhibition 
of cap-dependent translation.  Moreover, in our recent study using RIP-Chip analysis 
(104), irradiation of MDA-MB-231 cells was found to increase eIF4E binding to over 
1000 unique transcripts, a significant number of which were associated with the 
functional category of DNA Replication, Recombination and Repair.  Thus, the INK128-
mediated inhibition of gene translation may also play a role in its radiosensitizing actions, 
which will be the subject of future studies. 
 mTOR is the primary kinase involved in the regulation of cap-dependent 
translation initiation due in part to it control of 4E-BP1 phosphoryaltion (49).  Using 
immunohistochemical staining we showed a time and dose-dependent inhibition of 
mTOR activity in both Miapaca-2 and PSN1 tumor xenografts.  It has been shown that 
inhibition of mTOR by an ATP-competitive inhibitor results in the decrease of 4E-BP1 
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phosphorylation (92, 103).  This effect has been translated to an increase in binding of 
4E-BP1 and a concomitant decrease in the amount of eIF4G binding to the 5’ mRNA cap 
in vitro (93).  However, to the best of our knowledge, the effects of mTOR ATP-
competitive inhibition on eIF4F cap-complex formation have not been evaluated in vivo.  
Using m7-GTP batch chromatography in PSN1 tumor xenografts we showed inhibition of 
mTOR activity by INK128 does indeed translate to an inhibition of cap-complex 
formation in human tumor xenografts.  This inhibition of cap-dependent translation in 
vivo is consistent with the hypothesis that an inhibition of radiation-induced translation is 
involved in the mechanism of radiosensitization by the mTOR ATP-competitive inhibitor 
INK128.   
The study of in vivo pharmacodynamics and pharmacokinetic properties of a drug 
is important for the potential clinical translation of a drug, particularly when designing 
protocols combining multiple treatment modalities.  These effects are evidenced by our in 
vivo tumor growth delay experiments as well as in vitro clonogenic survival data.  The 
initial in vivo tumor growth delay experiment showing a lack of radiosensitization with a 
single dose of INK128 given immediately after radiation, emphasize the understanding of 
target engagement in vivo.  Both immunohistochemical analysis as well as analysis of 
cap-complex formation in vivo suggest mTOR activity in PSN1 tumor xenografts is 
beginning to return to baseline as early as 6h after the initial drug treatment.  When 
combined with the in vitro clonogenic survival data suggesting that mTOR inhibition for 
greater than 6h is required for effective radiosensitization, a redesign of the protocol to 
include additional drug dosing was performed.  In this protocol, INK128, when given 
twice daily with radiation, significantly enhanced radiation-induced tumor growth delay, 
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once again emphasizing the need for a thorough understanding of the pharmacodynamics 
and pharmacokinetics of drugs both in vitro and in vivo.  There are several ATP-
competitive inhibitors currently in clinical trials (including INK128) (64).  The data 
presented here showing that INK128 enhances pancreatic cancer radiosensitivity both in 
vitro and in vivo suggests that these inhibitors delivered in combination with radiotherapy 
may be of value as a treatment strategy for pancreatic cancer.  
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CHAPTER 7 
Overall Conclusions 
As described in the Chapter 1, radiation-induced control of gene expression 
appears to be controlled primarily at the level of mRNA translation (21-22).  The data 
presented in this thesis begin to elucidate the specific role of critical components of the 
translational machinery in determining the cellular response to ionizing radiation.   While 
there are numerous regulatory proteins in involved in translational control, eIF4E, S6K, 
and the mTOR kinase, which regulates both eIF4E and S6K, affect the rate-limiting step 
of mRNA translation; translation initiation (82).  As such the work presented in this 
thesis focused on determining the role of each protein in the radiation response.  In the 
case of both eIF4E and S6K, the initial studies aimed at determining the role of each 
protein in controlling cellular radiosensitivity focused on the use of siRNAs targeting 
these components.  In each case, siRNA specific to eIF4E and S6K enhanced the cellular 
radiosensitivity of tumor lines of various histologies.   
For a radiosensitizing compound to be clinically useful it must enhance the 
response of the tumor to radiation while sparing the normal tissue, as normal tissue 
toxicity is the dose-limiting factor in radiotherapy.  As described previously, inhibition of 
eIF4E, S6K, and mTOR expression or activity enhanced the radiosensitivity of various 
tumors, while having no effect on the in vitro radiosensitivity of normal tissues.  While 
these were studies were performed only in vitro they begin to address whether these 
regulatory components of the translational machinery could potentially serve as tumor 
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specific targets.  While the exact reason for this tumor specificity remains to be 
determined it is possible to speculate that the established differences in translational 
regulation between tumor and normal cells may be explanatory.  In the context of cellular 
signaling, tumors have been shown to have aberrant activation of numerous signaling 
pathways that transduce their signals through mTOR/eIF4E/S6K and hence activate 
mRNA translation (e.g. RTK, RAS/MAPK, and PI3K) (34, 57-58).  In fact 4E-BP1, the 
major regulator of eIF4E activity, has been referred to as a funnel factor (56), in so much 
as it exists as a downstream effector of many of the aforementioned hyper-activated 
oncogenic signaling pathways.  Specifically, the translational response to radiation has 
been shown to differ greatly in tumor and normal cells (21).  Lastly, in the context of 
combination therapy with standard DNA damaging chemotherapies and translation 
inhibitors, the combination was only synergistic when tumors had deregulated translation 
(85).  As such it is possible to conclude that the tumor specific radiosensitization seen 
with inhibition of these components of the translational machinery may be due to 
activation of oncogenic signaling pathways leading to an aberrant translational program.  
Future studies comparing the translational response of tumor versus normal cells in the 
context of mTOR inhibition may be used to begin to understand the tumor selectivity of 
targeting the above-mentioned components of the translational machinery. 
mRNA translation and components of the translational machinery have been 
implicated in cellular transformation and oncogenesis (28).  All three critical components 
of the translational machinery studied in this thesis have individually been shown to be 
critical for various aspects of cancer initiation and progression (e.g. cell growth, invasion, 
and cellular transformation) (34, 39, 66, 88).  Overexpression and hyperactivity of both 
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eIF4E (41-42) and the mTOR kinase (60) have been shown to impart a poor prognosis on 
patients with various tumors .  As such, agents aimed at targeting these components have 
been developed and are currently available for clinical use (64).  Some of the agents such 
as the ISIS eIF4E antisense, mTOR ATP-competitive inhibitors (e.g. INK128), and S6K 
inhibitors (e.g. LY2584702) have been mentioned previously in this dissertation.  The 
work presented here begins to highlight the importance of the translational machinery in 
determining tumor survival after radiation.   Given the clinical availability of agents 
targeting the translational machinery as well as the data presented showing that inhibition 
of these components enhances tumor cell radiosensitivity, it is logical to suggest 
evaluation of these agents in combination with radiation in the clinical trial setting. 
On the basis of analysis γH2AX induction and dispersal, both eIF4E as well as 
competitive mTOR inhibition appear to inhibit the repair of radiation-induced DNA 
DSBs.  Although direct interaction of eIF4E, mTOR, or an mTOR substrate with a 
component of the DNA repair machinery cannot be eliminated, the critical role of both 
proteins in the translational response to a wide variety of environmental and stress signals 
may provide a mechanistic basis for the observed inhibition of DNA DSB repair.  Several 
studies have shown that inhibition of mTOR activity results in inhibition of translation of 
mRNA corresponding to DNA repair genes (103, 105).  As detailed in Chapter 2, using 
microarray analysis of eIF4E-bound mRNAs, radiation was shown to induce eIF4E 
binding to more than 1000 unique transcripts.  A significant proportion of these mRNAs 
encode proteins related to DNA replication, recombination, and repair.  In agreement 
with our results a recent study using microarray analysis of polyribosome-bound mRNA 
found that radiation-induced translation of mRNAs that were involved in DNA damage 
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repair, several of which overlapped with proteins our study showed to be increasingly 
bound to eIF4G after irradiation.  Importantly, Singh and colleagues (55) have shown that 
DNA DSBs are generated not only from the initial radiation exposure, but also from 
chemical processing occurring for hours after exposure to radiation.  In this situation, a 
rapid induction in DNA damage response proteins may contribute to cell survival after 
radiation.  While our initial studies with eIF4E knockdown were unable to determine 
whether the tumor cell radiosensitization was due to an inhibition of radiation-induced 
gene expression, or changes in mRNA translation prior to irradiation, subsequent studies, 
with post-radiation addition of PP242 and INK128, suggest that the mechanism of 
radiosensitization involves an inhibition of a radiation-induced process (e.g. gene 
translation).  Thus, mTOR inhibition in the context of altering the radiation-induced 
translational response is currently the focus of additional studies in our laboratory. 
In summary, the data provided in this thesis have begun to characterize the role of 
the translational machinery in determining the cellular response to radiation.  While there 
is work that remains to be completed in understanding the exact mechanisms involved in 
the radiosensitization seen by targeting components of the translational machinery, we 
believe the work presented in this thesis argue that targeting components of the 
translational machinery is a strategy that deserves consideration for evaluation in the 
clinical trial setting.   
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Table A1: List of 1124 genes increasingly bound to eIF4E after irradiation 
 
Fold 
Increas
e 
Gene 
Symbol 
Gene Description 
2.2 ABCA11 ATP-binding 
cassette, sub-
family A (ABC1), 
member 11 
(pseudogene) 
3.1 ABHD4 abhydrolase 
domain containing 
4 
1.9 ABHD6 abhydrolase 
domain containing 
6 
1.5 ABT1 activator of basal 
transcription 1 
1.8 ACAD8 acyl-Coenzyme A 
dehydrogenase 
family, member 8 
1.8 ACAT1 acetyl-Coenzyme 
A acetyltransferase 
1 (acetoacetyl 
Coenzyme A 
thiolase) 
1.7 ACOT7 acyl-CoA 
thioesterase 7 
1.5 ACOT9 acyl-CoA 
thioesterase 9 
1.6 ACTR5 ARP5 actin-related 
protein 5 homolog 
(yeast) 
3 ADCK2 aarF domain 
containing kinase 2 
1.8 ADPGK ADP-dependent 
glucokinase 
2.4 ADSL adenylosuccinate 
lyase 
2.2 AGPAT2 1-acylglycerol-3-
phosphate O-
acyltransferase 2 
(lysophosphatidic 
acid 
acyltransferase, 
beta) 
1.5 AIM1L absent in 
melanoma 1-like 
1.5 AKR1C2 aldo-keto reductase 
family 1, member 
C2 (dihydrodiol 
dehydrogenase 2; 
bile acid binding 
protein; 3-alpha 
hydroxysteroid 
dehydrogenase, 
type III) 
1.8 AKR7A2 aldo-keto reductase 
family 7, member 
A2 (aflatoxin 
aldehyde 
reductase) 
4.1 ALKBH alkB, alkylation 
repair homolog (E. 
coli) 
1.9 AMFR autocrine motility 
factor receptor 
1.7 ANAPC5 anaphase 
promoting 
complex subunit 5 
1.8 ANKRD
40 
ankyrin repeat 
domain 40 
4.5 ANXA11 annexin A11 
1.5 AP4M1 adaptor-related 
protein complex 4, 
mu 1 subunit 
1.7 APBB1 amyloid beta (A4) 
precursor protein-
binding, family B, 
member 1 (Fe65) 
2 APLP2 amyloid beta (A4) 
precursor-like 
protein 2 
1.5 APOL3 apolipoprotein L, 3 
1.5 APTX aprataxin 
2.9 ARF3 ADP-ribosylation 
factor 3 
1.5 ARL6IP5 ADP-ribosylation-
like factor 6 
interacting protein 
5 
10.8 ARPC2 actin related 
protein 2/3 
complex, subunit 
2, 34kDa 
1.5 ARRB2 arrestin, beta 2 
1.8 ASB13 ankyrin repeat and 
SOCS box-
containing 13 
11.2 ASCIZ ATM/ATR-
Substrate Chk2-
Interacting Zn2+-
finger protein 
2.3 ATP1B3 ATPase, Na+/K+ 
transporting, beta 3 
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polypeptide 
1.7 ATP5B ATP synthase, H+ 
transporting, 
mitochondrial F1 
complex, beta 
polypeptide 
1.6 ATP5C1 ATP synthase, H+ 
transporting, 
mitochondrial F1 
complex, gamma 
polypeptide 1 
1.5 ATP5L ATP synthase, H+ 
transporting, 
mitochondrial F0 
complex, subunit g 
2 ATP6V0
E 
ATPase, H+ 
transporting, 
lysosomal 9kDa, 
V0 subunit e 
1.6 ATP6V1
D 
ATPase, H+ 
transporting, 
lysosomal 34kDa, 
V1 subunit D 
1.8 ATP8A2 ATPase, 
aminophospholipid 
transporter-like, 
Class I, type 8A, 
member 2 
1.8 ATPAF2 ATP synthase 
mitochondrial F1 
complex assembly 
factor 2 
2.2 B4GALT
4 
UDP-
Gal:betaGlcNAc 
beta 1,4- 
galactosyltransfera
se, polypeptide 4 
8.6 BBP Beta-amyloid 
binding protein 
precursor 
2.1 BBS4 Bardet-Biedl 
syndrome 4 
1.7 BCAT1 branched chain 
aminotransferase 1, 
cytosolic 
2.6 BCL10 B-cell 
CLL/lymphoma 10 
4.7 BCL2L1
1 
BCL2-like 11 
(apoptosis 
facilitator) 
3.5 BIRC5 baculoviral IAP 
repeat-containing 5 
(survivin) 
2.1 BMPR1A bone 
morphogenetic 
protein receptor, 
type IA 
1.7 BNIP2 BCL2/adenovirus 
E1B 19kDa 
interacting protein 
2 
1.9 BNIP3 BCL2/adenovirus 
E1B 19kDa 
interacting protein 
3 
1.7 BRE brain and 
reproductive 
organ-expressed 
(TNFRSF1A 
modulator) 
2.3 BTG1 B-cell 
translocation gene 
1, anti-proliferative 
1.6 C10orf57 chromosome 10 
open reading frame 
57 
2.7 C10orf61 chromosome 10 
open reading frame 
61 
2 C10orf97 chromosome 10 
open reading frame 
97 
1.7 C11orf24 chromosome 11 
open reading frame 
24 
4.8 C12orf41 chromosome 12 
open reading frame 
41 
1.6 C12orf49 chromosome 12 
open reading frame 
49 
1.6 C12orf52 chromosome 12 
open reading frame 
52 
1.7 C14orf13
8 
chromosome 14 
open reading frame 
138 
1.5 C14orf17
2 
chromosome 14 
open reading frame 
172 
1.5 C16orf45 chromosome 16 
open reading frame 
45 
1.7 C16orf58 chromosome 16 
open reading frame 
58 
1.6 C17orf39 chromosome 17 
open reading frame 
39 
1.8 C19orf2 chromosome 19 
open reading frame 
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2 
1.5 C19orf50 chromosome 19 
open reading frame 
50 
8.2 C1orf144 chromosome 1 
open reading frame 
144 
7.4 C1orf163 chromosome 1 
open reading frame 
163 
1.7 C1orf174 chromosome 1 
open reading frame 
174 
1.8 C1orf33 chromosome 1 
open reading frame 
33 
4.8 C20orf11
1 
chromosome 20 
open reading frame 
111 
1.7 C20orf24 chromosome 20 
open reading frame 
24 
3 C20orf29 chromosome 20 
open reading frame 
29 
5.3 C20orf44 chromosome 20 
open reading frame 
44 
3.8 C20orf45 chromosome 20 
open reading frame 
45 
3 C21orf91 chromosome 21 
open reading frame 
91 
4.8 C2orf43 chromosome 2 
open reading frame 
43 
1.5 C3orf18 chromosome 3 
open reading frame 
18 
1.7 C3orf37 chromosome 3 
open reading frame 
37 
1.8 C5orf30 chromosome 5 
open reading frame 
30 
3.7 C6orf106 chromosome 6 
open reading frame 
106 
4 C6orf49 chromosome 6 
open reading frame 
49 
1.8 C6orf82 chromosome 6 
open reading frame 
82 
1.6 C7orf26 chromosome 7 
open reading frame 
26 
10 C8orf30
A 
chromosome 8 
open reading frame 
30A 
3 C9orf78 chromosome 9 
open reading frame 
78 
5.4 C9orf82 chromosome 9 
open reading frame 
82 
4.1 CABIN1 calcineurin binding 
protein 1 
6.1 CALM1 calmodulin 1 
(phosphorylase 
kinase, delta) 
4.3 CAMLG calcium 
modulating ligand 
2.3 CAMTA
2 
calmodulin binding 
transcription 
activator 2 
4.7 CASP3 caspase 3, 
apoptosis-related 
cysteine peptidase 
1.8 CASP9 caspase 9, 
apoptosis-related 
cysteine peptidase 
1.5 CAV2 caveolin 2 
2.2 CCDC13
2 
coiled-coil domain 
containing 132 
3.9 CCNA1 cyclin A1 
1.7 CCNA2 cyclin A2 
1.6 CCNB1I
P1 
cyclin B1 
interacting protein 
1 
2.5 CCNE2 cyclin E2 
1.9 CCS copper chaperone 
for superoxide 
dismutase 
3 CD164 CD164 antigen, 
sialomucin 
1.7 CD59 CD59 antigen p18-
20 (antigen 
identified by 
monoclonal 
antibodies 16.3A5, 
EJ16, EJ30, EL32 
and G344) 
4.3 CD63 CD63 antigen 
(melanoma 1 
antigen) 
1.6 CDC2 cell division cycle 
2, G1 to S and G2 
to M 
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4.9 CDC25C cell division cycle 
25C 
2.2 CDC42E
P2 
CDC42 effector 
protein (Rho 
GTPase binding) 2 
1.6 CDCA4 cell division cycle 
associated 4 
1.7 CDKL3 cyclin-dependent 
kinase-like 3 
1.9 CDKN1
A 
cyclin-dependent 
kinase inhibitor 1A 
(p21, Cip1) 
1.7 CDKN2C cyclin-dependent 
kinase inhibitor 2C 
(p18, inhibits 
CDK4) 
1.5 CDKN3 cyclin-dependent 
kinase inhibitor 3 
(CDK2-associated 
dual specificity 
phosphatase) 
2.3 CDYL chromodomain 
protein, Y-like 
2 CENPB centromere protein 
B, 80kDa 
3.2 CENPO centromere protein 
O  
6.1 CEP57 centrosomal 
protein 57kDa 
1.5 CEPT1 choline/ethanolami
ne 
phosphotransferase 
1 
2.3 CHCHD7 coiled-coil-helix-
coiled-coil-helix 
domain containing 
7 
7.6 CHEK1 CHK1 checkpoint 
homolog (S. 
pombe) 
3.1 CHST10 carbohydrate 
sulfotransferase 10 
1.8 CIDEC cell death-inducing 
DFFA-like effector 
c 
1.6 CINP cyclin-dependent 
kinase 2-
interacting protein 
2.2 CIR CBF1 interacting 
corepressor  
3.1 CLIC1 chloride 
intracellular 
channel 1 
5.5 CLIC4 chloride 
intracellular 
channel 4 
2 CLINT1 clathrin interactor 
1 
1.5 CLN5 ceroid-
lipofuscinosis, 
neuronal 5 
1.7 CLTA clathrin, light 
polypeptide (Lca) 
7.5 CNGA1 cyclic nucleotide 
gated channel 
alpha 1 
2.3 CNIH3 cornichon homolog 
3 (Drosophila) 
1.9 CNKSR1 connector enhancer 
of kinase 
suppressor of Ras 
1 
5.5 CNP 2',3'-cyclic 
nucleotide 3' 
phosphodiesterase 
9.9 COG2 component of 
oligomeric golgi 
complex 2 
1.7 COPS2 COP9 constitutive 
photomorphogenic 
homolog subunit 2 
(Arabidopsis) 
6.1 COPS7B COP9 constitutive 
photomorphogenic 
homolog subunit 
7B (Arabidopsis) 
1.5 COPS8 COP9 constitutive 
photomorphogenic 
homolog subunit 8 
(Arabidopsis) 
1.9 COQ2 coenzyme Q2 
homolog, 
prenyltransferase 
(yeast) 
1.8 COTL1 coactosin-like 1 
(Dictyostelium) 
3.5 COX11 COX11 homolog, 
cytochrome c 
oxidase assembly 
protein (yeast) 
1.5 COX7A2 cytochrome c 
oxidase subunit 
VIIa polypeptide 2 
(liver) 
1.8 COX7B cytochrome c 
oxidase subunit 
VIIb 
1.5 CREB1 cAMP responsive 
element binding 
protein 1 
2.3 CREG1 cellular repressor 
of E1A-stimulated 
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genes 1 
2.1 CRELD1 cysteine-rich with 
EGF-like domains 
1 
15.7 CRI1 CREBBP/EP300 
inhibitor 1 
1.5 CSNK1A
1 
casein kinase 1, 
alpha 1 
6.2 CTBP2 C-terminal binding 
protein 2 
4.4 CTDSP1 CTD (carboxy-
terminal domain, 
RNA polymerase 
II, polypeptide A) 
small phosphatase 
1 
2.5 CTDSP2 CTD (carboxy-
terminal domain, 
RNA polymerase 
II, polypeptide A) 
small phosphatase 
2 
1.7 CTDSPL CTD (carboxy-
terminal domain, 
RNA polymerase 
II, polypeptide A) 
small phosphatase-
like 
2.4 CTGLF1 centaurin, gamma-
like family, 
member 1 
6.5 CTH cystathionase 
(cystathionine 
gamma-lyase) 
1.7 CTSB cathepsin B 
1.8 CTSS cathepsin S 
1.9 CXorf12 chromosome X 
open reading frame 
12 
3.9 CXorf15 chromosome X 
open reading frame 
15 
5.5 CYB5B cytochrome b5 
type B (outer 
mitochondrial 
membrane) 
2.5 CYB5R3 cytochrome b5 
reductase 3 
4.3 DBT dihydrolipoamide 
branched chain 
transacylase E2 
24.9 DCLRE1
B 
DNA cross-link 
repair 1B (PSO2 
homolog, S. 
cerevisiae) 
1.6 DCTD dCMP deaminase 
2.2 DCTN4 dynactin 4 (p62) 
2.9 DCTN5 dynactin 5 (p25) 
1.6 DDX19A DEAD (Asp-Glu-
Ala-As) box 
polypeptide 19A 
1.6 DDX28 DEAD (Asp-Glu-
Ala-Asp) box 
polypeptide 28 
3.1 DDX50 DEAD (Asp-Glu-
Ala-Asp) box 
polypeptide 50 
1.7 DENND2
D 
DENN/MADD 
domain containing 
2D 
3.1 DFFB DNA 
fragmentation 
factor, 40kDa, beta 
polypeptide 
(caspase-activated 
DNase) 
1.8 DHRS12 dehydrogenase/red
uctase (SDR 
family) member 12 
2.4 DHRS3 dehydrogenase/red
uctase (SDR 
family) member 3 
9.3 DIP death-inducing-
protein  
1.6 DKFZP5
64K0822 
hypothetical 
protein 
DKFZp564K0822 
2.9 DMWD dystrophia 
myotonica-
containing WD 
repeat motif 
2.1 DNAJB1
2 
DnaJ (Hsp40) 
homolog, 
subfamily B, 
member 12 
1.7 DNAJB9 DnaJ (Hsp40) 
homolog, 
subfamily B, 
member 9 
2.1 DNAJC1
7 
DnaJ (Hsp40) 
homolog, 
subfamily C, 
member 17 
2 DNAJC8 DnaJ (Hsp40) 
homolog, 
subfamily C, 
member 8 
1.9 DNAJC9 DnaJ (Hsp40) 
homolog, 
subfamily C, 
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member 9 
4.7 DR1 down-regulator of 
transcription 1, 
TBP-binding 
(negative cofactor 
2) 
2.5 DSTN destrin (actin 
depolymerizing 
factor) 
4.4 DTX2 deltex homolog 2 
(Drosophila) 
1.8 DUSP1 dual specificity 
phosphatase 1 
1.5 DYNLL1 dynein, light chain, 
LC8-type 1 
1.8 DYNLT1 dynein, light chain, 
Tctex-type 1 
1.7 DYNLT3 dynein, light chain, 
Tctex-type 3 
7.1 E2F6 E2F transcription 
factor 6 
1.6 EBAG9 estrogen receptor 
binding site 
associated, antigen, 
9 
3.9 EEF1B2 eukaryotic 
translation 
elongation factor 1 
beta 2 
1.5 EFCAB2 EF-hand calcium 
binding domain 2 
165.8 EFEMP2 EGF-containing 
fibulin-like 
extracellular 
matrix protein 2 
3.2 EFNA4 ephrin-A4 
1.8 EGFL9 EGF-like-domain, 
multiple 9 
3.7 EI24 etoposide induced 
2.4 mRNA 
1.7 EIF3S4 eukaryotic 
translation 
initiation factor 3, 
subunit 4 delta, 
44kDa 
4 EIF5 eukaryotic 
translation 
initiation factor 5 
1.7 EML2 echinoderm 
microtubule 
associated protein 
like 2 
2.3 EMP1 epithelial 
membrane protein 
1 
4.3 EMP2 epithelial 
membrane protein 
2 
1.6 ENDOG
L1 
endonuclease G-
like 1 
5.3 ENOSF1 enolase 
superfamily 
member 1 
1.7 ENOX1 ecto-NOX 
disulfide-thiol 
exchanger 1 
3.3 ENSA endosulfine alpha 
2.3 EPOR erythropoietin 
receptor 
1.9 ERCC8 excision repair 
cross-
complementing 
rodent repair 
deficiency, 
complementation 
group 8 
12.5 ETF1 eukaryotic 
translation 
termination factor 
1 
1.6 ETNK2 ethanolamine 
kinase 2 
2.8 ETS2 v-ets 
erythroblastosis 
virus E26 
oncogene homolog 
2 (avian) 
3.2 ETV7 ets variant gene 7 
(TEL2 oncogene) 
7 EXOC5 exocyst complex 
component 5 
2.5 EXOSC2 exosome 
component 2 
3.1 F2RL1 coagulation factor 
II (thrombin) 
receptor-like 1 
1.5 FAF1 Fas (TNFRSF6) 
associated factor 1 
2.6 FAHD2A fumarylacetoacetat
e hydrolase domain 
containing 2A 
1.7 FAM105
A 
family with 
sequence similarity 
105, member A 
2.4 FAM131
A 
family with 
sequence similarity 
131, member A 
4.7 FAM48A family with 
sequence similarity 
48, member A 
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7.3 FAM57A family with 
sequence similarity 
57, member A 
2.2 FAS Fas (TNF receptor 
superfamily, 
member 6) 
1.9 FASTK Fas-activated 
serine/threonine 
kinase 
2.1 FASTKD
5 
FAST kinase 
domains 5 
1.8 FAU Finkel-Biskis-
Reilly murine 
sarcoma virus 
(FBR-MuSV) 
ubiquitously 
expressed (fox 
derived); 
ribosomal protein 
S30 
1.6 FBL fibrillarin 
5 FBXL4 F-box and leucine-
rich repeat protein 
4 
1.7 FBXO28 F-box protein 28 
1.7 FBXO9 F-box protein 9 
2.2 FBXW11 F-box and WD-40 
domain protein 11 
1.6 FDFT1 farnesyl-
diphosphate 
farnesyltransferase 
1 
1.5 FKBP2 FK506 binding 
protein 2, 13kDa 
1.7 FLJ2222
2 
hypothetical 
protein FLJ22222 
1.8 FN3KRP fructosamine-3-
kinase-related 
protein 
1.5 FOXF2 forkhead box F2 
2.3 FRAG1 FGF receptor 
activating protein 1 
1.5 FTH1 ferritin, heavy 
polypeptide 1 
3.1 FTHP1 ferritin, heavy 
polypeptide 
pseudogene 1 
2.5 FTL ferritin, light 
polypeptide 
7.6 FUSIP1 FUS interacting 
protein 
(serine/arginine-
rich) 1 
2.1 FZR1 fizzy/cell division 
cycle 20 related 1 
(Drosophila) 
2 G3BP2 GTPase activating 
protein (SH3 
domain) binding 
protein 2  
12.8 GABAR
APL1 
GABA(A) 
receptor-associated 
protein like 1 
2.7 GAD1 glutamate 
decarboxylase 1 
(brain, 67kDa) 
1.9 GAS2L1 growth arrest-
specific 2 like 1 
2.7 GAS6 growth arrest-
specific 6 
3.2 GCDH glutaryl-Coenzyme 
A dehydrogenase 
6.9 GDF11 growth 
differentiation 
factor 11 
1.5 GENX-
3414 
genethonin 1 
1.5 GGA2 golgi associated, 
gamma adaptin ear 
containing, ARF 
binding protein 2 
1.5 GGH gamma-glutamyl 
hydrolase 
(conjugase, 
folylpolygammagl
utamyl hydrolase) 
1.6 GGPS1 geranylgeranyl 
diphosphate 
synthase 1 
8.4 GGTL4 gamma-
glutamyltransferas
e-like 4 
1.8 GHITM growth hormone 
inducible 
transmembrane 
protein 
1.8 GINS4 GINS complex 
subunit 4 (Sld5 
homolog) 
2.2 GLUD1 glutamate 
dehydrogenase 1 
4 GM2A GM2 ganglioside 
activator 
1.6 GNAS GNAS complex 
locus 
2.2 GNB1L guanine nucleotide 
binding protein (G 
protein), beta 
polypeptide 1-like 
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1.9 GPR110 G protein-coupled 
receptor 110 
2.3 GPR172
A 
G protein-coupled 
receptor 172A 
2.4 GPR30 G protein-coupled 
receptor 30 
3 GPX7 glutathione 
peroxidase 7 
2.7 GRB10 growth factor 
receptor-bound 
protein 10 
1.7 GRK6 G protein-coupled 
receptor kinase 6 
2 GRPEL1 GrpE-like 1, 
mitochondrial (E. 
coli) 
3 GSK3A glycogen synthase 
kinase 3 alpha 
4 GTDC1 glycosyltransferase
-like domain 
containing 1 
1.6 GTF2H2 general 
transcription factor 
IIH, polypeptide 2, 
44kDa 
1.9 GTF3C2 general 
transcription factor 
IIIC, polypeptide 
2, beta 110kDa 
1.9 GYG1 glycogenin 1 
11.8 HCP5 HLA complex P5 
1.7 HEMK1 HemK 
methyltransferase 
family member 1 
5.3 HEXB hexosaminidase B 
(beta polypeptide) 
1.9 HIGD1A HIG1 domain 
family, member 
1A 
1.6 HINT1 histidine triad 
nucleotide binding 
protein 1 
2.6 HIST1H1
E 
histone 1, H1e 
1.7 HIST1H2
BD 
histone 1, H2bd 
2.1 HIST1H2
BK 
histone 1, H2bk 
1.8 HIST1H2
BM 
histone 1, H2bm 
39.4 HLA-F major 
histocompatibility 
complex, class I, F 
1.5 HMOX1 heme oxygenase 
(decycling) 1 
2 HSBP1 heat shock factor 
binding protein 1 
1.5 HSD17B
7P2 
hydroxysteroid 
(17-beta) 
dehydrogenase 7 
pseudogene 2 
2.4 HSF2BP heat shock 
transcription factor 
2 binding protein 
1.6 HSPA4 heat shock 70kDa 
protein 4 
1.8 HSPBAP
1 
HSPB (heat shock 
27kDa) associated 
protein 1 
1.9 HSPC111 hypothetical 
protein HSPC111 
3.4 HTATIP HIV-1 Tat 
interacting protein, 
60kDa 
1.9 IDH2 isocitrate 
dehydrogenase 2 
(NADP+), 
mitochondrial 
2.1 IDH3B isocitrate 
dehydrogenase 3 
(NAD+) beta 
1.7 IDI1 isopentenyl-
diphosphate delta 
isomerase 1 
1.6 IER3 immediate early 
response 3 
1.6 IGFBP7 insulin-like growth 
factor binding 
protein 7 
2.7 IIP45 invasion inhibitory 
protein 45  
2 IL11 interleukin 11 
2.1 IL11RA interleukin 11 
receptor, alpha 
4.1 IL13RA1 interleukin 13 
receptor, alpha 1 
1.8 IL15 interleukin 15 
1.6 ING1 inhibitor of growth 
family, member 1 
5.1 ING2 inhibitor of growth 
family, member 2 
1.9 ING4 inhibitor of growth 
family, member 4 
1.6 INSIG1 insulin induced 
gene 1 
5.4 IPO13 importin 13 
1.7 IQCC IQ motif 
containing C 
6.4 IRX5 iroquois homeobox 
protein 5 
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2 ISG20L2 interferon 
stimulated 
exonuclease gene 
20kDa-like 2 
3.9 IVD isovaleryl 
Coenzyme A 
dehydrogenase 
4.6 JOSD1 Josephin domain 
containing 1 
2.2 KATNA1 katanin p60 
(ATPase-
containing) subunit 
A 1 
2.8 KCTD13 potassium channel 
tetramerisation 
domain containing 
13 
1.5 KCTD14 potassium channel 
tetramerisation 
domain containing 
14 
1.6 KDELR2 KDEL (Lys-Asp-
Glu-Leu) 
endoplasmic 
reticulum protein 
retention receptor 2 
20.5 KDELR3 KDEL (Lys-Asp-
Glu-Leu) 
endoplasmic 
reticulum protein 
retention receptor 3 
1.5 KIAA040
9 
KIAA0409 
1.9 KIF22 kinesin family 
member 22 
1.5 KLF2 Kruppel-like factor 
2 (lung) 
2 KLF4 Kruppel-like factor 
4 (gut) 
29.4 KLF6 Kruppel-like factor 
6 
1.6 KPNA2 karyopherin alpha 
2 (RAG cohort 1, 
importin alpha 1) 
1.5 KPNA6 karyopherin alpha 
6 (importin alpha 
7) 
2.2 LANCL1 LanC lantibiotic 
synthetase 
component C-like 
1 (bacterial) 
2.1 LARP6 La 
ribonucleoprotein 
domain family, 
member 6 
2.8 LASS2 LAG1 longevity 
assurance homolog 
2 (S. cerevisiae) 
63.1 LGALS1 lectin, galactoside-
binding, soluble, 1 
(galectin 1) 
1.6 LGALS8 lectin, galactoside-
binding, soluble, 8 
(galectin 8) 
1.6 LHFP lipoma HMGIC 
fusion partner 
2.8 LITAF lipopolysaccharide
-induced TNF 
factor 
2 LOC2601
0 
viral DNA 
polymerase-
transactivated 
protein 6 
2.1 LOC4412
94 
similar to 
CTAGE6 
1.9 LOC5410
3 
hypothetical 
protein LOC54103 
1.9 LONRF3 LON peptidase N-
terminal domain 
and ring finger 3 
3 LRRFIP2 leucine rich repeat 
(in FLII) 
interacting protein 
2 
2.1 LSM5 LSM5 homolog, 
U6 small nuclear 
RNA associated 
(S. cerevisiae) 
2.7 LYPLA1 lysophospholipase 
I 
1.7 LYRM1 LYR motif 
containing 1 
2.3 MAFF v-maf 
musculoaponeuroti
c fibrosarcoma 
oncogene homolog 
F (avian) 
1.7 MANEA mannosidase, 
endo-alpha 
1.8 MAP2K4 mitogen-activated 
protein kinase 
kinase 4 
1.5 MAP2K5 mitogen-activated 
protein kinase 
kinase 5 
2.3 MAP2K7 mitogen-activated 
protein kinase 
kinase 7 
1.7 MAP3K7
IP2 
mitogen-activated 
protein kinase 
kinase kinase 7 
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interacting protein 
2 
2.1 MAPK12 mitogen-activated 
protein kinase 12 
1.5 MAPKA
PK2 
mitogen-activated 
protein kinase-
activated protein 
kinase 2 
1.5 MBD1 methyl-CpG 
binding domain 
protein 1 
1.5 MBIP MAP3K12 binding 
inhibitory protein 1 
1.7 MCFP mitochondrial 
carrier family 
protein 
1.5 MCOLN
1 
mucolipin 1 
2.1 MCP membrane cofactor 
protein (CD46, 
trophoblast-
lymphocyte cross-
reactive antigen) 
1.5 MDH1 malate 
dehydrogenase 1, 
NAD (soluble) 
10.4 ME2 malic enzyme 2, 
NAD(+)-
dependent, 
mitochondrial 
2 ME3 malic enzyme 3, 
NADP(+)-
dependent, 
mitochondrial 
3.3 MECP2 methyl CpG 
binding protein 2 
(Rett syndrome) 
2.8 MED18 mediator of RNA 
polymerase II 
transcription, 
subunit 18 
homolog (yeast) 
5.3 MED9 mediator of RNA 
polymerase II 
transcription, 
subunit 9 homolog 
(yeast) 
2.4 MEST mesoderm specific 
transcript homolog 
(mouse) 
1.7 METTL2 methyltransferase 
like 2 
1.5 MFN2 mitofusin 2 
1.7 MFSD5 major facilitator 
superfamily 
domain containing 
5 
1.6 MGC143
76 
hypothetical 
protein 
MGC14376 
1.9 MGC275
2 
hypothetical 
protein MGC2752  
1.5 MGST2 microsomal 
glutathione S-
transferase 2 
1.5 MICA MHC class I 
polypeptide-related 
sequence A 
2.2 MID1IP1 MID1 interacting 
protein 1 
(gastrulation 
specific G12-like 
(zebrafish)) 
2.3 MIS12 MIS12 homolog 
(yeast) 
1.6 MKNK2 MAP kinase 
interacting 
serine/threonine 
kinase 2 
1.5 MLL4 myeloid/lymphoid 
or mixed-lineage 
leukemia 4 
1.9 MLX MAX-like protein 
X 
1.9 MLYCD malonyl-CoA 
decarboxylase 
1.7 MMD monocyte to 
macrophage 
differentiation-
associated 
1.5 MMP14 matrix 
metallopeptidase 
14 (membrane-
inserted) 
23 MMP9 matrix 
metallopeptidase 9 
(gelatinase B, 
92kDa gelatinase, 
92kDa type IV 
collagenase) 
2.7 MPZL1 myelin protein 
zero-like 1 
11.4 MR1 major 
histocompatibility 
complex, class I-
related 
1.5 MRPL3 mitochondrial 
ribosomal protein 
L3 
2.1 MRPL9 mitochondrial 
ribosomal protein 
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L9 
1.5 MRPS10 mitochondrial 
ribosomal protein 
S10 
1.7 MRPS12 mitochondrial 
ribosomal protein 
S12 
2.5 MRS2L MRS2-like, 
magnesium 
homeostasis factor 
(S. cerevisiae) 
2.8 MT1H metallothionein 1H 
40.7 MT1X metallothionein 1X 
1.7 MTA1 metastasis 
associated 1 
3.7 MTHFD2
L 
methylenetetrahydr
ofolate 
dehydrogenase 
(NADP+ 
dependent) 2-like 
2.8 MTO1 mitochondrial 
translation 
optimization 1 
homolog (S. 
cerevisiae) 
1.9 MTRR 5-
methyltetrahydrofo
late-homocysteine 
methyltransferase 
reductase 
1.5 MVK mevalonate kinase 
(mevalonic 
aciduria) 
4.4 MXRA7 matrix-remodelling 
associated 7 
1.6 MYCBP c-myc binding 
protein 
1.9 MYD88 myeloid 
differentiation 
primary response 
gene (88) 
2.3 MYL4 myosin, light 
polypeptide 4, 
alkali; atrial, 
embryonic 
3.6 MYNN myoneurin 
2.3 MYO9B myosin IXB 
1.8 MYOHD
1 
myosin head 
domain containing 
1 
2.4 MYST1 MYST histone 
acetyltransferase 1 
8.9 na similar to 60S 
ribosomal protein 
L13 (A52) 
2.2 NAB1 NGFI-A binding 
protein 1 (EGR1 
binding protein 1) 
1.7 NADK NAD kinase 
1.8 NAPG N-ethylmaleimide-
sensitive factor 
attachment protein, 
gamma 
1.5 NDUFA5 NADH 
dehydrogenase 
(ubiquinone) 1 
alpha subcomplex, 
5, 13kDa 
3.6 NEK11 NIMA (never in 
mitosis gene a)- 
related kinase 11 
1.5 NEK2 NIMA (never in 
mitosis gene a)-
related kinase 2 
1.5 NFYC nuclear 
transcription factor 
Y, gamma 
2.1 NGFRAP
1 
nerve growth 
factor receptor 
(TNFRSF16) 
associated protein 
1 
1.9 NGRN neugrin, neurite 
outgrowth 
associated 
1.8 NIPSNA
P1 
nipsnap homolog 1 
(C. elegans) 
2.5 NMD3 NMD3 homolog 
(S. cerevisiae) 
1.8 NMT1 N-
myristoyltransferas
e 1 
3.4 NMT2 N-
myristoyltransferas
e 2 
2.1 NOSIP nitric oxide 
synthase 
interacting protein 
1.5 NPAS2 neuronal PAS 
domain protein 2 
6.8 NSDHL NAD(P) dependent 
steroid 
dehydrogenase-like 
2.1 NSMAF neutral 
sphingomyelinase 
(N-SMase) 
activation 
associated factor 
4 OAZ1 ornithine 
103	  	  
decarboxylase 
antizyme 1 
1.5 OR7E47
P 
olfactory receptor, 
family 7, 
subfamily E, 
member 47 
pseudogene  
1.8 ORC4L origin recognition 
complex, subunit 
4-like (yeast) 
1.6 OTUB1 OTU domain, 
ubiquitin aldehyde 
binding 1 
1.8 P2RX5 purinergic receptor 
P2X, ligand-gated 
ion channel, 5 
12.7 P2RY2 purinergic receptor 
P2Y, G-protein 
coupled, 2 
1.6 PABPN1 poly(A) binding 
protein, nuclear 1 
1.5 PAIP1 poly(A) binding 
protein interacting 
protein 1 
1.8 PAOX polyamine oxidase 
(exo-N4-amino) 
2.2 PAX8 paired box gene 8 
1.5 PBX2 pre-B-cell 
leukemia 
transcription factor 
2 
4 PCGF2 polycomb group 
ring finger 2 
1.8 PCLO piccolo 
(presynaptic 
cytomatrix protein) 
2.9 PCOLCE
2 
procollagen C-
endopeptidase 
enhancer 2 
2.1 PCTP phosphatidylcholin
e transfer protein 
9 PCYT1A phosphate 
cytidylyltransferas
e 1, choline, alpha 
2.9 PDCD2 programmed cell 
death 2 
1.6 PDE10A phosphodiesterase 
10A 
1.9 PDS5A PDS5, regulator of 
cohesion 
maintenance, 
homolog A (S. 
cerevisiae) 
2.1 PEX16 peroxisomal 
biogenesis factor 
16 
1.7 PEX3 peroxisomal 
biogenesis factor 3 
2.4 PFKL phosphofructokina
se, liver 
1.7 PGF placental growth 
factor, vascular 
endothelial growth 
factor-related 
protein 
6.7 PGGT1B protein 
geranylgeranyltran
sferase type I, beta 
subunit 
1.5 PHB prohibitin 
1.5 PHF1 PHD finger protein 
1 
1.9 PHF2 PHD finger protein 
2 
1.6 PHTF1 putative 
homeodomain 
transcription factor 
1 
15.2 PHTF2 putative 
homeodomain 
transcription factor 
2 
3.3 PIAS2 protein inhibitor of 
activated STAT, 2 
7.7 PIGB phosphatidylinosit
ol glycan, class B 
2.5 PIK4CB phosphatidylinosit
ol 4-kinase, 
catalytic, beta 
polypeptide 
1.8 PIM2 pim-2 oncogene 
2.3 PIP5K1A phosphatidylinosit
ol-4-phosphate 5-
kinase, type I, 
alpha 
2 PKNOX1 PBX/knotted 1 
homeobox 1 
2.9 PLA2G4
B 
phospholipase A2, 
group IVB 
(cytosolic) 
3.3 PLAC1 placenta-specific 1 
1.5 PLAUR plasminogen 
activator, 
urokinase receptor 
1.5 PLEKH
M2 
pleckstrin 
homology domain 
containing, family 
M (with RUN 
domain) member 2 
1.6 PLSCR3 phospholipid 
scramblase 3 
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2.1 PMAIP1 phorbol-12-
myristate-13-
acetate-induced 
protein 1 
18.4 PMP22 peripheral myelin 
protein 22 
1.9 PMS2L3 postmeiotic 
segregation 
increased 2-like 3 
1.6 PMS2L5 postmeiotic 
segregation 
increased 2-like 5 
4.8 POLA2 polymerase (DNA 
directed), alpha 2 
(70kD subunit) 
2 POLDIP2 polymerase (DNA-
directed), delta 
interacting protein 
2 
6.2 POLDIP3 polymerase (DNA-
directed), delta 
interacting protein 
3 
9.4 POLE3 polymerase (DNA 
directed), epsilon 3 
(p17 subunit) 
1.6 PON3 paraoxonase 3 
2.7 POT1 POT1 protection of 
telomeres 1 
homolog (S. 
pombe) 
1.6 PPA1 pyrophosphatase 
(inorganic) 1 
2.3 PPFIA1 protein tyrosine 
phosphatase, 
receptor type, f 
polypeptide 
(PTPRF), 
interacting protein 
(liprin), alpha 1 
2.8 PPIA peptidylprolyl 
isomerase A 
(cyclophilin A)  
1.6 PPID peptidylprolyl 
isomerase D 
(cyclophilin D) 
2.5 PPP1R7 protein 
phosphatase 1, 
regulatory subunit 
7 
4.8 PPP2R1B protein 
phosphatase 2 
(formerly 2A), 
regulatory subunit 
A (PR 65), beta 
isoform 
10 PPP3R1 protein 
phosphatase 3 
(formerly 2B), 
regulatory subunit 
B, 19kDa, alpha 
isoform 
(calcineurin B, 
type I) 
2.2 PPT2 palmitoyl-protein 
thioesterase 2 
1.8 PRG1 proteoglycan 1, 
secretory granule 
1.5 PRKAB1 protein kinase, 
AMP-activated, 
beta 1 non-
catalytic subunit 
2.4 PRKD3 protein kinase D3 
4.3 PRKRIP1 PRKR interacting 
protein 1 (IL11 
inducible) 
2.2 PRPF4 PRP4 pre-mRNA 
processing factor 4 
homolog (yeast) 
5.6 PRSS23 protease, serine, 23 
1.5 PRUNE prune homolog 
(Drosophila) 
12.4 PSKH1 protein serine 
kinase H1 
1.8 PSMA1 proteasome 
(prosome, 
macropain) 
subunit, alpha type, 
1 
1.5 PSMA7 proteasome 
(prosome, 
macropain) 
subunit, alpha type, 
7 
5.5 PSMB4 proteasome 
(prosome, 
macropain) 
subunit, beta type, 
4 
1.6 PSMC5 proteasome 
(prosome, 
macropain) 26S 
subunit, ATPase, 5 
2 PSMD4 proteasome 
(prosome, 
macropain) 26S 
subunit, non-
ATPase, 4 
1.7 PSME1 proteasome 
(prosome, 
macropain) 
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activator subunit 1 
(PA28 alpha) 
2 PTP4A1 protein tyrosine 
phosphatase type 
IVA, member 1 
1.6 PTPLAD
1 
protein tyrosine 
phosphatase-like A 
domain containing 
1 
7.1 PTPN11 protein tyrosine 
phosphatase, non-
receptor type 11 
(Noonan syndrome 
1) 
11.7 PTPN2 protein tyrosine 
phosphatase, non-
receptor type 2 
1.6 PTPN3 protein tyrosine 
phosphatase, non-
receptor type 3 
1.6 PTPN9 protein tyrosine 
phosphatase, non-
receptor type 9 
3.9 PTPRA protein tyrosine 
phosphatase, 
receptor type, A 
1.7 PTTG1 pituitary tumor-
transforming 1 
7.8 QKI quaking homolog, 
KH domain RNA 
binding (mouse) 
1.9 RAB2 RAB2, member 
RAS oncogene 
family 
2.9 RAB23 RAB23, member 
RAS oncogene 
family 
8.8 RABEP1 rabaptin, RAB 
GTPase binding 
effector protein 1 
2 RABL2B RAB, member of 
RAS oncogene 
family-like 2B 
1.8 RAC3 ras-related C3 
botulinum toxin 
substrate 3 (rho 
family, small GTP 
binding protein 
Rac3) 
1.5 RAD17 RAD17 homolog 
(S. pombe) 
1.8 RAD51 RAD51 homolog 
(RecA homolog, E. 
coli) (S. cerevisiae) 
1.7 RAD51A
P1 
RAD51 associated 
protein 1 
1.9 RAD9A RAD9 homolog A 
(S. pombe) 
1.7 RALA v-ral simian 
leukemia viral 
oncogene homolog 
A (ras related) 
6.5 RANBP3 RAN binding 
protein 3 
1.7 RANGA
P1 
Ran GTPase 
activating protein 1 
2.2 RBMS2 RNA binding 
motif, single 
stranded 
interacting protein 
2 
1.7 RBMX2 RNA binding motif 
protein, X-linked 2 
1.5 RCL1 RNA terminal 
phosphate cyclase-
like 1 
3.7 RCP9 Calcitonin gene-
related peptide-
receptor 
component protein 
2.3 RGS19 regulator of G-
protein signalling 
19 
1.5 RHEB Ras homolog 
enriched in brain 
2.4 RHOA ras homolog gene 
family, member A 
7 RHOBT
B3 
Rho-related BTB 
domain containing 
3 
1.8 RHOT1 ras homolog gene 
family, member T1 
1.6 RHOT2 ras homolog gene 
family, member T2 
1.6 RIPK2 receptor-
interacting serine-
threonine kinase 2 
2 RNF146 ring finger protein 
146 
1.5 RNF41 ring finger protein 
41 
1.9 RNPEPL
1 
arginyl 
aminopeptidase 
(aminopeptidase 
B)-like 1 
3.2 RPA1 replication protein 
A1, 70kDa 
2.4 RPL13 ribosomal protein 
L13 
2.4 RPL18 ribosomal protein 
L18 
2.6 RPL35 ribosomal protein 
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L35 
18.5 RPL35A ribosomal protein 
L35a 
1.7 RPS10 ribosomal protein 
S10  
2 RPS14 ribosomal protein 
S14 
1.9 RPS20 ribosomal protein 
S20 
3 RPS6KA
4 
ribosomal protein 
S6 kinase, 90kDa, 
polypeptide 4 
1.5 RPS6KB
1 
ribosomal protein 
S6 kinase, 70kDa, 
polypeptide 1 
4.5 RRAGD Ras-related GTP 
binding D 
1.5 RRM2 ribonucleotide 
reductase M2 
polypeptide 
1.9 RRP15 ribosomal RNA 
processing 15 
homolog (S. 
cerevisiae) 
2 RRS1 RRS1 ribosome 
biogenesis 
regulator homolog 
(S. cerevisiae) 
1.7 RSU1 Ras suppressor 
protein 1 
1.5 RY1 putative nucleic 
acid binding 
protein RY-1  
1.9 S100A10 S100 calcium 
binding protein 
A10 (annexin II 
ligand, calpactin I, 
light polypeptide 
(p11)) 
2 S100A4 S100 calcium 
binding protein A4 
(calcium protein, 
calvasculin, 
metastasin, murine 
placental homolog) 
3.1 SAP30 sin3-associated 
polypeptide, 
30kDa 
170.9 SAPS2 SAPS domain 
family, member 2 
2.3 SCARB2 scavenger receptor 
class B, member 2 
2 SCMH1 sex comb on 
midleg homolog 1 
(Drosophila) 
2.5 SCPEP1 serine 
carboxypeptidase 1 
1.5 SDAD1 SDA1 domain 
containing 1 
2.1 SDCCA
G3 
serologically 
defined colon 
cancer antigen 3 
4.8 SEC22L1 SEC22 vesicle 
trafficking protein-
like 1 (S. 
cerevisiae) 
15.1 SEC23A Sec23 homolog A 
(S. cerevisiae) 
1.6 SECISBP
2 
SECIS binding 
protein 2 
1.8 SECTM1 secreted and 
transmembrane 1 
1.5 SENP2 SUMO1/sentrin/S
MT3 specific 
peptidase 2 
6.7 SEPHS1 selenophosphate 
synthetase 1 
2.2 SERGEF secretion 
regulating guanine 
nucleotide 
exchange factor 
1.5 SET SET translocation 
(myeloid 
leukemia-
associated) 
1.6 SETDB1 SET domain, 
bifurcated 1 
2.5 SF4 splicing factor 4 
1.9 SH2D3A SH2 domain 
containing 3A 
15.6 SIAH1 seven in absentia 
homolog 1 
(Drosophila) 
1.6 SIP1 survival of motor 
neuron protein 
interacting protein 
1 
19.4 SIRT3 sirtuin (silent 
mating type 
information 
regulation 2 
homolog) 3 (S. 
cerevisiae) 
2.2 SIX2 sine oculis 
homeobox 
homolog 2 
(Drosophila) 
1.8 SLC12A
9 
solute carrier 
family 12 
(potassium/chlorid
e transporters), 
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member 9 
2.9 SLC22A
14 
solute carrier 
family 22 (organic 
cation transporter), 
member 14 
1.6 SLC25A
14 
solute carrier 
family 25 
(mitochondrial 
carrier, brain), 
member 14 
7.2 SLC25A
5 
solute carrier 
family 25 
(mitochondrial 
carrier; adenine 
nucleotide 
translocator), 
member 5 
2 SLC31A
1 
solute carrier 
family 31 (copper 
transporters), 
member 1 
2 SLC31A
2 
solute carrier 
family 31 (copper 
transporters), 
member 2 
1.6 SLC35A
2 
solute carrier 
family 35 (UDP-
galactose 
transporter), 
member A2 
1.5 SLC35C2 solute carrier 
family 35, member 
C2 
3.5 SLC35F2 solute carrier 
family 35, member 
F2 
1.5 SLC38A
6 
solute carrier 
family 38, member 
6 
1.5 SLC39A
6 
solute carrier 
family 39 (zinc 
transporter), 
member 6 
3.9 SLC39A
8 
solute carrier 
family 39 (zinc 
transporter), 
member 8 
2 SLC41A
3 
solute carrier 
family 41, member 
3 
1.8 SLC43A
1 
solute carrier 
family 43, member 
1 
28.4 SLCO1B
3 
solute carrier 
organic anion 
transporter family, 
member 1B3 
1.5 SMAD2 SMAD, mothers 
against DPP 
homolog 2 
(Drosophila) 
3.5 SMARC
D2 
SWI/SNF related, 
matrix associated, 
actin dependent 
regulator of 
chromatin, 
subfamily d, 
member 2 
1.5 SMN1 survival of motor 
neuron 1, telomeric 
1.5 SNAI2 snail homolog 2 
(Drosophila) 
2.2 SNRPD1 small nuclear 
ribonucleoprotein 
D1 polypeptide 
16kDa 
2.8 SNRPE small nuclear 
ribonucleoprotein 
polypeptide E 
1.5 SNRPF small nuclear 
ribonucleoprotein 
polypeptide F 
1.6 SNRPG small nuclear 
ribonucleoprotein 
polypeptide G 
2.4 SOCS2 suppressor of 
cytokine signaling 
2 
2.1 SOD1 superoxide 
dismutase 1, 
soluble 
(amyotrophic 
lateral sclerosis 1 
(adult)) 
2.3 SORBS3 sorbin and SH3 
domain containing 
3 
59.9 SORT1 sortilin 1 
1.8 SPCS3 signal peptidase 
complex subunit 3 
homolog (S. 
cerevisiae) 
2.6 SPHK1 sphingosine kinase 
1 
26.2 SPOP speckle-type POZ 
protein 
32.5 SPRY4 sprouty homolog 4 
(Drosophila) 
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4.2 SRD5A1 steroid-5-alpha-
reductase, alpha 
polypeptide 1 (3-
oxo-5 alpha-steroid 
delta 4-
dehydrogenase 
alpha 1) 
9 SREBF2 sterol regulatory 
element binding 
transcription factor 
2 
2.1 SRI sorcin 
1.5 SRP72 signal recognition 
particle 72kDa 
1.7 SRPK1 SFRS protein 
kinase 1 
58.5 SRPRB signal recognition 
particle receptor, B 
subunit 
2.4 SS18 synovial sarcoma 
translocation, 
chromosome 18 
14.9 SSBP3 single stranded 
DNA binding 
protein 3 
1.9 STAT1 signal transducer 
and activator of 
transcription 1, 
91kDa 
1.7 STK11 serine/threonine 
kinase 11 (Peutz-
Jeghers syndrome) 
9.1 STK6 serine/threonine 
kinase 6 
12.5 STOM stomatin 
10.7 STX18 syntaxin 18 
1.5 SULT1A
1 
sulfotransferase 
family, cytosolic, 
1A, phenol-
preferring, member 
1 
7.9 SULT1A
3 
sulfotransferase 
family, cytosolic, 
1A, phenol-
preferring, member 
3 
1.8 SUMO3 SMT3 suppressor 
of mif two 3 
homolog 3 (yeast) 
3.7 SYPL1 synaptophysin-like 
1 
1.9 TAF6 TAF6 RNA 
polymerase II, 
TATA box binding 
protein (TBP)-
associated factor, 
80kDa 
1.6 TANK TRAF family 
member-associated 
NFKB activator 
2.5 TAX1BP
3 
Tax1 (human T-
cell leukemia virus 
type I) binding 
protein 3 
2.2 TBC1D2
2A 
TBC1 domain 
family, member 
22A 
3.1 TBC1D8 TBC1 domain 
family, member 8 
(with GRAM 
domain) 
1.5 TCEAL1 transcription 
elongation factor A 
(SII)-like 1 
2.3 TCFL5 transcription 
factor-like 5 (basic 
helix-loop-helix) 
2.6 TCP11L1 t-complex 11 
(mouse) like 1 
1.5 TEGT testis enhanced 
gene transcript 
(BAX inhibitor 1) 
3.2 TENC1 tensin like C1 
domain containing 
phosphatase 
(tensin 2) 
2.9 TFAM transcription factor 
A, mitochondrial 
9.5 TFCP2 transcription factor 
CP2 
1.5 TFDP1 transcription factor 
Dp-1 
7.9 TFDP2 transcription factor 
Dp-2 (E2F 
dimerization 
partner 2) 
5.1 TFPI tissue factor 
pathway inhibitor 
(lipoprotein-
associated 
coagulation 
inhibitor) 
1.7 TGDS TDP-glucose 4,6-
dehydratase 
8.3 THAP10 THAP domain 
containing 10 
1.6 THG1L tRNA-histidine 
guanylyltransferase 
1-like (S. 
cerevisiae) 
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2.5 TIA1 TIA1 cytotoxic 
granule-associated 
RNA binding 
protein 
3.4 TIMM17
A 
translocase of inner 
mitochondrial 
membrane 17 
homolog A (yeast) 
1.5 TINF2 TERF1 (TRF1)-
interacting nuclear 
factor 2 
4.2 TK2 thymidine kinase 
2, mitochondrial 
1.9 TMBIM4 transmembrane 
BAX inhibitor 
motif containing 4 
1.5 TMCO1 transmembrane 
and coiled-coil 
domains 1 
1.5 TMED9 transmembrane 
emp24 protein 
transport domain 
containing 9 
1.9 TMPO thymopoietin 
9 TMSB10 thymosin, beta 10 
13218.
9 
TNFRSF
11B 
tumor necrosis 
factor receptor 
superfamily, 
member 11b 
(osteoprotegerin) 
1.8 TNFRSF
14 
tumor necrosis 
factor receptor 
superfamily, 
member 14 
(herpesvirus entry 
mediator) 
2.6 TNFSF10 tumor necrosis 
factor (ligand) 
superfamily, 
member 10 
2 TNFSF13 tumor necrosis 
factor (ligand) 
superfamily, 
member 13 
2.3 TNFSF9 tumor necrosis 
factor (ligand) 
superfamily, 
member 9 
3.7 TOR1A torsin family 1, 
member A (torsin 
A) 
2.6 TOR1AI
P1 
torsin A interacting 
protein 1 
3.5 TP53AP1 TP53 activated 
protein 1 
2 TPD52 tumor protein D52 
3.2 TPM4 tropomyosin 4 
1.5 TRAM1 translocation 
associated 
membrane protein 
1 
2.2 TRAPPC
2 
trafficking protein 
particle complex 2 
1.9 TRAPPC
4 
trafficking protein 
particle complex 4 
2.7 TRBC1 T cell receptor beta 
constant 1 
2.5 TRIM68 tripartite motif-
containing 68 
2.7 TSPAN3 tetraspanin 3 
5.2 TSPAN9 tetraspanin 9 
3.8 TTC19 tetratricopeptide 
repeat domain 19 
1.8 TXNL2 thioredoxin-like 2 
10.6 UBA52 ubiquitin A-52 
residue ribosomal 
protein fusion 
product 1 
1.8 UBAP1 ubiquitin 
associated protein 
1 
1.5 UBE2D3 ubiquitin-
conjugating 
enzyme E2D 3 
(UBC4/5 homolog, 
yeast) 
4.5 UBE2G1 ubiquitin-
conjugating 
enzyme E2G 1 
(UBC7 homolog, 
yeast) 
2.8 UBE2J1 ubiquitin-
conjugating 
enzyme E2, J1 
(UBC6 homolog, 
yeast) 
4.4 UBE2L3 ubiquitin-
conjugating 
enzyme E2L 3 
1.5 UBE2L6 ubiquitin-
conjugating 
enzyme E2L 6 
1.5 UBE2N ubiquitin-
conjugating 
enzyme E2N 
(UBC13 homolog, 
yeast) 
2.5 UBE2V1 ubiquitin-
conjugating 
110	  	  
enzyme E2 variant 
1 
2.3 UBE2V2 ubiquitin-
conjugating 
enzyme E2 variant 
2 
1.5 UBE3B ubiquitin protein 
ligase E3B 
3.5 UBL3 ubiquitin-like 3 
1.9 UBXD6 UBX domain 
containing 6 
1.7 UCHL5I
P 
UCHL5 interacting 
protein 
1.7 UFC1 ubiquitin-fold 
modifier 
conjugating 
enzyme 1 
3.5 UNG2 uracil-DNA 
glycosylase 2 
2.4 USP3 ubiquitin specific 
peptidase 3 
1.7 VBP1 von Hippel-Lindau 
binding protein 1 
8.5 VEGF vascular 
endothelial growth 
factor 
1.6 VGF VGF nerve growth 
factor inducible 
6.4 VPS37C vacuolar protein 
sorting 37C (yeast) 
1.6 VRK3 vaccinia related 
kinase 3 
3.2 WASPIP Wiskott-Aldrich 
syndrome protein 
interacting protein 
13.8 WBP5 WW domain 
binding protein 5 
1.7 WDR23 WD repeat domain 
23 
5.8 WDR62 WD repeat domain 
62 
1.9 WHSC1 Wolf-Hirschhorn 
syndrome 
candidate 1 
6.1 WIPI2 WD repeat 
domain, 
phosphoinositide 
interacting 2 
2.1 WSB2 WD repeat and 
SOCS box-
containing 2 
3.6 XAB1 XPA binding 
protein 1, GTPase 
2.1 XAF1 XIAP associated 
factor-1 
7.9 YWHAQ tyrosine 3-
monooxygenase/tr
yptophan 5-
monooxygenase 
activation protein, 
theta polypeptide 
3.4 ZC3H14 zinc finger CCCH-
type containing 14 
1.5 ZDHHC6 zinc finger, 
DHHC-type 
containing 6 
1.7 ZFP36 zinc finger protein 
36, C3H type, 
homolog (mouse) 
6.3 ZNF133 zinc finger protein 
133 (clone pHZ-
13) 
1.7 ZNF143 zinc finger protein 
143 (clone pHZ-1) 
1.5 ZNF22 zinc finger protein 
22 (KOX 15) 
3.6 ZNF232 zinc finger protein 
232 
1.7 ZNF239 zinc finger protein 
239 
1.5 ZNF277 zinc finger protein 
277 
2.7 ZNF278 zinc finger protein 
278 
27 ZNF34 zinc finger protein 
34 (KOX 32) 
4.5 ZNF410 zinc finger protein 
410 
13 ZNF435 zinc finger protein 
435 
57.8 ZNF45 zinc finger protein 
45 
4.2 ZNF473 zinc finger protein 
473 
8.3 ZNF673 zinc finger protein 
673 
25 ZNF768 zinc finger protein 
768 
2 ZNF9 zinc finger protein 
9 (a cellular 
retroviral nucleic 
acid binding 
protein) 
1.6 ZSCAN5 zinc finger and 
SCAN domain 
containing 5 
   
Not 
Bound 
to 
Bound 
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 AASDHP
PT 
aminoadipate-
semialdehyde 
dehydrogenase-
phosphopantethein
yl transferase 
 ABCA2 ATP-binding 
cassette, sub-
family A (ABC1), 
member 2 
 ACVR1 activin A receptor, 
type I 
 ADAM1
0 
ADAM 
metallopeptidase 
domain 10 
 ADH5 alcohol 
dehydrogenase 5 
(class III), chi 
polypeptide 
 AGA aspartylglucosamin
idase 
 AK2 adenylate kinase 2 
 ALDH1B
1 
aldehyde 
dehydrogenase 1 
family, member B1 
 ALDH3A
2 
aldehyde 
dehydrogenase 3 
family, member 
A2 
 ALMS1 Alstrom syndrome 
1 
 AMD1 adenosylmethionin
e decarboxylase 1 
 ANGPT1 angiopoietin 1 
 ANKRD
49 
ankyrin repeat 
domain 49 
 APOL2 apolipoprotein L, 2 
 APS adaptor protein 
with pleckstrin 
homology and src 
homology 2 
domains 
 ARIH2 ariadne homolog 2 
(Drosophila) 
 ARL8B ADP-ribosylation 
factor-like 8B 
 ARNTL2 aryl hydrocarbon 
receptor nuclear 
translocator-like 2 
 ARSB arylsulfatase B 
 ASF1A ASF1 anti-
silencing function 
1 homolog A (S. 
cerevisiae) 
 ASTE1 asteroid homolog 1 
(Drosophila) 
 B2M beta-2-
microglobulin 
 B4GALT
1 
UDP-
Gal:betaGlcNAc 
beta 1,4- 
galactosyltransfera
se, polypeptide 1 
 BAIAP2 BAI1-associated 
protein 2 
 BECN1 beclin 1 (coiled-
coil, myosin-like 
BCL2 interacting 
protein) 
 BFSP1 beaded filament 
structural protein 
1, filensin 
 BNIP3L BCL2/adenovirus 
E1B 19kDa 
interacting protein 
3-like 
 BRD2 bromodomain 
containing 2 
 BRD9 bromodomain 
containing 9 
 BRMS1 breast cancer 
metastasis 
suppressor 1 
 BSDC1 BSD domain 
containing 1 
 BTF3 basic transcription 
factor 3 
 BTN3A3 butyrophilin, 
subfamily 3, 
member A3 
 BUB1 BUB1 budding 
uninhibited by 
benzimidazoles 1 
homolog (yeast) 
 BZW1 basic leucine 
zipper and W2 
domains 1 
 C14orf11
8 
chromosome 14 
open reading frame 
118 
 C15orf39 chromosome 15 
open reading frame 
39 
 C16orf34 chromosome 16 
open reading frame 
34 
 C16orf5 chromosome 16 
open reading frame 
5 
 C17orf70 chromosome 17 
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open reading frame 
70 
 C1orf108 chromosome 1 
open reading frame 
108 
 C1orf121 chromosome 1 
open reading frame 
121 
 C1orf166 chromosome 1 
open reading frame 
166 
 C1QDC1 C1q domain 
containing 1 
 C20orf18 chromosome 20 
open reading frame 
18 
 C20orf3 chromosome 20 
open reading frame 
3 
 C21orf55 chromosome 21 
open reading frame 
55 
 C2orf24 chromosome 2 
open reading frame 
24 
 C2orf56 chromosome 2 
open reading frame 
56 
 C4orf16 chromosome 4 
open reading frame 
16 
 C6orf62 chromosome 6 
open reading frame 
62 
 C6orf68 chromosome 6 
open reading frame 
68 
 C7orf25 chromosome 7 
open reading frame 
25 
 C8orf41 chromosome 8 
open reading frame 
41 
 CANT1 calcium activated 
nucleotidase 1 
 CASP10 caspase 10, 
apoptosis-related 
cysteine peptidase 
 CBX3 chromobox 
homolog 3 (HP1 
gamma homolog, 
Drosophila) 
 CCDC59 coiled-coil domain 
containing 59 
 CCNG2 cyclin G2 
 CCNJ cyclin J 
 CCNT2 cyclin T2 
 CDCA8 cell division cycle 
associated 8 
 CDH11 cadherin 11, type 
2, OB-cadherin 
(osteoblast) 
 CDK10 cyclin-dependent 
kinase (CDC2-
like) 10 
 CDKAL1 CDK5 regulatory 
subunit associated 
protein 1-like 1 
 CDS2 CDP-
diacylglycerol 
synthase 
(phosphatidate 
cytidylyltransferas
e) 2 
 CDV3 CDV3 homolog 
(mouse) 
 CERK ceramide kinase 
 CES2 carboxylesterase 2 
(intestine, liver) 
 CFLAR CASP8 and 
FADD-like 
apoptosis regulator 
 CH25H cholesterol 25-
hydroxylase 
 CHCHD3 coiled-coil-helix-
coiled-coil-helix 
domain containing 
3 
 CHST4 carbohydrate (N-
acetylglucosamine 
6-O) 
sulfotransferase 4 
 CLK1 CDC-like kinase 1 
 CLN8 ceroid-
lipofuscinosis, 
neuronal 8 
(epilepsy, 
progressive with 
mental retardation) 
 COG5 component of 
oligomeric golgi 
complex 5 
 COL1A1 collagen, type I, 
alpha 1 
 COX15 COX15 homolog, 
cytochrome c 
oxidase assembly 
protein (yeast) 
 CRBN cereblon 
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 CREM cAMP responsive 
element modulator 
 CRKL v-crk sarcoma 
virus CT10 
oncogene homolog 
(avian)-like 
 CSGlcA-
T 
chondroitin sulfate 
glucuronyltransfera
se 
 CSNK1E casein kinase 1, 
epsilon 
 CTAGE5 CTAGE family, 
member 5 
 CTBP1 C-terminal binding 
protein 1 
 CTSO cathepsin O 
 CUL1 cullin 1 
 CXorf34 chromosome X 
open reading frame 
34 
 CXorf45 chromosome X 
open reading frame 
45 
 CYB561 cytochrome b-561 
 CYP26B
1 
cytochrome P450, 
family 26, 
subfamily B, 
polypeptide 1 
 CYP2R1 cytochrome P450, 
family 2, 
subfamily R, 
polypeptide 1 
 CYP51A
1 
cytochrome P450, 
family 51, 
subfamily A, 
polypeptide 1 
 DARS2 aspartyl-tRNA 
synthetase 2 
(mitochondrial) 
 DBF4 DBF4 homolog (S. 
cerevisiae) 
 DCUN1
D2 
DCN1, defective in 
cullin neddylation 
1, domain 
containing 2 (S. 
cerevisiae) 
 DCUN1
D4 
DCN1, defective in 
cullin neddylation 
1, domain 
containing 4 (S. 
cerevisiae) 
 DDX17 DEAD (Asp-Glu-
Ala-Asp) box 
polypeptide 17 
 DHODH dihydroorotate 
dehydrogenase 
 DHRS7 dehydrogenase/red
uctase (SDR 
family) member 7 
 DKFZP5
64O0523 
hypothetical 
protein 
DKFZp564O0523 
 DLG1 discs, large 
homolog 1 
(Drosophila) 
 DLX4 distal-less 
homeobox 4 
 DNAJB4 DnaJ (Hsp40) 
homolog, 
subfamily B, 
member 4 
 DNAJC1
0 
DnaJ (Hsp40) 
homolog, 
subfamily C, 
member 10 
 DRAM damage-regulated 
autophagy 
modulator  
 DYRK3 dual-specificity 
tyrosine-(Y)-
phosphorylation 
regulated kinase 3 
 ECHDC1 enoyl Coenzyme A 
hydratase domain 
containing 1 
 EDIL3 EGF-like repeats 
and discoidin I-like 
domains 3 
 EGFR Epidermal growth 
factor receptor 
(EGFR) 
 EIF2AK1 eukaryotic 
translation 
initiation factor 2-
alpha kinase 1 
 EIF4E2 eukaryotic 
translation 
initiation factor 4E 
family member 2 
 ELAVL1 ELAV (embryonic 
lethal, abnormal 
vision, 
Drosophila)-like 1 
(Hu antigen R) 
 EPB41L4
B 
erythrocyte 
membrane protein 
band 4.1 like 4B 
 EPN2 epsin 2 
 ETFDH electron-
transferring-
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flavoprotein 
dehydrogenase 
 EVA1 epithelial V-like 
antigen 1 
 EXOC7 exocyst complex 
component 7 
 EXTL2 exostoses 
(multiple)-like 2 
 EXTL3 exostoses 
(multiple)-like 3 
 FAIM Fas apoptotic 
inhibitory 
molecule 
 FAM32A family with 
sequence similarity 
32, member A 
 FAM46C family with 
sequence similarity 
46, member C 
 FAM69A Family with 
sequence similarity 
69, member A 
 FANCC Fanconi anemia, 
complementation 
group C 
 FARP1 FERM, RhoGEF 
(ARHGEF) and 
pleckstrin domain 
protein 1 
(chondrocyte-
derived) 
 FBXL2 F-box and leucine-
rich repeat protein 
2 
 FBXL5 F-box and leucine-
rich repeat protein 
5 
 FEZ2 fasciculation and 
elongation protein 
zeta 2 (zygin II) 
 FKBP14 FK506 binding 
protein 14, 22 kDa 
 FLJ1118
4 
hypothetical 
protein FLJ11184 
 FNBP3 formin binding 
protein 3 
 FOXK2 forkhead box K2 
 FRAT1 frequently 
rearranged in 
advanced T-cell 
lymphomas 
 FZD6 frizzled homolog 6 
(Drosophila) 
 G6PC3 glucose 6 
phosphatase, 
catalytic, 3 
 GALNT1 UDP-N-acetyl-
alpha-D-
galactosamine:poly
peptide N-
acetylgalactosamin
yltransferase 1 
(GalNAc-T1) 
 GAPDH glyceraldehyde-3-
phosphate 
dehydrogenase 
 GCAT glycine C-
acetyltransferase 
(2-amino-3-
ketobutyrate 
coenzyme A 
ligase) 
 GCLC glutamate-cysteine 
ligase, catalytic 
subunit 
 GCNT1 glucosaminyl (N-
acetyl) transferase 
1, core 2 (beta-1,6-
N-
acetylglucosaminyl
transferase) 
 GDAP2 ganglioside 
induced 
differentiation 
associated protein 
2 
 GLB1L galactosidase, beta 
1-like 
 GLMN glomulin, FKBP 
associated protein 
 GLO1 glyoxalase I 
 GMFB glia maturation 
factor, beta 
 GNA11 guanine nucleotide 
binding protein (G 
protein), alpha 11 
(Gq class) 
 GNL1 guanine nucleotide 
binding protein-
like 1 
 GOLGA1 golgi autoantigen, 
golgin subfamily a, 
1 
 GRB2 growth factor 
receptor-bound 
protein 2 
 GTF2F2 general 
transcription factor 
IIF, polypeptide 2, 
30kDa 
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 GTF2H1 general 
transcription factor 
IIH, polypeptide 1, 
62kDa 
 GTF3C4 general 
transcription factor 
IIIC, polypeptide 
4, 90kDa 
 H2AFY H2A histone 
family, member Y 
 H3F3A H3 histone, family 
3A 
 HADHB hydroxyacyl-
Coenzyme A 
dehydrogenase/3-
ketoacyl-
Coenzyme A 
thiolase/enoyl-
Coenzyme A 
hydratase 
(trifunctional 
protein), beta 
subunit 
 HERC4 hect domain and 
RLD 4 
 HFE hemochromatosis 
 HIP2 huntingtin 
interacting protein 
2 
 HIST2H2
BE 
histone 2, H2be 
 HLA-
DPA1 
major 
histocompatibility 
complex, class II, 
DP alpha 1 
 HMGA1 high mobility 
group AT-hook 1 
 HMGN4 high mobility 
group nucleosomal 
binding domain 4 
 HNRPDL heterogeneous 
nuclear 
ribonucleoprotein 
D-like 
 HTATSF
1 
HIV TAT specific 
factor 1 
 HUS1 HUS1 checkpoint 
homolog (S. 
pombe) 
 HYPK Huntingtin 
interacting protein 
K 
 IDH3A isocitrate 
dehydrogenase 3 
(NAD+) alpha 
 IDS iduronate 2-
sulfatase (Hunter 
syndrome) 
 IFIT3 interferon-induced 
protein with 
tetratricopeptide 
repeats 3 
 IFNAR1 interferon (alpha, 
beta and omega) 
receptor 1 
 IGFBP3 insulin-like growth 
factor binding 
protein 3 
 IL27RA interleukin 27 
receptor, alpha 
 IMPDH2 IMP (inosine 
monophosphate) 
dehydrogenase 2 
 IQCB1 IQ motif 
containing B1 
 IRAK4 interleukin-1 
receptor-associated 
kinase 4 
 ITCH itchy homolog E3 
ubiquitin protein 
ligase (mouse) 
 ITM2B integral membrane 
protein 2B 
 ITPK1 inositol 1,3,4-
triphosphate 5/6 
kinase 
 JMJD4 jumonji domain 
containing 4 
 KATNB1 katanin p80 (WD 
repeat containing) 
subunit B 1 
 KCNS3 potassium voltage-
gated channel, 
delayed-rectifier, 
subfamily S, 
member 3 
 KCTD2 potassium channel 
tetramerisation 
domain containing 
2 
 KIAA049
4 
KIAA0494 
 KIAA049
5 
KIAA0495 
 KIAA065
2 
KIAA0652 
 KIAA089
2 
KIAA0892 
 KIAA097
4 
KIAA0974 mRNA 
 KIAA112 KIAA1128 
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8 
 KIAA201
0 
KIAA2010 
 KLHL12 kelch-like 12 
(Drosophila) 
 KRIT1 KRIT1, ankyrin 
repeat containing 
 LAP3 leucine 
aminopeptidase 3 
 LBH limb bud and heart 
development 
homolog (mouse) 
 LDLRAP
1 
low density 
lipoprotein 
receptor adaptor 
protein 1 
 LEPR leptin receptor 
 LEPROT leptin receptor 
overlapping 
transcript 
 LEPROT
L1 
leptin receptor 
overlapping 
transcript-like 1 
 LIF leukemia 
inhibitory factor 
(cholinergic 
differentiation 
factor) 
 LMF2 lipase maturation 
factor 2  
 LOC1274
06 
similar to laminin 
receptor 1 
(ribosomal protein 
SA) 
 LOC1453
87 
LOC145387 
 LOC6392
0 
transposon-derived 
Buster3 
transposase-like 
 LOC9224
9 
hypothetical 
protein LOC92249 
 LPXN leupaxin 
 M6PR mannose-6-
phosphate receptor 
(cation dependent) 
 MAEA macrophage 
erythroblast 
attacher 
 MAP2K3 mitogen-activated 
protein kinase 
kinase 3 
 MAP3K7 mitogen-activated 
protein kinase 
kinase kinase 7 
 MBD4 methyl-CpG 
binding domain 
protein 4 
 MCM4 MCM4 
minichromosome 
maintenance 
deficient 4 (S. 
cerevisiae) 
 MDH2 malate 
dehydrogenase 2, 
NAD 
(mitochondrial) 
 MELK maternal 
embryonic leucine 
zipper kinase 
 MGAT2 mannosyl (alpha-
1,6-)-glycoprotein 
beta-1,2-N-
acetylglucosaminyl
transferase 
 MGC127
60 
hypothetical 
protein 
MGC12760 
 MGC326
2 
hypothetical 
protein MGC3262 
 MIPEP mitochondrial 
intermediate 
peptidase 
 MKRN1 makorin, ring 
finger protein, 1 
 MMP24 matrix 
metalloproteinase 
24 (membrane-
inserted) 
 MNS1 meiosis-specific 
nuclear structural 1 
 MON1B MON1 homolog B 
(yeast) 
 MOSPD1 motile sperm 
domain containing 
1 
 MRP63 mitochondrial 
ribosomal protein 
63 
 MSRB2 methionine 
sulfoxide reductase 
B2 
 MSTO1 misato homolog 1 
(Drosophila) 
 MTCH1 mitochondrial 
carrier homolog 1 
(C. elegans) 
 MTHFD2 methylenetetrahydr
ofolate 
dehydrogenase 
(NADP+ 
dependent) 2, 
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methenyltetrahydro
folate 
cyclohydrolase 
 MTUS1 mitochondrial 
tumor suppressor 1 
 MUM1 melanoma 
associated antigen 
(mutated) 1 
 MXD4 MAX dimerization 
protein 4 
 NDRG3 NDRG family 
member 3 
 NET1 neuroepithelial cell 
transforming gene 
1 
 NFIC nuclear factor I/C 
(CCAAT-binding 
transcription 
factor) 
 NFIL3 nuclear factor, 
interleukin 3 
regulated 
 NFKBIA nuclear factor of 
kappa light 
polypeptide gene 
enhancer in B-cells 
inhibitor, alpha 
 NFYA nuclear 
transcription factor 
Y, alpha 
 NR2C1 nuclear receptor 
subfamily 2, group 
C, member 1 
 NR2C2 nuclear receptor 
subfamily 2, group 
C, member 2 
 NR2F6 nuclear receptor 
subfamily 2, group 
F, member 6 
 NRF1 nuclear respiratory 
factor 1 
 NUDT13 nudix (nucleoside 
diphosphate linked 
moiety X)-type 
motif 13 
 OSR2 odd-skipped 
related 2 
(Drosophila) 
 PACS2 phosphofurin 
acidic cluster 
sorting protein 2 
 PAICS phosphoribosylami
noimidazole 
carboxylase, 
phosphoribosylami
noimidazole 
succinocarboxamid
e synthetase 
 PAK4 p21(CDKN1A)-
activated kinase 4 
 PAM peptidylglycine 
alpha-amidating 
monooxygenase 
 PARP16 poly (ADP-ribose) 
polymerase family, 
member 16 
 PARVA parvin, alpha 
 PBLD phenazine 
biosynthesis-like 
protein domain 
containing 
 PDCD4 programmed cell 
death 4 (neoplastic 
transformation 
inhibitor) 
 PDE8A phosphodiesterase 
8A 
 PDGFA platelet-derived 
growth factor alpha 
polypeptide 
 PDLIM5 PDZ and LIM 
domain 5 
 PHLDA1 pleckstrin 
homology-like 
domain, family A, 
member 1 
 PIGO phosphatidylinosit
ol glycan, class O 
 PIP5K2A phosphatidylinosit
ol-4-phosphate 5-
kinase, type II, 
alpha 
 PIP5K2B phosphatidylinosit
ol-4-phosphate 5-
kinase, type II, 
beta 
 PKP3 plakophilin 3 
 PLA2G6 phospholipase A2, 
group VI 
(cytosolic, 
calcium-
independent) 
 PLK4 polo-like kinase 4 
(Drosophila) 
 POLR2D polymerase (RNA) 
II (DNA directed) 
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polypeptide D 
 PPCS phosphopantotheno
ylcysteine 
synthetase 
 PPIC peptidylprolyl 
isomerase C 
(cyclophilin C) 
 PPM1G protein 
phosphatase 1G 
(formerly 2C), 
magnesium-
dependent, gamma 
isoform 
 PPP2CB protein 
phosphatase 2 
(formerly 2A), 
catalytic subunit, 
beta isoform 
 PRDM2 PR domain 
containing 2, with 
ZNF domain 
 PRDX3 peroxiredoxin 3 
 PREI3 preimplantation 
protein 3 
 PRKACB protein kinase, 
cAMP-dependent, 
catalytic, beta 
 PRPS1 phosphoribosyl 
pyrophosphate 
synthetase 1 
 PRR14 proline rich 14 
 PRSS3 protease, serine, 3 
(mesotrypsin) 
 PSMC3 proteasome 
(prosome, 
macropain) 26S 
subunit, ATPase, 3 
 PSMC3I
P 
PSMC3 interacting 
protein 
 PSMD14 proteasome 
(prosome, 
macropain) 26S 
subunit, non-
ATPase, 14 
 PSPC1 paraspeckle 
component 1 
 PSTPIP2 proline-serine-
threonine 
phosphatase 
interacting protein 
2 
 PTDSS1 phosphatidylserine 
synthase 1 
 PTEN phosphatase and 
tensin homolog 
(mutated in 
multiple advanced 
cancers 1) 
 PTENP1 phosphatase and 
tensin homolog 
(mutated in 
multiple advanced 
cancers 1), 
pseudogene 1 
 PTN pleiotrophin 
(heparin binding 
growth factor 8, 
neurite growth-
promoting factor 1) 
 PTTG1IP pituitary tumor-
transforming 1 
interacting protein 
 PUS3 pseudouridylate 
synthase 3 
 PYGO1 pygopus homolog 
1 (Drosophila) 
 RAB11A RAB11A, member 
RAS oncogene 
family 
 RAB27B RAB27B, member 
RAS oncogene 
family 
 RAB8A RAB8A, member 
RAS oncogene 
family 
 RABIF RAB interacting 
factor 
 RAD51L
3 
RAD51-like 3 (S. 
cerevisiae) 
 RAP1GD
S1 
RAP1, GTP-GDP 
dissociation 
stimulator 1 
 RBMS3 RNA binding 
motif, single 
stranded 
interacting protein 
 RCC1 regulator of 
chromosome 
condensation 1 
 REXO2 REX2, RNA 
exonuclease 2 
homolog (S. 
cerevisiae) 
 RGL2 ral guanine 
nucleotide 
dissociation 
stimulator-like 2 
 RGS10 regulator of G-
protein signalling 
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10 
 RINT1 RAD50 interactor 
1 
 RIOK3 RIO kinase 3 
(yeast) 
 RIPK1 receptor 
(TNFRSF)-
interacting serine-
threonine kinase 1 
 RNF11 ring finger protein 
11 
 RNF13 ring finger protein 
13 
 RNF139 ring finger protein 
139 
 RNF216 ring finger protein 
216 
 RNF24 ring finger protein 
24 
 RNF4 ring finger protein 
4 
 RNF44 ring finger protein 
44 
 RP4-
692D3.1 
hypothetical 
protein 
LOC728621 
 RPL12 ribosomal protein 
L12 
 RPL13A ribosomal protein 
L13a 
 RPL15 ribosomal protein 
L15 
 RPL18A ribosomal protein 
L18a 
 RPL21 ribosomal protein 
L21 
 RPL22 ribosomal protein 
L22 
 RPL28 ribosomal protein 
L28 
 RPL31 ribosomal protein 
L31 
 RPL38 ribosomal protein 
L38 
 RPL5 ribosomal protein 
L5 
 RPN1 ribophorin I 
 RPS12 ribosomal protein 
S12 
 RPS19 ribosomal protein 
S19 
 RPS21 ribosomal protein 
S21 
 RPS27A ribosomal protein 
S27a 
 RPS28 ribosomal protein 
S28 
 RPS6 ribosomal protein 
S6 
 RTF1 Rtf1, Paf1/RNA 
polymerase II 
complex 
component, 
homolog (S. 
cerevisiae) 
 SAP18 sin3-associated 
polypeptide, 
18kDa 
 SC4MOL sterol-C4-methyl 
oxidase-like 
 SCAMP1 secretory carrier 
membrane protein 
1 
 SCAMP5 secretory carrier 
membrane protein 
5 
 SCML1 sex comb on 
midleg-like 1 
(Drosophila) 
 SCRN3 secernin 3 
 SCYE1 small inducible 
cytokine subfamily 
E, member 1 
(endothelial 
monocyte-
activating) 
 SCYL3 SCY1-like 3 (S. 
cerevisiae) 
 SDC2 syndecan 2 
(heparan sulfate 
proteoglycan 1, 
cell surface-
associated, 
fibroglycan) 
 SDC4 syndecan 4 
(amphiglycan, 
ryudocan) 
 SDFR1 stromal cell 
derived factor 
receptor 1 
 SEC11L1 SEC11-like 1 (S. 
cerevisiae) 
 SEMA4F sema domain, 
immunoglobulin 
domain (Ig), 
transmembrane 
domain (TM) and 
short cytoplasmic 
domain, 
(semaphorin) 4F 
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 SEPT11 septin 11 
 SERINC
3 
serine incorporator 
3 
 SF3A1 splicing factor 3a, 
subunit 1, 120kDa 
 SFN stratifin 
 SFRS14 splicing factor, 
arginine/serine-rich 
14 
 SFXN3 sideroflexin 3 
 SHOX2 short stature 
homeobox 2 
 SIRT5 sirtuin (silent 
mating type 
information 
regulation 2 
homolog) 5 (S. 
cerevisiae) 
 SIX1 sine oculis 
homeobox 
homolog 1 
(Drosophila) 
 SKP1A S-phase kinase-
associated protein 
1A (p19A) 
 SLC25A
37 
solute carrier 
family 25, member 
37 
 SLC26A
4 
solute carrier 
family 26, member 
4 
 SLC35E1 solute carrier 
family 35, member 
E1 
 SMAD5 SMAD, mothers 
against DPP 
homolog 5 
(Drosophila) 
 SMARC
D3 
SWI/SNF related, 
matrix associated, 
actin dependent 
regulator of 
chromatin, 
subfamily d, 
member 3 
 SMS spermine synthase 
 SNN stannin 
 SOD2 superoxide 
dismutase 2, 
mitochondrial 
 SP110 SP110 nuclear 
body protein 
 SP2 Sp2 transcription 
factor 
 SPATA2
L 
spermatogenesis 
associated 2-like 
 SRR serine racemase 
 SSRP1 structure specific 
recognition protein 
1 
 ST13 suppression of 
tumorigenicity 13 
(colon carcinoma) 
(Hsp70 interacting 
protein) 
 STC1 stanniocalcin 1 
 STCH stress 70 protein 
chaperone, 
microsome-
associated, 60kDa 
 STK24 serine/threonine 
kinase 24 (STE20 
homolog, yeast) 
 STOML1 stomatin (EPB72)-
like 1 
 STX12 syntaxin 12 
 STX6 syntaxin 6 
 STX7 syntaxin 7 
 STYK1 serine/threonine/tyr
osine kinase 1 
 SVIL supervillin 
 SYBL1 synaptobrevin-like 
1 
 TACSTD
2 
tumor-associated 
calcium signal 
transducer 2 
 TAF1A TATA box binding 
protein (TBP)-
associated factor, 
RNA polymerase I, 
A, 48kDa 
 TBXA2R thromboxane A2 
receptor 
 TDP1 tyrosyl-DNA 
phosphodiesterase 
1 
 TERF1 telomeric repeat 
binding factor 
(NIMA-
interacting) 1 
 TES testis derived 
transcript (3 LIM 
domains) 
 TEX261 testis expressed 
sequence 261 
 TGFBR2 transforming 
growth factor, beta 
receptor II 
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(70/80kDa) 
 TGIF2 TGFB-induced 
factor 2 (TALE 
family homeobox) 
 THAP1 THAP domain 
containing, 
apoptosis 
associated protein 
1 
 TIMM44 translocase of inner 
mitochondrial 
membrane 44 
homolog (yeast) 
 TIMP3 TIMP 
metallopeptidase 
inhibitor 3 (Sorsby 
fundus dystrophy, 
pseudoinflammator
y) 
 TM7SF1 transmembrane 7 
superfamily 
member 1 
(upregulated in 
kidney) 
 TMEFF1 transmembrane 
protein with EGF-
like and two 
follistatin-like 
domains 1 
 TNFRSF
1A 
tumor necrosis 
factor receptor 
superfamily, 
member 1A 
 TOB1 transducer of 
ERBB2, 1 
 TOM1L1 target of myb1-like 
1 (chicken) 
 TPI1 triosephosphate 
isomerase 1 
 TPK1 thiamin 
pyrophosphokinase 
1 
 TPM1 tropomyosin 1 
(alpha) 
 TTC4 tetratricopeptide 
repeat domain 4 
 TULP3 tubby like protein 
3 
 TWISTN
B 
TWIST neighbor 
 TXK TXK tyrosine 
kinase 
 TXNDC thioredoxin 
domain containing 
 UBE2NL ubiquitin-
conjugating 
enzyme E2N-like 
 UFM1 ubiquitin-fold 
modifier 1 
 UIMC1 ubiquitin 
interaction motif 
containing 1  
 UQCRB ubiquinol-
cytochrome c 
reductase binding 
protein 
 VAMP3 vesicle-associated 
membrane protein 
3 (cellubrevin) 
 VAPA VAMP (vesicle-
associated 
membrane 
protein)-associated 
protein A, 33kDa 
 VPS24 vacuolar protein 
sorting 24 (yeast) 
 WDR46 WD repeat domain 
46 
 WDR48 WD repeat domain 
48 
 XPO6 exportin 6 
 XPO7 exportin 7 
 YRDC yrdC domain 
containing (E.coli) 
 YWHAZ tyrosine 3-
monooxygenase/tr
yptophan 5-
monooxygenase 
activation protein, 
zeta polypeptide 
 ZBED1 zinc finger, BED-
type containing 1 
 ZCCHC1
0 
zinc finger, CCHC 
domain containing 
10 
 ZCCHC4 zinc finger, CCHC 
domain containing 
4 
 ZFAND1 zinc finger, AN1-
type domain 1 
 ZFP37 zinc finger protein 
37 homolog 
(mouse) 
 ZNF177 zinc finger protein 
177 
 ZNF227 zinc finger protein 
227 
 ZNF230 zinc finger protein 
230 
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 ZNF306 zinc finger protein 
306 
 ZNF330 zinc finger protein 
330 
 ZNF505 zinc finger protein 
505 
 ZNF557 zinc finger protein 
557 
 ZNF675 zinc finger protein 
675 
 ZWINT ZW10 interactor 
 ZXDC ZXD family zinc 
finger C 
 
